<!DOCTYPE html>
<html>
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <link rel="shortcut icon" href="data:image/vnd.microsoft.icon;base64,AAABAAEAEBAQAAEABAAoAQAAFgAAACgAAAAQAAAAIAAAAAEABAAAAAAAgAAAAAAAAAAAAAAAEAAAAAAAAAAAAAAA25g0AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAERAAAAAAAAAREAAAAAAAABEQAAAAAAAAERAAAAAAAAARERERAAAAABEREREAAAAAEREREQAAAAAREAAAAAAAABEQAAAAAAAAEREREQAAAAARERERAAAAABEREREAAAAAAAAAAAAAAAAAAAAAAAD//wAA//8AAPH/AADx/wAA8f8AAPH/AADwDwAA8A8AAPAPAADx/wAA8f8AAPAPAADwDwAA8A8AAP//AAD//wAA" />
    <title></title>
    <script src="https://unpkg.com/lore-engine@1.1.10/dist/lore.min.js"></script>
    <script src="https://unpkg.com/smiles-drawer@2.0.2/dist/smiles-drawer.min.js"></script>
    <link 
      rel="stylesheet" 
      href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.10.2/css/all.css" 
      integrity="sha256-piqEf7Ap7CMps8krDQsSOTZgF+MU/0MPyPW2enj5I40=" 
      crossorigin="anonymous" />
    <link
      href="https://fonts.googleapis.com/css?family=Open+Sans:400,600"
      rel="stylesheet"
    />
    <style>
      body {
        margin: 0px;
        padding: 0px;
        height: 100%;
        user-select: none;
        overflow: hidden;
        white-space: nowrap;
      }

      #lore {
        position: absolute;
        width: 100%;
        height: 100%;
      }

      #title {
        position: absolute;
        z-index: 9999;
        pointer-events: none;
        text-height: 1;
        opacity: 0.0;
        transition: opacity 0.5s ease-in;
        
          padding-bottom: 20px;
        
          font-size: 1.0em;
        
          color: #888888;
        
          font-family: 'Open Sans';
        
      }

      #x-axis {
        position: absolute;
        z-index: 9999;
        pointer-events: none;
        text-height: 1;
        opacity: 0.0;
        transition: opacity 0.5s ease-in;
        
          padding-top: 20px;
        
          font-size: 0.7em;
        
          color: #888888;
        
          font-family: 'Open Sans';
        
      }

      #y-axis {
        position: absolute;
        z-index: 9999;
        pointer-events: none;
        text-height: 1;
        transition: opacity 0.5s ease-in;
        
          padding-bottom: 20px;
        
          font-size: 0.7em;
        
          color: #888888;
        
          font-family: 'Open Sans';
        
          transform: rotate(-90deg);
        
      }

      #tip {
        position: absolute;
        z-index: 9999;
        left: 10px;
        top: 10px;
        padding: 5px;
        font-family: 'Open Sans';
        background-color: rgba(255, 255, 255, 1.0);
        border-radius: 2px;
        border-left: 5px solid #000;
        pointer-events: none;
        opacity: 0.0;
        transition: opacity 0.1s ease-out;
        filter: drop-shadow(0px 0px 10px rgba(0, 0, 0, 1.0));
      }

      #tip.show {
        opacity: 1.0;
        transition: opacity 0.1s ease-out;
      }

      #tip-text {
        position: relative;
        
        max-width: 250px;
        
        font-size: 0.8em;
        font-weight: bold;
        white-space: normal;
        line-break: normal;
      }

      #hover-indicator {
        display: none;
        position: absolute;
        z-index: 999;
        border: 1px solid #fff;
        background-color: rgba(255, 255, 255, 0.25);
        border-radius: 50%;
        pointer-events: none;
      }

      #hover-indicator.show {
        display: block !important
      }

      .selected-indicator {
        position: absolute;
        z-index: 999;
        pointer-events: none;
      }

      .selected-indicator .crosshair-x {
        position: absolute;
        top: 0; left: 0; bottom: 0; right: 0;
        height: 2px;
        width: 100%;
        margin: auto;
        
          background-color: #fff;
        
      }

      .selected-indicator .crosshair-y {
        position: absolute;
        top: 0; left: 0; bottom: 0; right: 0;
        width: 2px;
        height: 100%;
        margin: auto;
        
          background-color: #fff;
        
      }

      #legend {
        position: absolute;
        z-index: 9998;
        
          bottom: 10px;
        
          right: 10px;
        
          padding: 10px;
        
          border: 1px solid #262626;
        
          border-radius: 2px;
        
          background-color: #111111;
        
          filter: drop-shadow(0px 0px 10px rgba(0, 0, 0, 0.5));
        
          color: #eeeeee;
        
          font-family: 'Open Sans';
        
      }

      #legend .container {
        display: flex;
        flex: auto;
        align-items: flex-start;
        
        flex-direction: column;
        
      }

      #legend .legend-section {
        width: 100%;
      }

      #legend .legend-section:not(:first-child) {
        
      }

      #legend h2 {
        font-size: 1em;
        font-weight: 600;
        padding-top: 0;
        margin-top: 0;
        margin-bottom: 5px;
        text-align: center;
        max-width: 250px;
        white-space: normal;
      }

      #legend h3 {
        font-size: 0.8em;
        margin-top: 10px;
        margin-bottom: 0px;
        max-width: 250px;
        white-space: normal;
      }

      #legend select {
        width: 100%;
        margin-bottom: 5px;
        background: transparent;
        color: #fff;
        border-radius: 2px;
        font-size: 0.75em;
      }

      #legend select option {
        background: #000;
      }

      #legend .legend-element, #legend .legend-element-range {
        position: relative;
        display: flex;
        flex: auto;
        align-items: flex-start;
        padding-bottom: 2px;
        padding-top: 2px;
      }

      #legend .legend-element {
        align-items: flex-start;
      }

      #legend .legend-element-range {
        flex-direction: column;
      }

      #legend .color-box {
        
          width: 15px;
        
          height: 15px;
        
          border: solid 0px;
        
      }

      #legend .color-stripe {
        
          width: 15px;
        
          height: 1px;
        
          border: solid 0px;
        
      }

      #legend .legend-label {
        height: 15px;
        font-size: 0.7em;
        padding-left: 5px;
      }

      #legend .legend-label.max {
        position: absolute;
        top: 0px;
        margin-left: 15px;
      }

      #legend .legend-label.min {
        position: absolute;
        bottom: 2px;
        margin-left: 15px;
      }

      #selected {
        position: absolute;
        display: none;
        z-index: 9998;
        width: 250px;
        
          bottom: 10px;
        
          left: 10px;
        
          padding: 0px;
        
          border: 1px solid #262626;
        
          border-radius: 2px;
        
          background-color: #111111;
        
          filter: drop-shadow(0px 0px 10px rgba(0, 0, 0, 0.5));
        
          color: #eeeeee;
        
          font-family: 'Open Sans';
        
      }

      #selected #selected-controls {
        display: flex;
        align-items: center;
        justify-content: flex-end;
        padding: 5px 10px;
        border-bottom: 1px solid #262626;
        font-size: 0.8em;
        font-weight: bold;
      }

      #selected #selected-controls * {
        display: inline-block;
      }

      #selected #selected-controls #selected-title {
        flex-grow: 1;
        white-space: nowrap; 
        overflow: hidden;
        text-overflow: ellipsis;
        color: #aaa;
      }

      #selected #selected-controls a {
        margin: 0px 2px;
        font-size: 1.5em;
        color: #fff;
        opacity: 0.75;
        transition: 0.2s;
      }

      #selected #selected-controls a:hover {
        opacity: 1.0;
      }

      #selected #selected-controls a#selected-remove {
        position: absolute;
        right: 10px;
        top: 42px;
        color: #e74c3c;
      }

      #selected #selected-container {
        padding: 10px;
        font-size: 0.8em;
      }

      #selected #selected-container img {
        margin-left: -10px;
      }

      #selected #selected-container .label {
        font-weight: bold;
        color: #aaa;
        font-size: 0.7em;
      }

      #selected #selected-container .label:not(:first-child) {
        margin-top: 2px;
      }

      #selected #selected-container .content {
        white-space: nowrap; 
        overflow: hidden;
        text-overflow: ellipsis;
      }

      #selected #selected-container .content a {
        text-decoration: none;
        color: #3498db;
      }

      #controls {
        position: absolute;
        z-index: 9998;
        
          top: 10px;
        
          right: 10px;
        
          padding: 2px;
        
          border: 1px solid #262626;
        
          border-radius: 2px;
        
          background-color: #111111;
        
          filter: drop-shadow(0px 0px 10px rgba(0, 0, 0, 0.5));
        
          color: #eeeeee;
        
          font-family: 'Open Sans';
        
      }

      #controls a {
        display: inline-block;
        padding: 5px 10px;
        font-size: 1.2em;
        color: #fff;
        opacity: 0.75;
        transition: 0.2s;
      }

      #controls a:hover {
        opacity: 1.0;
      }

      #controls #more-controls {
        display: inline-block;
      }

      #impress {
        position: absolute;
        z-index: 9999;
        top: 10px;
        left: 10px;
        font-size: 0.7em;
        color: #eee;
      }

      #impress a {
        color: #3498db;
        text-decoration: none;
      }

      #overlay-structure-container {
        position: absolute;
        z-index: 9999;
        top: 50px;
        left: 275px;
        right: 100px;
        bottom: 10px;
        opacity: .5;
        pointer-events: none;
      }

      #overlay-structure {
        display: block;
        margin-left: auto;
        margin-right: auto;
        margin-top: auto;
        margin-bottom: auto;
      }





      .show {
        opacity: 1.0 !important;
      }

      .hide {
        display: none !important;
      }

      @media only screen and (max-width: 600px) {
        #selected {
          position: absolute;
          display: none;
          z-index: 9998;
          width: 125px;
          opacity: 0.8;
          background-filter: blur(10px);
        }

        #selected img {
          width: 125px;
        }

        #tip {
          display: none;
        }
      }
    </style>
  </head>

  <body>
    
    
    
    
      <div id="impress">made with <a href="http://tmap.gdb.tools" target="_blank">tmap</a> and <a href="https://github.com/reymond-group/faerun-python" target="_blank">faerun</a>  <br> <a href="#" style=color:#FE674C>i.lukac@charnwood-molecular.com</a> </div>
    

    <div id="overlay-structure-container" data-binding-id="overlayStructureContainer" class="">
      <canvas id="overlay-structure" data-binding-id="overlayStructure" width="450" height="687">

      </canvas></div>
    </div>

    <div id="tip" data-bind="tip">
      <div id="tip-text" data-bind="tipText"></div>
    </div>
    <div id="selected" data-bind="selected">
      <div id="selected-controls" data-bind="selectedControls">
        <a id="selected-toggle" data-bind="selectedToggle" href="#">
          <i class="fas fa-toggle-on"></i>
        </a>
        <span>&nbsp;&nbsp;</span>
        <span id="selected-title" data-bind="selectedTitle"></span>
        <span>&nbsp;&nbsp;</span>
        <span id="selected-current" data-bind="selectedCurrent" data-bind="selectedCurrent">0</span><span> / </span><span id="selected-total" data-bind="selectedTotal">0</span>
        <span>&nbsp;&nbsp;</span>
        <a id="selected-prev" data-bind="selectedPrev" href="#">
          <i class="fas fa-angle-left"></i>
        </a>
        <span>&nbsp;</span>
        <a id="selected-next" data-bind="selectedNext" href="#">
          <i class="fas fa-angle-right"></i>
        </a>
        <a id="selected-remove" data-bind="selectedRemove" href="#">
          <i class="fas fa-times"></i>
        </a>
      </div>
      <div id="selected-container" data-bind="selectedContainer">
      </div>
    </div>
    <div id="controls" data-bind="controls">
      <div id="more-controls" data-bind="moreControls" class="hide">
        <a id="search" data-bind="search" href="#">
          <i class="fas fa-search"></i>
        </a>
        <a id="download" data-bind="download" href="#">
          <i class="fas fa-download"></i>
        </a>
        <a id="export" data-bind="export" href="#">
          <i class="fas fa-camera"></i>
        </a>
        <a id="largepreview" data-bind="largepreview" href="#">
          <i class="fas fa-expand"></i>
        </a>
      </div>
      <a id="show-controls" data-bind="showControls" href="#">
        <i class="fas fa-bars"></i>
      </a>
    </div>
    <div id="hover-indicator" data-bind="hoverIndicator"></div>
    <canvas id="lore"></canvas>

    
    <script>
      const data = {
Approved: {
x: [652.393,190.902,521.164,473.851,237.009,502.704,285.285,416.956,607.271,144.586,298.015,271.141,243.194,366.797,326.692,429.371,92.198,234.329,399.227,471.252,519.446,72.579,206.809,333.686,526.477,478.092,254.358,572.777,535.986,450.835,173.687,710.168,451.606,218.055,493.076,535.724,688.17,382.924,667.496,325.223,91.329,456.287,139.944,283.365,687.968,418.53,246.724,234.464,479.061,355.58,529.675,71.696,269.107,640.856,641.153,617.717,659.336,481.909,615.028,509.417,328.553,431.081,212.148,353.539,82.364,389.288,515.803,636.162,403.415,439.565,310.643,213.97,483.047,439.043,355.431,145.282,540.838,242.355,625.334,615.456,236.67,380.866,117.71,284.838,522.911,562.552,358.563,428.384,208.148,311.026,262.441,218.473,515.676,228.094,144.492,461.676,528.436,220.286,293.305,477.096,557.113,384.312,447.067,532.777,211.161,432.366,285.071,689.474,212.899,448.696,140.396,449.575,375.076,679.387,405.61,494.997,305.854,114.229,616.436,583.857,588.615,296.882,507.32,79.38,84.064,648.842,233.709,408.842,172.444,316.411,679.556,422.42,609.728,393.969,395.123,406.695,652.744,319.807,372.908,544.162,496.689,368.187,241.0,510.071,574.012,580.395,321.041,632.862,227.991,159.461,163.843,389.367,315.563,644.586,227.978,667.007,585.877,612.506,314.18,227.145,671.63,375.362,672.315,670.277,81.509,576.589,277.772,245.743,232.575,431.736,216.434,276.113,388.141,162.928,656.841,241.977,431.382,270.176,167.545,22.184,355.014,318.87,121.829,124.126,672.292,307.175,639.195,459.281,570.403,610.384,216.681,537.612,478.183,144.751,166.709,424.204,407.045,422.801,443.288,234.875,351.189,274.134,235.675,440.597,69.709,158.511,666.522,413.769,449.245,421.053,612.115,53.745,99.692,360.906,501.572,137.512,552.77,523.24,526.671,296.379,539.373,397.478,325.139,319.124,390.11,355.273,227.55,402.104,47.028,249.239,233.915,504.493,397.672,284.933,380.759,449.107,217.824,518.046,456.201,158.616,158.519,545.1,653.066,356.389,623.713,316.181,124.618,572.834,414.689,443.593,322.646,271.663,237.776,226.98,511.071,424.374,348.107,241.709,219.781,276.998,535.994,443.771,527.195,409.304,493.409,118.014,583.037,115.199,588.942,615.951,327.45,116.225,468.828,249.876,69.925,575.073,139.849,196.29,472.96,385.055,265.891,262.243,530.444,380.466,545.781,516.61,294.154,304.993,532.031,258.365,153.184,377.259,393.577,328.101,646.797,465.572,479.738,478.355,447.019,637.546,378.393,314.605,524.362,291.932,404.37,250.106,414.675,446.524,508.763,221.208,369.921,482.761,150.999,325.134,435.161,253.164,441.231,364.098,543.46,264.573,374.89,312.413,288.155,695.337,373.442,610.239,228.282,253.232,317.711,408.51,224.375,25.092,232.7,674.43,673.658,411.981,597.464,274.042,277.933,296.628,491.403,674.929,42.561,472.09,308.084,236.073,321.645,65.963,569.169,626.066,627.295,374.988,354.361,333.076,175.182,372.846,538.091,46.631,602.786,337.348,597.71,562.565,384.617,520.848,444.925,19.957,381.961,460.595,541.176,512.652,603.112,482.963,302.844,69.615,204.345,297.723,609.458,656.271,605.815,186.6,240.96,112.839,210.998,591.887,142.828,655.412,701.505,239.634,471.42,46.028,606.793,693.631,655.884,459.344,457.08,615.014,481.324,613.329,408.502,187.721,281.271,203.595,392.186,162.583,256.573,422.008,515.648,427.364,234.157,562.522,649.79,495.719,617.404,543.207,614.012,654.684,508.274,138.774,700.152,492.807,574.662,380.923,263.721,321.373,605.559,614.383,319.107,67.485,105.609,169.761,690.887,297.967,219.292,181.41,567.203,314.392,17.904,78.176,153.837,374.014,250.03,543.932,145.762,217.717,271.043,178.575,385.197,622.001,374.943,164.266,519.517,633.167,647.817,563.17,101.658,233.211,388.782,85.12,341.005,300.604,681.566,479.74,674.423,205.051,444.056,319.968,268.108,443.903,569.088,187.535,474.744,449.939,239.222,729.37,468.835,425.161,109.121,657.355,289.111,328.617,496.218,318.396,162.249,704.586,276.719,464.96,568.604,350.311,459.662,683.5,428.07,328.129,408.927,434.321,512.477,627.284,232.489,203.756,485.618,90.646,617.373,466.797,361.847,676.101,564.82,632.858,678.067,676.869,569.294,577.265,689.143,482.442,273.146,365.044,445.467,543.492,606.595,173.372,158.875,466.689,367.182,324.914,617.194,571.831,576.33,380.286,460.607,515.697,274.814,387.195,469.3,95.008,459.746,62.378,519.088,160.089,463.358,328.075,206.533,125.495,375.124,146.89,478.713,378.763,574.136,253.81,550.763,609.42,68.69,545.951,381.188,62.606,480.659,238.461,342.825,555.515,285.895,352.929,96.816,365.022,242.354,375.373,501.329,370.06,425.796,474.805,187.543,624.136,216.124,475.246,300.885,435.616,658.023,469.936,289.405,144.106,248.129,490.919,152.455,43.641,643.506,236.919,224.427,419.239,420.836,305.397,650.657,227.578,738.923,514.512,65.959,613.163,279.869,438.744,717.155,670.273,547.59,139.764,115.843,208.343,136.857,542.592,306.491,377.345,240.904,135.644,513.698,644.723,288.522,378.768,86.095,412.116,236.885,668.222,112.294,385.623,433.926,63.112,437.969,447.699,323.488,267.665,430.425,329.401,187.54,703.682,300.7,638.16,281.257,158.349,58.68,135.895,52.618,568.731,609.308,462.789,415.077,327.043,310.323,261.454,231.77,697.02,328.257,562.484,704.41,134.059,188.905,533.968,268.984,159.745,39.881,374.94,165.491,195.262,607.704,55.711,458.411,682.525,74.161,230.339,382.917,545.369,165.747,484.395,481.779,412.684,560.219,75.888,197.695,18.563,195.842,555.529,284.635,237.926,195.641,239.645,238.195,280.053,161.153,288.264,466.522,504.424,494.814,554.656,365.372,261.583,563.109,415.707,373.809,65.438,316.56,750.0,374.99,424.806,98.407,357.116,33.747,286.198,557.713,745.925,634.461,368.451,289.089,468.723,494.083,28.313,370.131,639.074,474.225,235.707,613.494,535.543,84.113,688.088,187.483,103.391,234.276,376.029,73.774,374.91,80.014,579.587,558.166,572.062,374.887,391.012,467.967,491.471,391.057,479.164,515.66,403.097,531.146,392.619,503.463,450.194,587.75,10.352,67.617,427.703,321.125,547.373,219.656,417.407,470.319,698.092,280.28,133.385,511.38,84.303,550.99,484.52,389.499,360.408,439.211,704.232,619.003,62.737,345.871,698.82,438.171,289.607,311.426,372.645,374.975,241.848,685.896,67.722,628.737,644.832,87.418,192.142,476.685,59.685,469.11,253.845,424.961,175.555,462.099,691.051,89.028,614.123,385.075,705.346,645.048,154.242,558.762,542.16,699.383,564.298,564.243,563.2,145.349,65.093,468.788,391.059,699.142,154.147,154.112,514.11,475.204,201.11,3.972,272.948,179.941,145.987,548.136,627.976,550.27,478.559,127.018,116.075,476.298,113.416,31.316,200.096,490.562,487.383,547.044,375.014,557.08,307.495,154.929,353.313,322.933,306.323,442.7,71.59,140.662,223.743,86.632,471.293,689.668,382.472,493.492,697.614,631.632,41.941,235.865,675.691,242.697,185.995,255.217,442.997,608.792,64.099,314.895,127.883,559.209,380.854,235.772,598.031,635.919,260.249,134.015,566.414,167.311,238.606,485.316,84.509,129.953,368.808,441.29,465.366,296.691,552.141,522.387,649.678,144.705,212.855,368.891,286.949,0.0,275.753,229.461,283.021,139.721,241.712,159.234,187.159,612.818,435.045,451.986,605.617,328.812,326.824,587.07,24.956,467.065,696.777,331.608,537.064,111.493,567.578,473.709,503.159,213.828,629.371,372.513,412.329,114.585,259.942,190.807,560.434,701.38,238.628,157.653,706.25,545.071,346.077,138.062,185.702,326.122,701.696,363.217,195.126,673.878,674.766,295.037,202.83,112.463,448.471,452.969,207.992,628.222,117.384,501.001,67.193,470.392,238.553,121.225,468.174,694.365,115.796,510.987,434.942,158.164,192.774,708.037,163.009,475.601,194.7,514.956,399.766,429.618,89.313,64.858,94.245,175.559,634.056,388.399],
y: [449.044,654.41,47.797,212.42,143.187,373.68,634.299,293.513,611.793,460.647,168.393,622.353,203.263,241.208,567.76,633.202,357.021,377.836,467.287,208.352,356.5,259.235,212.066,572.65,671.132,250.917,600.367,103.438,339.455,620.868,533.982,232.782,257.324,186.738,477.671,692.729,358.551,396.739,209.944,571.274,452.693,622.833,435.384,334.242,538.355,285.315,134.728,115.455,667.839,403.993,79.553,262.349,409.713,631.684,219.78,295.925,417.864,606.887,298.424,477.174,209.093,488.026,152.996,231.621,165.907,165.678,67.342,587.69,555.6,620.758,190.51,186.621,390.242,646.481,413.381,230.127,507.649,705.596,590.041,577.561,711.961,247.402,452.52,638.148,355.846,624.685,405.42,77.706,150.559,72.17,710.924,212.568,667.678,163.196,464.976,501.839,139.231,545.17,547.117,235.935,117.65,287.361,613.612,342.665,212.359,190.835,537.159,459.785,273.717,266.355,247.26,107.227,109.383,456.897,393.158,608.475,521.261,191.363,308.028,626.533,598.251,387.435,528.193,247.536,248.042,552.47,715.526,286.316,355.366,562.626,391.449,102.605,225.755,187.339,731.685,457.993,574.342,35.179,477.611,136.451,568.72,446.974,678.446,683.933,160.88,92.157,668.07,631.985,667.577,112.461,110.837,474.194,486.306,629.461,212.597,453.232,263.02,665.584,553.259,215.628,213.637,480.241,183.021,194.78,185.833,175.433,405.348,367.24,657.921,295.433,158.931,291.943,145.266,290.045,572.795,350.952,391.126,577.224,260.937,389.827,307.404,47.801,245.529,407.445,205.153,190.878,211.11,391.393,146.616,381.858,626.546,697.376,487.313,443.744,296.619,193.142,724.635,438.917,610.879,120.399,423.112,406.805,278.283,538.218,151.57,435.256,557.083,450.121,623.529,720.067,300.933,278.102,188.18,402.631,473.884,155.287,513.047,65.593,134.473,164.598,393.535,464.521,214.409,221.714,187.711,322.62,551.417,469.335,284.228,697.974,284.534,477.697,653.633,286.306,482.436,249.738,547.625,353.204,391.79,290.119,107.78,397.717,570.939,327.967,632.548,662.076,589.325,190.81,197.706,535.938,671.581,580.678,263.251,186.583,364.991,283.783,82.409,362.536,157.63,419.291,242.945,544.676,348.378,456.259,643.368,252.113,176.535,472.03,262.914,653.247,3.356,463.763,745.684,198.414,470.339,177.968,431.771,649.175,229.081,569.614,342.024,714.378,135.873,390.077,382.091,262.393,541.946,181.769,683.618,611.465,124.133,491.959,563.259,196.254,231.903,689.881,595.161,385.663,609.335,218.312,661.444,69.46,44.686,334.233,726.689,601.566,546.767,538.033,688.208,352.702,337.374,588.92,225.951,8.903,708.853,128.728,642.105,92.827,499.957,299.632,193.683,549.361,551.24,532.921,679.043,232.583,663.439,604.36,62.179,389.521,187.465,397.191,381.732,166.287,173.495,644.294,278.599,415.893,733.95,59.817,646.447,381.793,285.815,585.905,654.18,629.923,218.822,153.869,100.247,669.11,419.288,675.226,316.771,72.423,654.268,77.842,92.487,472.177,460.419,575.078,607.192,628.405,665.23,141.83,637.318,382.267,250.522,253.463,390.962,253.105,616.615,610.426,334.026,156.021,617.604,334.076,386.036,467.784,460.381,382.244,447.601,194.648,544.063,601.564,151.147,447.702,213.413,345.621,519.124,288.15,382.203,576.111,568.223,387.67,255.033,233.244,251.38,230.121,645.805,657.562,529.68,541.035,733.446,434.721,125.406,285.898,258.621,91.676,288.359,633.613,450.827,564.626,312.859,650.678,633.449,459.531,247.574,229.927,354.051,567.266,479.434,201.763,343.843,364.694,659.729,650.859,44.495,462.568,222.68,290.748,361.668,645.102,153.963,266.866,115.891,59.305,378.462,188.275,254.818,340.002,194.145,385.72,138.115,622.463,724.152,286.297,661.675,662.305,113.926,300.097,657.28,397.042,548.029,116.151,222.514,242.102,211.696,419.069,220.988,59.731,402.07,416.883,216.317,448.085,525.65,662.502,412.656,549.304,205.119,648.2,383.426,699.835,628.302,391.047,750.0,435.736,383.746,473.838,636.359,186.833,645.543,199.446,107.408,399.589,287.909,326.432,104.582,308.407,624.662,574.971,82.467,199.773,394.118,392.865,676.806,581.732,429.139,643.615,391.982,439.964,301.321,507.493,250.244,391.835,132.617,586.308,546.514,385.384,473.741,159.698,381.733,316.326,710.72,253.009,633.573,129.14,287.004,550.478,662.947,703.979,188.715,364.735,582.379,476.135,96.546,570.661,497.599,251.871,579.053,125.126,319.264,367.587,508.654,269.712,65.942,431.128,509.278,366.182,453.022,174.509,189.289,151.07,607.053,386.012,484.029,199.656,201.006,405.046,467.015,145.961,286.447,550.703,410.042,272.106,469.223,114.808,282.438,419.425,235.48,408.604,681.375,500.608,477.219,341.492,103.58,589.491,379.234,301.161,272.84,231.814,174.352,389.416,477.362,514.968,749.764,147.274,370.539,606.654,439.743,475.938,216.462,371.359,665.164,443.994,716.56,555.353,560.228,634.808,388.41,145.39,548.754,405.11,292.436,189.129,393.832,573.306,655.167,226.277,256.047,620.527,233.981,647.886,334.034,201.29,143.286,152.315,476.765,633.706,57.416,669.404,427.351,392.34,431.477,553.562,217.31,737.257,523.707,545.298,524.423,245.49,493.022,299.285,89.228,0.0,353.347,354.155,477.501,206.534,535.991,357.3,269.982,572.655,446.285,281.381,657.016,512.894,304.042,375.859,552.953,293.342,632.168,461.822,190.953,236.468,344.783,582.168,516.759,686.803,710.829,562.713,431.092,511.944,356.133,538.57,463.328,467.592,107.742,398.374,514.649,286.326,741.229,101.366,659.287,584.982,401.127,286.207,388.127,246.334,346.16,414.999,482.828,207.436,553.247,342.028,364.886,429.55,266.923,525.397,532.13,631.951,18.072,44.47,604.316,389.181,248.127,303.5,638.698,299.973,335.824,521.678,482.927,384.774,117.506,88.893,367.775,95.452,409.497,335.971,385.409,386.197,384.914,250.583,287.068,728.885,36.301,416.016,190.987,223.114,515.61,129.687,394.596,240.156,437.196,216.432,533.18,375.676,140.734,74.788,163.059,190.775,170.998,272.213,120.932,280.405,660.289,208.652,717.442,34.463,183.838,421.059,52.96,204.133,77.022,213.451,391.393,271.147,242.62,413.801,485.197,536.719,24.802,401.622,349.843,715.97,19.808,574.527,55.568,423.442,528.467,162.366,510.38,29.604,477.2,94.833,110.062,340.11,405.518,273.623,473.498,224.53,106.286,284.057,57.291,502.232,507.783,708.95,400.344,505.737,302.735,227.695,439.259,499.329,24.322,548.094,15.69,195.424,107.185,446.278,319.555,218.576,435.45,660.989,212.148,395.063,220.758,223.203,391.676,503.36,350.191,516.764,220.055,289.181,572.714,508.237,738.465,565.349,530.025,357.937,120.752,365.99,207.945,354.504,412.728,727.323,535.148,576.337,197.431,585.73,658.241,381.842,237.222,394.325,318.316,596.6,412.329,466.468,311.776,313.836,104.279,106.157,204.222,480.709,665.027,310.975,16.087,477.301,188.023,511.313,440.374,550.297,181.829,496.712,535.055,573.186,381.805,578.574,406.577,472.351,207.993,202.49,451.561,355.816,611.093,304.485,222.294,534.551,73.706,172.244,513.58,737.708,658.667,275.325,436.693,306.744,419.183,286.329,532.947,139.355,480.896,414.441,421.14,410.603,104.841,108.295,477.167,208.323,391.667,570.068,453.415,627.779,84.875,746.457,412.016,54.505,427.22,741.063,572.725,441.634,566.598,280.519,580.356,618.799,274.386,614.446,570.802,361.336,177.227,401.007,330.395,214.422,198.831,89.834,222.117,518.856,110.632,41.558,623.188,416.973,73.517,111.414,476.688,289.375,373.337,214.251,462.931,440.449,534.099,229.899,142.517,469.963,442.813,535.93,371.804,396.592,333.351,273.407,574.488,161.971,538.153,445.808,213.673,256.304,312.455,456.469,673.05,594.246,527.897,488.657,109.172,362.909,589.985,706.792,366.362,454.97,147.78,622.33,529.437,335.523,341.977,565.068,222.543,339.472,49.668,118.532,485.111,180.982,460.315,361.181,354.557,389.442,215.799],
z: [375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0],
labels: ['CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1__Name: Lupron__Applicant: TAP Pharmaceuticals__Active moiety: leuprolide acetate__Approval Year: 1985__Route: Injection__logP: -1.2__MW: 1209.4__Class: Carboxylic acids and derivatives','CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1__Name: Seldane__Applicant: Merrell-Dow__Active moiety: terfenadine__Approval Year: 1985__Route: Oral__logP: 6.4__MW: 471.7__Class: Benzene and substituted derivatives','CC(=O)OC[C@H]1O[C@@H]([S-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O.CC[PH+](CC)CC.[Au]__Name: Ridaura__Applicant: SmithKline & French__Active moiety: auranofin__Approval Year: 1985__Route: Oral__logP: 1.9__MW: 679.5__Class: Carboxylic acids and derivatives','CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21__Name: Marinol__Applicant: Unimed__Active moiety: dronabinol__Approval Year: 1985__Route: Oral__logP: 5.7__MW: 314.5__Class: Benzopyrans','CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O__Name: Fortaz__Applicant: Glaxo__Active moiety: ceftazidime__Approval Year: 1985__Route: Injection__logP: -1.3__MW: 546.6__Class: Lactams','CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO__Name: Hexabrix__Applicant: Mallinckrodt__Active moiety: ioxaglate meglumine, ioxaglate sodium__Approval Year: 1985__Route: Injection__logP: 0.1__MW: 1464.1__Class: Benzene and substituted derivatives','Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1__Name: Sulcosyn__Applicant: Syntex__Active moiety: sulconazole nitrate__Approval Year: 1985__Route: Topical__logP: 6.5__MW: 397.8__Class: Benzene and substituted derivatives','CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1__Name: Betoptic__Applicant: Alcon__Active moiety: betaxolol hydrochloride__Approval Year: 1985__Route: Ophthalmic__logP: 2.4__MW: 307.4__Class: Phenols','CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC.CCCCCCCC(=O)OCC(O)CO.CCCCCCCCCC(=O)OCC(O)CO.OCC(O)CO__Name: Moctanin__Applicant: Ascot Hospital__Active moiety: monooctanoin__Approval Year: 1985__Route: Perfusion, Biliary__logP: 5.8__MW: 901.2__Class: Glycerolipids','O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F__Name: Tambocor__Applicant: Riker__Active moiety: flecainide acetate__Approval Year: 1985__Route: Oral__logP: 3.4__MW: 414.3__Class: Benzene and substituted derivatives','NCCNCCNCCN__Name: Cuprid__Applicant: Merck Sharp & Dohme__Active moiety: trientine hydrochloride__Approval Year: 1985__Route: Oral__logP: -1.9__MW: 146.2__Class: Organonitrogen compounds','Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1__Name: Femstat__Applicant: Syntex__Active moiety: butoconazole nitrate__Approval Year: 1985__Route: Vaginal__logP: 6.6__MW: 411.8__Class: Benzene and substituted derivatives','C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12__Name: Primaxin__Applicant: Merck Sharp & Dohme__Active moiety: cilastatin sodium, imipenem__Approval Year: 1985__Route: Intravenous__logP: -0.2__MW: 299.4__Class: Lactams','CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O__Name: Betagan__Applicant: Allergan__Active moiety: levobunolol hydrochloride__Approval Year: 1985__Route: Ophthalmic__logP: 2.3__MW: 291.4__Class: Tetralins','Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2__Name: Versed__Applicant: Hoffmann-La Roche__Active moiety: midazolam hydrochloride__Approval Year: 1985__Route: Injection__logP: 4.3__MW: 325.8__Class: Benzodiazepines','CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1__Name: Suprol__Applicant: Ortho__Active moiety: suprofen__Approval Year: 1985__Route: Oral__logP: 3.2__MW: 260.3__Class: Organooxygen compounds','[111In+3].[O-]c1cccc2cccnc12.[O-]c1cccc2cccnc12.[O-]c1cccc2cccnc12__Name: indium In 111 Oxyquinoline__Applicant: Amersham__Active moiety: indium In 111 oxyquinoline__Approval Year: 1985__Route: Injection__logP: 3.5__MW: 543.4__Class: Quinolines and derivatives','CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1__Name: Cordarone__Applicant: Ives__Active moiety: amiodarone hydrochloride__Approval Year: 1985__Route: Oral__logP: 6.9__MW: 645.3__Class: Organooxygen compounds','CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O__Name: Vasotec__Applicant: Merck Sharp & Dohme__Active moiety: enalapril maleate__Approval Year: 1985__Route: Oral__logP: 1.6__MW: 376.5__Class: Carboxylic acids and derivatives','CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21__Name: Cesamet__Applicant: Eli Lilly__Active moiety: nabilone__Approval Year: 1985__Route: Oral__logP: 6.3__MW: 372.5__Class: Naphthopyrans','CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I__Name: Omnipaque__Applicant: Sterling__Active moiety: iohexol__Approval Year: 1985__Route: Injection, Oral, Rectal__logP: -1.6__MW: 821.1__Class: Benzene and substituted derivatives','CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C__Name: Temovate__Applicant: Glaxo__Active moiety: clobetasol propionate__Approval Year: 1985__Route: Topical__logP: 4.1__MW: 467.0__Class: Steroids and steroid derivatives','CO[C@@]1(NC(=O)C2SC(=C(C(N)=O)C(=O)[O-])S2)C(=O)N2C(C(=O)[O-])=C(CSc3nnnn3C)CS[C@@H]21__Name: Cefotan__Applicant: Stuart__Active moiety: cefotetan disodium__Approval Year: 1985__Route: Injection__logP: -4.1__MW: 573.6__Class: Lactams','Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21__Name: Dormalin__Applicant: Schering__Active moiety: quazepam__Approval Year: 1985__Route: Oral__logP: 5.0__MW: 386.8__Class: Benzodiazepines','C[N+](C)(C)C[C@H](O)CC(=O)[O-]__Name: Carnitor__Applicant: Sigma-Tau__Active moiety: L-carnitine__Approval Year: 1985__Route: Oral__logP: -1.8__MW: 161.2__Class: Organonitrogen compounds','Cc1cccc(C)c1OCC(C)N__Name: Mexitil__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: mexiletine hydrochloride__Approval Year: 1985__Route: Oral__logP: 2.0__MW: 179.3__Class: Phenol ethers','CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1__Name: Wellbutrin__Applicant: Burroughs Wellcome__Active moiety: bupropion hydrochloride__Approval Year: 1985__Route: Oral__logP: 3.3__MW: 239.7__Class: Organooxygen compounds','NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1__Name: Virazole__Applicant: Viratek__Active moiety: ribavirin__Approval Year: 1985__Route: Inhalation__logP: -3.0__MW: 244.2__Class: Triazole ribonucleosides and ribonucleotides','C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I__Name: Isovue__Applicant: Squibb__Active moiety: iopamidol__Approval Year: 1985__Route: Injection__logP: -1.0__MW: 777.1__Class: Benzene and substituted derivatives','CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1__Name: Orudis__Applicant: Wyeth__Active moiety: ketoprofen__Approval Year: 1986__Route: Oral__logP: 3.1__MW: 254.3__Class: Benzene and substituted derivatives','CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1__Name: Nix__Applicant: Burroughs Wellcome__Active moiety: permethrin__Approval Year: 1986__Route: Topical__logP: 6.1__MW: 391.3__Class: Fatty Acyls','O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1__Name: Buspar__Applicant: Bristol-Myers__Active moiety: buspirone hydrochloride__Approval Year: 1986__Route: Oral__logP: 2.1__MW: 385.5__Class: Diazinanes','CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C__Name: Tegison__Applicant: Hoffmann-La Roche__Active moiety: etretinate__Approval Year: 1986__Route: Oral__logP: 5.6__MW: 354.5__Class: Prenol lipids','NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1__Name: Pepcid__Applicant: Merck Sharp & Dohme__Active moiety: famotidine__Approval Year: 1986__Route: Oral__logP: -0.8__MW: 337.5__Class: Azoles','N=C(N)NC(=O)Cc1c(Cl)cccc1Cl__Name: Tenex__Applicant: Robins__Active moiety: guanfacine hydrochloride__Approval Year: 1986__Route: Oral__logP: 1.5__MW: 246.1__Class: Benzene and substituted derivatives','CC(=O)OC(C)C[N+](C)(C)C__Name: Provocholine__Applicant: Hoffmann-La Roche__Active moiety: methacholine chloride__Approval Year: 1986__Route: Inhalation__logP: 0.6__MW: 160.2__Class: Organonitrogen compounds','CC(C)CC(NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1)C(C)C)C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(CCCNC(=N)N)C(=O)NC(C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(=O)N1CCCC1C(N)=O)C(C)O)C(C)O)C(C)O)C(C)O__Name: Cibacalcin__Applicant: Ciba-Geigy__Active moiety: calcitonin (human)__Approval Year: 1986__Route: Injection__logP: -21.5__MW: 3431.9__Class: Polypeptides','Cc1cccc(C)c1NC(=O)CN(CC(=O)[O-])CC(=O)[O-].[Tc+4]__Name: Technescan Hida__Applicant: Merck Sharp & Dohme__Active moiety: technetium Tc-99m lidofenin__Approval Year: 1986__Route: Injection__logP: -2.0__MW: 390.3__Class: Carboxylic acids and derivatives','CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21__Name: Noroxin__Applicant: Merck Sharp & Dohme__Active moiety: norfloxacin__Approval Year: 1986__Route: Oral__logP: 1.3__MW: 319.3__Class: Quinolines and derivatives','CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1__Name: Lamprene__Applicant: Ciba-Geigy__Active moiety: clofazimine__Approval Year: 1986__Route: Oral__logP: 7.5__MW: 473.4__Class: Diazanaphthalenes','COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1__Name: Enkaid__Applicant: Bristol-Myers__Active moiety: encainide hydrochloride__Approval Year: 1986__Route: Oral__logP: 4.4__MW: 352.5__Class: Benzene and substituted derivatives','CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2__Name: Atrovent__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: ipratropium bromide__Approval Year: 1986__Route: Inhalation__logP: 2.9__MW: 332.5__Class: Tropane alkaloids','CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1__Name: Alfenta__Applicant: Janssen__Active moiety: alfentanil hydrochloride__Approval Year: 1986__Route: Injection__logP: 1.4__MW: 416.5__Class: Benzene and substituted derivatives','CC(C)(C)NCC(O)c1ccc(O)c(CO)n1__Name: Exirel__Applicant: Pfizer__Active moiety: pirbuterol acetate__Approval Year: 1986__Route: Inhalation__logP: 0.7__MW: 240.3__Class: Benzene and substituted derivatives','NC[C@H]1CC[C@H](C(=O)O)CC1__Name: Cyklokapron__Applicant: KabiVitrum__Active moiety: tranexamic acid__Approval Year: 1986__Route: Oral__logP: 0.8__MW: 157.2__Class: Carboxylic acids and derivatives','COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1__Name: Brevibloc__Applicant: DuPont__Active moiety: esmolol hydrochloride__Approval Year: 1986__Route: Injection__logP: 1.5__MW: 295.4__Class: Phenol ethers','C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O__Name: Azactam__Applicant: Squibb__Active moiety: aztreonam__Approval Year: 1986__Route: Injection__logP: -1.2__MW: 435.4__Class: Lactams','CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C__Name: Unasyn__Applicant: Pfizer__Active moiety: sulbactam sodium, ampicillin sodium__Approval Year: 1986__Route: Injection__logP: -0.6__MW: 594.7__Class: Lactams','CC(C(=O)[O-])c1ccc(-c2ccccc2)c(F)c1__Name: Ocufen__Applicant: Allergan__Active moiety: flurbiprofen sodium__Approval Year: 1986__Route: Ophthalmic__logP: 2.3__MW: 243.3__Class: Benzene and substituted derivatives','Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br__Name: Choletec__Applicant: Squibb__Active moiety: technetium Tc-99m mebrofenin__Approval Year: 1987__Route: Injection__logP: 1.8__MW: 387.2__Class: Carboxylic acids and derivatives','Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O__Name: Retrovir__Applicant: Burroughs Wellcome__Active moiety: zidovudine__Approval Year: 1987__Route: Oral__logP: -0.2__MW: 267.2__Class: Pyrimidine nucleosides','C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl__Name: Elocon__Applicant: Schering__Active moiety: mometasone furoate__Approval Year: 1987__Route: Topical__logP: 4.9__MW: 521.4__Class: Steroids and steroid derivatives','COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC__Name: Hytrin__Applicant: Abbott Laboratories__Active moiety: terazosin hydrochloride__Approval Year: 1987__Route: Oral__logP: 1.1__MW: 387.4__Class: Diazinanes','CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21__Name: Mevacor__Applicant: Merck Sharp & Dohme__Active moiety: lovastatin__Approval Year: 1987__Route: Oral__logP: 4.2__MW: 404.5__Class: Lactones','O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O__Name: Cipro__Applicant: Miles__Active moiety: ciprofloxacin hydrochloride__Approval Year: 1987__Route: Oral__logP: 1.6__MW: 331.3__Class: Quinolines and derivatives','O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21__Name: Novantrone__Applicant: Lederle__Active moiety: mitoxantrone hydrochloride__Approval Year: 1987__Route: Injection__logP: -0.1__MW: 444.5__Class: Anthracenes','CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C__Name: Parathar__Applicant: Rorer__Active moiety: teriparatide acetate__Approval Year: 1987__Route: Injection__logP: -15.2__MW: 4117.8__Class: nan','O=C(O)Cc1ccccc1__Name: Ucephan__Applicant: Kendall McGaw__Active moiety: sodium phenylacetate, sodium benzoate__Approval Year: 1987__Route: Oral__logP: 1.3__MW: 136.1__Class: Benzene and substituted derivatives','Nc1ccc(O)c(C(=O)O)c1__Name: Rowasa__Applicant: Reid-Rowell__Active moiety: mesalamine__Approval Year: 1987__Route: Rectal__logP: 0.7__MW: 153.1__Class: Benzene and substituted derivatives','CC(C)NC(C)Cc1ccc([123I])cc1__Name: Spectamine__Applicant: Medi-Physics__Active moiety: iofetamine hydrochloride  I 123__Approval Year: 1987__Route: Injection__logP: 3.2__MW: 299.2__Class: Benzene and substituted derivatives','CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1__Name: Prozac__Applicant: Eli Lilly__Active moiety: fluoxetine hydrochloride__Approval Year: 1987__Route: Oral__logP: 4.4__MW: 309.3__Class: Benzene and substituted derivatives','NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O__Name: Prinivil__Applicant: Merck Sharp & Dohme__Active moiety: lisinopril__Approval Year: 1987__Route: Oral__logP: 1.2__MW: 405.5__Class: Carboxylic acids and derivatives','CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@H]12)c1csc(N)n1__Name: Cefmax__Applicant: TAP Pharmaceuticals__Active moiety: cefmenoxime hydrochloride__Approval Year: 1987__Route: Injection__logP: -0.9__MW: 511.6__Class: Lactams','CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1.CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1__Name: Levatol__Applicant: Eli Lilly__Active moiety: penbutolol sulfate__Approval Year: 1987__Route: Oral__logP: 6.9__MW: 582.9__Class: Phenol ethers','C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C__Name: Deursil__Applicant: Gipharmex__Active moiety: ursodiol__Approval Year: 1987__Route: Oral__logP: 4.5__MW: 392.6__Class: Steroids and steroid derivatives','CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1__Name: Terazol 7__Applicant: Ortho__Active moiety: terconazole__Approval Year: 1987__Route: Vaginal__logP: 4.5__MW: 532.5__Class: Diazinanes','CC(O)C(=O)O.Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1__Name: Corotrope__Applicant: Sterling-Winthrop__Active moiety: milrinone lactate__Approval Year: 1987__Route: Injection__logP: 1.1__MW: 301.3__Class: Pyridines and derivatives','C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O__Name: Bactroban__Applicant: Beecham__Active moiety: mupirocin__Approval Year: 1987__Route: Topical__logP: 2.6__MW: 500.6__Class: Fatty Acyls','Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1__Name: Iopidine__Applicant: Alcon__Active moiety: apraclonidine hydrochloride__Approval Year: 1987__Route: Ophthalmic__logP: 1.8__MW: 245.1__Class: Benzene and substituted derivatives','CC(C(=O)O)c1ccc2c(c1)[nH]c1ccc(Cl)cc12__Name: Rimadyl__Applicant: Hoffmann-La Roche__Active moiety: carprofen__Approval Year: 1987__Route: Oral__logP: 4.2__MW: 273.7__Class: Indoles and derivatives','CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12__Name: Naftin__Applicant: Herbert Labs__Active moiety: naftifine hydrochloride__Approval Year: 1988__Route: Topical__logP: 5.0__MW: 287.4__Class: Naphthalenes','CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1__Name: Axid__Applicant: Eli Lilly__Active moiety: nizatidine__Approval Year: 1988__Route: Oral__logP: 1.3__MW: 331.5__Class: Azoles','CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)O)CCN(CC(=O)[O-])CC(=O)O.[Gd+3]__Name: Magnevist__Applicant: Berlex__Active moiety: gadopentetate dimeglumine__Approval Year: 1988__Route: Injection__logP: -13.4__MW: 938.0__Class: Carboxylic acids and derivatives','O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl__Name: Voltaren__Applicant: Ciba__Active moiety: diclofenac sodium__Approval Year: 1988__Route: Oral__logP: 3.0__MW: 295.1__Class: Benzene and substituted derivatives','CC(S)C(=O)NCC(=O)O__Name: Thiola__Applicant: Mission Pharmacal__Active moiety: tiopronin__Approval Year: 1988__Route: Oral__logP: -0.5__MW: 163.2__Class: Carboxylic acids and derivatives','CCCCC(CC)COC(=O)c1ccc(N(C)C)cc1__Name: Photoplex__Applicant: Herbert Labs__Active moiety: avobenzone, padimate-O__Approval Year: 1988__Route: Topical__logP: 4.1__MW: 277.4__Class: Benzene and substituted derivatives','C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O__Name: Sandostatin__Applicant: Sandoz__Active moiety: octreotide acetate__Approval Year: 1988__Route: Injection__logP: -0.8__MW: 1019.3__Class: Carboxylic acids and derivatives','COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1__Name: Cardene__Applicant: Syntex__Active moiety: nicardipine hydrochloride__Approval Year: 1988__Route: Oral__logP: 3.7__MW: 479.5__Class: Pyridines and derivatives','CCCCCCCC/C=C\CCCCCCCC(=O)O.NCCO__Name: Ethamolin__Applicant: Glaxo__Active moiety: ethanolamine oleate__Approval Year: 1988__Route: Injection__logP: 5.0__MW: 343.6__Class: Fatty Acyls','CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC__Name: Cytotec__Applicant: Searle__Active moiety: misoprostol__Approval Year: 1988__Route: Oral__logP: 4.0__MW: 382.5__Class: Fatty Acyls','COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1__Name: Nimotop__Applicant: Miles__Active moiety: nimodipine__Approval Year: 1988__Route: Oral__logP: 3.0__MW: 418.4__Class: Pyridines and derivatives','CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2__Name: Cartrol__Applicant: Abbott Laboratories__Active moiety: carteolol hydrochloride__Approval Year: 1988__Route: Oral__logP: 1.7__MW: 292.4__Class: Quinolines and derivatives','COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1__Name: Hismanal__Applicant: Janssen__Active moiety: astemizole__Approval Year: 1988__Route: Oral__logP: 5.4__MW: 458.6__Class: Benzimidazoles','Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1__Name: Oxistat__Applicant: Glaxo__Active moiety: oxiconazole nitrate__Approval Year: 1988__Route: Topical__logP: 6.1__MW: 429.1__Class: Benzene and substituted derivatives','O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I__Name: Optiray__Applicant: Mallinckrodt__Active moiety: ioversol__Approval Year: 1988__Route: Injection__logP: -2.0__MW: 807.1__Class: Benzene and substituted derivatives','O=P1(NCCCl)OCCCN1CCCl__Name: Ifex__Applicant: Bristol-Myers__Active moiety: ifosfamide__Approval Year: 1988__Route: Injection__logP: 1.9__MW: 261.1__Class: Oxazaphosphinanes','Cc1cccc(C)c1NC(=O)CN(CC(=O)O)CC(=O)O.[99Tc]__Name: Ceretec__Applicant: Amersham__Active moiety: technetium Tc-99m exametazime__Approval Year: 1988__Route: Injection__logP: 0.7__MW: 393.2__Class: Organonitrogen compounds','O=S(=O)([O-])CCS__Name: Mesnex__Applicant: Asta__Active moiety: mesna__Approval Year: 1988__Route: Intravenous__logP: -0.5__MW: 141.2__Class: Organic sulfonic acids and derivatives','CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1__Name: Ceradon__Applicant: Takeda__Active moiety: cefotiam hydrochloride__Approval Year: 1988__Route: Injection__logP: -0.7__MW: 525.6__Class: Lactams','CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21__Name: Permax__Applicant: Eli Lilly__Active moiety: pergolide mesylate__Approval Year: 1988__Route: Oral__logP: 4.3__MW: 314.5__Class: Quinolines and derivatives','CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1__Name: Eulexin__Applicant: Schering__Active moiety: flutamide__Approval Year: 1989__Route: Oral__logP: 3.2__MW: 276.2__Class: Benzene and substituted derivatives','Cc1cc(O)c(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)[O-])=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)cn1__Name: Cefpiramide__Applicant: Wyeth-Ayerst__Active moiety: cefpiramide sodium__Approval Year: 1989__Route: Injection__logP: -1.0__MW: 611.6__Class: Carboxylic acids and derivatives','O=C([O-])C1(C(=O)[O-])CCC1.[Pt+2]__Name: Paraplatin__Applicant: Bristol-Myers__Active moiety: carboplatin__Approval Year: 1989__Route: Injection__logP: -2.3__MW: 337.2__Class: Carboxylic acids and derivatives','C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC(=O)O)c3csc(N)n3)[C@H]2SC1__Name: Suprax__Applicant: Lederle__Active moiety: cefixime__Approval Year: 1989__Route: Oral__logP: -0.5__MW: 453.5__Class: Lactams','OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1__Name: Lariam__Applicant: Department of the Army__Active moiety: mefloquine hydrochloride__Approval Year: 1989__Route: Oral__logP: 4.4__MW: 378.3__Class: Quinolines and derivatives','C#CCN(C)[C@H](C)Cc1ccccc1__Name: Eldepryl__Applicant: Somerset__Active moiety: selegiline hydrochloride__Approval Year: 1989__Route: Oral__logP: 2.2__MW: 187.3__Class: Benzene and substituted derivatives','Nc1nc([O-])c2ncn(COC(CO)CO)c2n1__Name: Cytovene__Applicant: Syntex__Active moiety: ganciclovir sodium__Approval Year: 1989__Route: Injection__logP: -2.2__MW: 254.2__Class: Imidazopyrimidines','COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1__Name: Losec__Applicant: Merck Sharp & Dohme__Active moiety: omeprazole__Approval Year: 1989__Route: Oral__logP: 2.9__MW: 345.4__Class: Benzimidazoles','CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1__Name: Clozaril__Applicant: Sandoz__Active moiety: clozapine__Approval Year: 1989__Route: Oral__logP: 3.7__MW: 326.8__Class: Benzodiazepines','CC(C)c1cccc(C(C)C)c1O__Name: Diprivan__Applicant: ICI__Active moiety: propofol__Approval Year: 1989__Route: Injection__logP: 3.6__MW: 178.3__Class: Benzene and substituted derivatives','Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O__Name: Adenocard__Applicant: Medco__Active moiety: adenosine__Approval Year: 1989__Route: Injection__logP: -2.0__MW: 267.2__Class: Purine nucleosides','CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1__Name: Rythmol__Applicant: Knoll__Active moiety: propafenone hydrochloride__Approval Year: 1989__Route: Oral__logP: 3.2__MW: 341.5__Class: Linear 13-diarylpropanoids','NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O__Name: Toradol__Applicant: Syntex__Active moiety: ketorolac tromethamine__Approval Year: 1989__Route: Injection__logP: -0.0__MW: 376.4__Class: Organooxygen compounds','CN(C(=O)CC(=O)N(C)c1c(I)c(C(=O)NC(CO)C(O)CO)c(I)c(C(=O)NC(CO)C(O)CO)c1I)c1c(I)c(C(=O)NC(CO)C(O)CO)c(I)c(C(=O)NC(CO)C(O)CO)c1I__Name: Osmovist__Applicant: Berlex__Active moiety: iotrolan__Approval Year: 1989__Route: Intrathecal__logP: -3.9__MW: 1626.2__Class: Benzene and substituted derivatives','CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)[O-])=C(CSc3nnnn3C)CS[C@@H]21__Name: Zefazone__Applicant: Upjohn__Active moiety: cefmetazole sodium__Approval Year: 1989__Route: Injection__logP: -2.1__MW: 470.5__Class: Carboxylic acids and derivatives','CC(N/C(=N\C#N)Nc1ccncc1)C(C)(C)C__Name: Pindac__Applicant: Eli Lilly__Active moiety: pinacidil__Approval Year: 1989__Route: Oral__logP: 2.4__MW: 245.3__Class: Pyridines and derivatives','CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21__Name: Anafranil__Applicant: Ciba-Geigy__Active moiety: clomipramine hydrochloride__Approval Year: 1989__Route: Oral__logP: 4.5__MW: 314.9__Class: Benzazepines','CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O__Name: Zoladex__Applicant: ICI__Active moiety: goserelin acetate__Approval Year: 1989__Route: Implantation__logP: -2.9__MW: 1269.4__Class: Carboxylic acids and derivatives','C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N__Name: Dalgan__Applicant: Wyeth-Ayerst__Active moiety: dezocine__Approval Year: 1989__Route: Injection__logP: 3.1__MW: 245.4__Class: Tetralins','CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C__Name: Betamet__Applicant: Bausch & Lomb__Active moiety: metipranolol hydrochloride__Approval Year: 1989__Route: Ophthalmic__logP: 2.3__MW: 309.4__Class: Phenol esters','C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC__Name: Ortho Cyclen__Applicant: RW Johnson__Active moiety: norgestimate, ethinyl estradiol__Approval Year: 1989__Route: Oral__logP: 4.7__MW: 369.5__Class: Steroids and steroid derivatives','CC(C)NCCCC1(C(N)=O)c2ccccc2-c2ccccc21__Name: Decabid__Applicant: Eli Lilly__Active moiety: indecainide hydrochloride__Approval Year: 1989__Route: Oral__logP: 3.2__MW: 308.4__Class: Fluorenes','OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F__Name: Diflucan__Applicant: Pfizer__Active moiety: fluconazole__Approval Year: 1990__Route: Oral__logP: 0.7__MW: 306.3__Class: Benzene and substituted derivatives','CC(C)C[C@H](NC(=O)[C@@H](Cc1cccc2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O__Name: Synarel__Applicant: Syntex__Active moiety: nafarelin acetate__Approval Year: 1990__Route: Nasal__logP: -1.4__MW: 1322.5__Class: Polypeptides','O=C([O-])CN=C([O-])CN=C([O-])CN=C([O-])C[S-].[Tc]__Name: TechneScan MAG3__Applicant: Mallinckrodt__Active moiety: technetium Tc-99m mertiatide__Approval Year: 1990__Route: Injection__logP: -5.4__MW: 356.2__Class: Carboxylic acids and derivatives','c1ccc([C@H]2CN3CCSC3=N2)cc1__Name: Ergamisol__Applicant: Janssen__Active moiety: levamisole hydrochloride__Approval Year: 1990__Route: Oral__logP: 2.1__MW: 204.3__Class: Imidazothiazoles','CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2__Name: Ethmozine__Applicant: DuPont__Active moiety: moricizine hydrochloride__Approval Year: 1990__Route: Oral__logP: 4.1__MW: 427.5__Class: Benzothiazines','CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1__Name: Arduan__Applicant: Organon__Active moiety: pipecuronium bromide__Approval Year: 1990__Route: Injection__logP: 3.6__MW: 602.9__Class: Steroids and steroid derivatives','O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O__Name: Dipentum__Applicant: Pharmacia__Active moiety: olsalazine sodium__Approval Year: 1990__Route: Oral__logP: 0.2__MW: 300.2__Class: Azobenzenes','CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC__Name: Exosurf__Applicant: Burroughs Wellcome__Active moiety: colfosceril palmitate, cetyl alcohol, tyloxapol__Approval Year: 1990__Route: Intratracheal__logP: 11.2__MW: 735.1__Class: Glycerophospholipids','CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O__Name: Idamycin__Applicant: Adria__Active moiety: idarubicin hydrochloride__Approval Year: 1990__Route: Injection__logP: 1.0__MW: 497.5__Class: Anthracyclines','COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC__Name: Cardura__Applicant: Pfizer__Active moiety: doxazosin mesylate__Approval Year: 1990__Route: Oral__logP: 1.7__MW: 451.5__Class: Diazinanes','NCCCC(N)(C(=O)O)C(F)F__Name: Ornidyl__Applicant: Marion Merrell Dow__Active moiety: eflornithine hydrochloride__Approval Year: 1990__Route: Injection__logP: -0.2__MW: 182.2__Class: Carboxylic acids and derivatives','CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C__Name: Cutivate__Applicant: Glaxo__Active moiety: fluticasone propionate__Approval Year: 1990__Route: Topical__logP: 4.4__MW: 500.6__Class: Steroids and steroid derivatives','CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C__Name: Ultravate__Applicant: Bristol-Myers Squibb__Active moiety: halobetasol propionate__Approval Year: 1990__Route: Topical__logP: 4.1__MW: 485.0__Class: Steroids and steroid derivatives','O=NC1CCCCC1N=O__Name: Cardiotec__Applicant: Squibb__Active moiety: technetium Tc-99m teboroxime__Approval Year: 1990__Route: Injection__logP: 1.8__MW: 142.2__Class: Organic cation','COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@@H]1c1cccc2nonc12__Name: Dynacirc__Applicant: Sandoz__Active moiety: isradipine__Approval Year: 1990__Route: Oral__logP: 2.6__MW: 371.4__Class: Benzoxadiazoles','[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[Tc]__Name: Cardiolite__Applicant: DuPont__Active moiety: technetium Tc-99m sestamibi__Approval Year: 1990__Route: Injection__logP: 8.0__MW: 777.0__Class: Organooxygen compounds','CN(C)c1nc(N(C)C)nc(N(C)C)n1__Name: Hexalen__Applicant: US Bioscience__Active moiety: altretamine__Approval Year: 1990__Route: Oral__logP: 0.1__MW: 210.3__Class: Organonitrogen compounds','Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2__Name: ProSom__Applicant: Abbott Laboratories__Active moiety: estazolam__Approval Year: 1990__Route: Oral__logP: 3.3__MW: 294.7__Class: Benzodiazepines','CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)[C@@H](C)CC)C(C)C)[C@@H](C)O__Name: Geref__Applicant: Serono__Active moiety: sermorelin acetate__Approval Year: 1990__Route: Injection__logP: -14.3__MW: 3357.9__Class: Polypeptides','CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1__Name: Vascor__Applicant: McNeil Laboratories__Active moiety: bepridil hydrochloride__Approval Year: 1990__Route: Oral__logP: 4.8__MW: 366.5__Class: Benzene and substituted derivatives','CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23__Name: Floxin__Applicant: RW Johnson__Active moiety: ofloxacin__Approval Year: 1990__Route: Oral__logP: 1.5__MW: 361.4__Class: Quinolines and derivatives','Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1__Name: Rev-Eyes__Applicant: Angelini__Active moiety: dapiprazole hydrochloride__Approval Year: 1990__Route: Ophthalmic__logP: 2.3__MW: 325.5__Class: Diazinanes','Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O__Name: Zofran__Applicant: Glaxo__Active moiety: ondansetron hydrochloride__Approval Year: 1991__Route: Injection__logP: 3.1__MW: 293.4__Class: Indoles and derivatives','CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21__Name: Altace__Applicant: Hoechst-Roussel__Active moiety: ramipril__Approval Year: 1991__Route: Oral__logP: 2.4__MW: 416.5__Class: Carboxylic acids and derivatives','O=C(O)[C@H](S)[C@H](S)C(=O)O__Name: Chemet__Applicant: McNeil__Active moiety: succimer__Approval Year: 1991__Route: Oral__logP: -0.2__MW: 182.2__Class: Fatty Acyls','CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3__Name: Lodine__Applicant: Wyeth-Ayerst__Active moiety: etodolac__Approval Year: 1991__Route: Oral__logP: 3.4__MW: 287.4__Class: Indoles and derivatives','COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC__Name: Nuromax__Applicant: Burroughs Wellcome__Active moiety: doxacurium chloride__Approval Year: 1991__Route: Injection__logP: 7.7__MW: 1035.2__Class: Isoquinolines and derivatives','Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O__Name: Fludara__Applicant: Berlex__Active moiety: fludarabine phosphate__Approval Year: 1991__Route: Injection__logP: -1.7__MW: 365.2__Class: Purine nucleotides','CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)[O-])C(C)C__Name: Monopril__Applicant: Bristol-Myers Squibb__Active moiety: fosinopril sodium__Approval Year: 1991__Route: Oral__logP: 4.8__MW: 562.7__Class: Carboxylic acids and derivatives','CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O__Name: Lotensin__Applicant: Ciba__Active moiety: benazepril hydrochloride__Approval Year: 1991__Route: Oral__logP: 2.6__MW: 424.5__Class: Carboxylic acids and derivatives','CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl__Name: Plendil__Applicant: Merck Sharp & Dohme__Active moiety: felodipine__Approval Year: 1991__Route: Oral__logP: 4.0__MW: 384.3__Class: Pyridines and derivatives','O=C([O-])P(=O)([O-])[O-]__Name: Foscavir__Applicant: Astra__Active moiety: foscarnet sodium__Approval Year: 1991__Route: Injection__logP: -2.8__MW: 123.0__Class: Organic phosphonic acids and derivatives','O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1__Name: Videx__Applicant: Bristol-Myers Squibb__Active moiety: didanosine__Approval Year: 1991__Route: Oral__logP: -0.2__MW: 236.2__Class: Purine nucleosides','OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O__Name: Nipent__Applicant: Parke-Davis__Active moiety: pentostatin__Approval Year: 1991__Route: Injection__logP: -1.2__MW: 268.3__Class: Imidazodiazepines','NCCC(O)(P(=O)([O-])O)P(=O)([O-])O__Name: Aredia__Applicant: Ciba-Geigy__Active moiety: pamidronate disodium__Approval Year: 1991__Route: Injection__logP: -2.9__MW: 233.1__Class: Organic phosphonic acids and derivatives','CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21__Name: Pravachol__Applicant: Bristol-Myers Squibb__Active moiety: pravastatin sodium__Approval Year: 1991__Route: Oral__logP: 1.1__MW: 423.5__Class: Hydroxy acids and derivatives','Clc1ccccc1CN1CCc2sccc2C1__Name: Ticlid__Applicant: Syntex__Active moiety: ticlopidine hydrochloride__Approval Year: 1991__Route: Oral__logP: 4.0__MW: 263.8__Class: Thienopyridines','CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O__Name: Biaxin__Applicant: Abbott Laboratories__Active moiety: clarithromycin__Approval Year: 1991__Route: Oral__logP: 2.4__MW: 748.0__Class: Organooxygen compounds','CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O__Name: Zithromax__Applicant: Pfizer__Active moiety: azithromycin__Approval Year: 1991__Route: Oral__logP: 1.9__MW: 749.0__Class: Organooxygen compounds','CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O__Name: Accupril__Applicant: Parke-Davis__Active moiety: quinapril hydrochloride__Approval Year: 1991__Route: Oral__logP: 2.6__MW: 438.5__Class: Carboxylic acids and derivatives','CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2__Name: Romazicon__Applicant: Roche__Active moiety: flumazenil__Approval Year: 1991__Route: Injection__logP: 1.8__MW: 303.3__Class: Benzodiazepines','CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21__Name: Zocor__Applicant: Merck Sharp & Dohme__Active moiety: simvastatin__Approval Year: 1991__Route: Oral__logP: 4.6__MW: 418.6__Class: Lactones','CC=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1__Name: Cefzil__Applicant: Bristol-Myers Squibb__Active moiety: cefprozil__Approval Year: 1991__Route: Oral__logP: 0.7__MW: 389.4__Class: Lactams','CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1__Name: Supprelin__Applicant: Johnson & Johnson__Active moiety: histrelin acetate__Approval Year: 1991__Route: Injection__logP: -0.8__MW: 1323.5__Class: Carboxylic acids and derivatives','COc1ccc2cc(CCC(C)=O)ccc2c1__Name: Relafen__Applicant: SmithKline Beecham__Active moiety: nabumetone__Approval Year: 1991__Route: Oral__logP: 3.4__MW: 228.3__Class: Naphthalenes','O=[N+]([O-])O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@H]12__Name: Ismo__Applicant: Wyeth__Active moiety: isosorbide mononitrate__Approval Year: 1991__Route: Oral__logP: -1.3__MW: 191.1__Class: Furofurans','CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21__Name: Zoloft__Applicant: Pfizer__Active moiety: sertraline hydrochloride__Approval Year: 1991__Route: Oral__logP: 5.2__MW: 306.2__Class: Tetralins','N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CC[C@H]12)c1ccccc1__Name: Lorabid__Applicant: Eli Lilly__Active moiety: loracarbef__Approval Year: 1991__Route: Oral__logP: 0.7__MW: 349.8__Class: Lactams','CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21__Name: Penetrex__Applicant: Warner-Lambert__Active moiety: enoxacin__Approval Year: 1991__Route: Oral__logP: 0.7__MW: 320.3__Class: Diazanaphthalenes','COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2__Name: Mivacron__Applicant: Burroughs Wellcome__Active moiety: mivacurium chloride__Approval Year: 1992__Route: Intravenous__logP: 9.0__MW: 1029.3__Class: Isoquinolines and derivatives','CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1__Name: Omniflox__Applicant: Abbott Laboratories__Active moiety: temafloxacin hydrochloride__Approval Year: 1992__Route: Oral__logP: 2.9__MW: 417.4__Class: Quinolines and derivatives','CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21__Name: Maxaquin__Applicant: Searle__Active moiety: lomefloxacin hydrochloride__Approval Year: 1992__Route: Oral__logP: 1.8__MW: 351.4__Class: Quinolines and derivatives','CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C__Name: Proscar__Applicant: Merck Sharp & Dohme__Active moiety: finasteride__Approval Year: 1992__Route: Oral__logP: 3.8__MW: 372.6__Class: Steroids and steroid derivatives','Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1__Name: Hivid__Applicant: Roche__Active moiety: zalcitabine__Approval Year: 1992__Route: Oral__logP: -0.5__MW: 211.2__Class: Pyrimidine nucleosides','COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O__Name: Vumon__Applicant: Bristol-Myers Squibb__Active moiety: teniposide__Approval Year: 1992__Route: Injection__logP: 2.8__MW: 656.7__Class: Lignan lactones','CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12__Name: Halfan__Applicant: SmithKline Beecham__Active moiety: halofantrine hydrochloride__Approval Year: 1992__Route: Oral__logP: 8.6__MW: 500.4__Class: Phenanthrenes and derivatives','CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=S(=O)(O)c1ccccc1__Name: Norvasc__Applicant: Pfizer__Active moiety: amlodipine besylate__Approval Year: 1992__Route: Oral__logP: 3.2__MW: 567.1__Class: Pyridines and derivatives','CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1__Name: Zebeta__Applicant: Lederle__Active moiety: bisoprolol fumarate__Approval Year: 1992__Route: Oral__logP: 2.4__MW: 325.4__Class: Benzene and substituted derivatives','COCC1=C(C(=O)OC(C)OC(=O)OC(C)C)N2C(=O)[C@@H](NC(=O)/C(=N\OC)c3csc(N)n3)[C@H]2SC1__Name: Vantin__Applicant: Upjohn__Active moiety: cefpodoxime proxetil__Approval Year: 1992__Route: Oral__logP: 0.8__MW: 557.6__Class: Lactams','C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1__Name: Actinex__Applicant: Block__Active moiety: masoprocol__Approval Year: 1992__Route: Topical__logP: 3.6__MW: 302.4__Class: Dibenzylbutane lignans','CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O__Name: Sporanox__Applicant: Janssen__Active moiety: itraconazole__Approval Year: 1992__Route: Oral__logP: 5.6__MW: 705.6__Class: Diazinanes','FC(F)OC(F)C(F)(F)F__Name: Suprane__Applicant: Anaquest__Active moiety: desflurane__Approval Year: 1992__Route: Inhalation__logP: 2.1__MW: 168.0__Class: Organofluorides','O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1__Name: Daypro__Applicant: Searle__Active moiety: oxaprozin__Approval Year: 1992__Route: Oral__logP: 4.0__MW: 293.3__Class: Azoles','CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1__Name: Betapace__Applicant: Bristol-Myers Squibb__Active moiety: sotalol hydrochloride__Approval Year: 1992__Route: Oral__logP: 1.1__MW: 272.4__Class: Benzene and substituted derivatives','CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3]__Name: ProHance__Applicant: Squibb__Active moiety: gadoteridol__Approval Year: 1992__Route: Injection__logP: -6.2__MW: 558.7__Class: Carboxylic acids and derivatives','O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21__Name: Mepron__Applicant: Burroughs Wellcome__Active moiety: atovaquone__Approval Year: 1992__Route: Oral__logP: 5.5__MW: 366.8__Class: Naphthalenes','C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC__Name: Desogen__Applicant: Organon__Active moiety: desogestrel, ethinyl estradiol__Approval Year: 1992__Route: Oral__logP: 4.9__MW: 310.5__Class: Steroids and steroid derivatives','Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1__Name: Ambien__Applicant: Lorex__Active moiety: zolpidem tartrate__Approval Year: 1992__Route: Oral__logP: 3.2__MW: 307.4__Class: Azoles','CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O__Name: Mycobutin__Applicant: Adria__Active moiety: rifabutin__Approval Year: 1992__Route: Oral__logP: 4.6__MW: 847.0__Class: Macrolactams','CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1.O=C(O)CCC(=O)O__Name: Imitrex__Applicant: Glaxo__Active moiety: sumatriptan succinate__Approval Year: 1992__Route: Subcutaneous__logP: 1.3__MW: 413.5__Class: Indoles and derivatives','CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C__Name: Taxol__Applicant: Bristol-Myers Squibb__Active moiety: paclitaxel__Approval Year: 1992__Route: Injection__logP: 3.7__MW: 853.9__Class: Prenol lipids','Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1__Name: Paxil__Applicant: SmithKline Beecham__Active moiety: paroxetine hydrochloride__Approval Year: 1992__Route: Oral__logP: 3.3__MW: 329.4__Class: Piperidines','CCCc1c2oc(C(=O)[O-])cc(=O)c2cc2c(=O)cc(C(=O)[O-])n(CC)c12__Name: Tilade__Applicant: Fisons__Active moiety: nedocromil sodium__Approval Year: 1992__Route: Inhalation__logP: -0.2__MW: 369.3__Class: Benzopyrans','CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12__Name: Lamisil__Applicant: Sandoz__Active moiety: terbinafine hydrochloride__Approval Year: 1992__Route: Topical__logP: 4.9__MW: 291.4__Class: Naphthalenes','Cn1cc([S+](C)[O-])c(=O)c2ccc(F)cc21__Name: Manoplax__Applicant: Boots__Active moiety: flosequinan__Approval Year: 1992__Route: Oral__logP: 1.4__MW: 239.3__Class: Quinolines and derivatives','CNC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)NC)CC(=O)[O-])CC(=O)[O-].[Gd+3]__Name: Omniscan__Applicant: Sterling-Winthrop__Active moiety: gadodiamide__Approval Year: 1993__Route: Injection__logP: -7.4__MW: 573.7__Class: Carboxylic acids and derivatives','Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1__Name: Leustatin__Applicant: Johnson & Johnson__Active moiety: cladribine__Approval Year: 1993__Route: Injection__logP: -0.3__MW: 285.7__Class: Purine nucleosides','CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O__Name: Lovenox__Applicant: Rhone-Poulenc Rorer__Active moiety: enoxaparin sodium__Approval Year: 1993__Route: Subcutaneous__logP: -10.7__MW: 1134.9__Class: Organooxygen compounds','CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1__Name: Claritin__Applicant: Schering__Active moiety: loratadine__Approval Year: 1993__Route: Oral__logP: 4.9__MW: 382.9__Class: Benzocycloheptapyridines','CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1__Name: Orlaam__Applicant: Biometric Res__Active moiety: levomethadyl acetate hydrochloride__Approval Year: 1993__Route: Oral__logP: 4.7__MW: 353.5__Class: Benzene and substituted derivatives','NC(=O)OCC(COC(N)=O)c1ccccc1__Name: Felbatol__Applicant: Wallace__Active moiety: felbamate__Approval Year: 1993__Route: Oral__logP: 1.0__MW: 238.2__Class: Benzene and substituted derivatives','COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC__Name: Propulsid__Applicant: Janssen__Active moiety: cisapride monohydrate__Approval Year: 1993__Route: Oral__logP: 3.4__MW: 466.0__Class: Phenol ethers','FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br__Name: Imagent GI__Applicant: Alliance__Active moiety: perflubron__Approval Year: 1993__Route: Oral__logP: 6.3__MW: 499.0__Class: Organofluorides','Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1__Name: Demadex__Applicant: Boehringer Mannheim__Active moiety: torsemide__Approval Year: 1993__Route: Oral__logP: 2.5__MW: 348.4__Class: Pyridines and derivatives','Nc1c2c(nc3ccccc13)CCCC2__Name: Cognex__Applicant: Parke-Davis__Active moiety: tacrine hydrochloride__Approval Year: 1993__Route: Oral__logP: 2.7__MW: 198.3__Class: Quinolines and derivatives','CC(N)C12CC3CC(CC(C3)C1)C2__Name: Flumadine__Applicant: Forest__Active moiety: rimantadine hydrochloride__Approval Year: 1993__Route: Oral__logP: 2.6__MW: 179.3__Class: Organonitrogen compounds','N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1.NC(CO)(CO)CO.NC(CO)(CO)CO__Name: Alomide__Applicant: Alcon__Active moiety: lodoxamide tromethamine__Approval Year: 1993__Route: Ophthalmic__logP: -4.4__MW: 553.9__Class: Carboxylic acids and derivatives','CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)[O-])C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O.C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O__Name: Zosyn__Applicant: Lederle__Active moiety: tazobactam sodium, pipercillin sodium__Approval Year: 1993__Route: Injection__logP: -3.1__MW: 816.9__Class: Carboxylic acids and derivatives','C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1__Name: Livostin__Applicant: Iolab__Active moiety: levocabastine hydrochloride__Approval Year: 1993__Route: Ophthalmic__logP: 4.9__MW: 420.5__Class: Piperidines','COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC.O=C(O)[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O__Name: Neutrexin__Applicant: US BioScience__Active moiety: trimetrexate glucuronate__Approval Year: 1993__Route: Injection__logP: -0.4__MW: 563.6__Class: Diazanaphthalenes','COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1__Name: Effexor__Applicant: Wyeth-Ayerst__Active moiety: venlafaxine hydrochloride__Approval Year: 1993__Route: Oral__logP: 3.0__MW: 277.4__Class: Phenol ethers','CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2__Name: Kytril__Applicant: SmithKline Beecham__Active moiety: granisetron hydrochloride__Approval Year: 1993__Route: Injection__logP: 2.3__MW: 312.4__Class: Benzopyrazoles','C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@@H](O)C2CC2)C[C@@H](O)C[C@@H]1O__Name: Dovonex__Applicant: Bristol-Myers__Active moiety: calcipotriene__Approval Year: 1993__Route: Topical__logP: 5.1__MW: 412.6__Class: Steroids and steroid derivatives','Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2__Name: Risperdal__Applicant: Janssen__Active moiety: risperidone__Approval Year: 1993__Route: Oral__logP: 3.6__MW: 410.5__Class: Pyridopyrimidines','NCC1(CC(=O)O)CCCCC1__Name: Neurontin__Applicant: Parke-Davis__Active moiety: gabapentin__Approval Year: 1993__Route: Oral__logP: 1.4__MW: 171.2__Class: Carboxylic acids and derivatives','CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC__Name: Aceon__Applicant: RW Johnson Pharmaceutical Development__Active moiety: perindopril erbumine__Approval Year: 1993__Route: Oral__logP: 2.7__MW: 441.6__Class: Carboxylic acids and derivatives','CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1__Name: Lipidil__Applicant: Fournier__Active moiety: fenofibrate__Approval Year: 1993__Route: Oral__logP: 4.7__MW: 360.8__Class: Benzene and substituted derivatives','CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21__Name: Lescol__Applicant: Sandoz__Active moiety: fluvastatin sodium__Approval Year: 1993__Route: Oral__logP: 3.3__MW: 410.5__Class: Pyrroles','O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O__Name: Serevent__Applicant: Glaxo__Active moiety: salmeterol xinafoate__Approval Year: 1994__Route: Inhalation__logP: 6.4__MW: 603.8__Class: Benzene and substituted derivatives','CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1__Name: Rhinocort__Applicant: GH Besselaar__Active moiety: budesonide__Approval Year: 1994__Route: Nasal__logP: 2.7__MW: 430.5__Class: Steroids and steroid derivatives','C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1__Name: Zemuron__Applicant: Organon__Active moiety: rocuronium bromide__Approval Year: 1994__Route: Injection__logP: 4.4__MW: 529.8__Class: Steroids and steroid derivatives','Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1__Name: Semprex-D__Applicant: Burroughs Wellcome__Active moiety: acrivastine, pseudoephedrine hydrochloride__Approval Year: 1994__Route: Oral__logP: 4.0__MW: 348.4__Class: Benzene and substituted derivatives','N=C(N)NCc1cccc([131I])c1.N=C(N)NCc1cccc([131I])c1__Name: iobenguane Sulfate I 131__Applicant: CIS US__Active moiety: iobenguane sulfate I 131__Approval Year: 1994__Route: Injection__logP: 2.5__MW: 558.2__Class: Benzene and substituted derivatives','C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC__Name: Prograf__Applicant: Fujisawa__Active moiety: tacrolimus__Approval Year: 1994__Route: Oral__logP: 4.6__MW: 804.0__Class: Macrolide lactams','C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)O)CC(=O)[O-])CC(=O)[O-])CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O.[111In+3]__Name: Octreoscan__Applicant: Mallinckrodt Medical__Active moiety: indium In 111 pentetreotide__Approval Year: 1994__Route: Injection__logP: -7.8__MW: 1502.5__Class: Peptidomimetics','Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O__Name: Zerit__Applicant: Bristol-Myers Squibb__Active moiety: stavudine__Approval Year: 1994__Route: Oral__logP: -0.7__MW: 224.2__Class: Nucleoside and nucleotide analogues','CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O__Name: Famvir__Applicant: SmithKline Beecham__Active moiety: famciclovir__Approval Year: 1994__Route: Oral__logP: 0.5__MW: 321.3__Class: Imidazopyrimidines','NCCS__Name: Cystagon__Applicant: Mylan__Active moiety: cysteamine bitartrate__Approval Year: 1994__Route: Oral__logP: -0.1__MW: 77.2__Class: Thiols','OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O__Name: fludeoxyglucose F 18__Applicant: Downstate Clinicl__Active moiety: fludeoxyglucose F 18__Approval Year: 1994__Route: Injection__logP: -2.2__MW: 181.1__Class: Organooxygen compounds','CCOC(=O)[C@H](C[S-])[N-]CCN[C@@H](C[S-])C(=O)OCC.O=[99Tc+4]__Name: Neurolite__Applicant: Dupont Merck__Active moiety: technetium Tc-99m bicisate__Approval Year: 1994__Route: Injection__logP: -0.2__MW: 436.3__Class: Carboxylic acids and derivatives','COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1__Name: Luvox__Applicant: Solvay__Active moiety: fluvoxamine maleate__Approval Year: 1994__Route: Oral__logP: 3.2__MW: 318.3__Class: Benzene and substituted derivatives','CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21__Name: Trusopt__Applicant: Merck__Active moiety: dorzolamide hydrochloride__Approval Year: 1994__Route: Ophthalmic__logP: 0.6__MW: 324.4__Class: Thiophenes','CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1__Name: Serzone__Applicant: Bristol-Myers__Active moiety: nefazodone hydrochloride__Approval Year: 1994__Route: Oral__logP: 3.6__MW: 470.0__Class: Diazinanes','CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2__Name: Navelbine__Applicant: Burroughs Wellcome__Active moiety: vinorelbine tartrate__Approval Year: 1994__Route: Injection__logP: 4.8__MW: 778.9__Class: Vinca alkaloids','Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1__Name: Lamictal__Applicant: Burroughs Wellcome__Active moiety: lamotrigine__Approval Year: 1994__Route: Oral__logP: 2.0__MW: 256.1__Class: Benzene and substituted derivatives','CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2__Name: Renormax__Applicant: Sandoz__Active moiety: spirapril hydrochloride__Approval Year: 1994__Route: Oral__logP: 2.4__MW: 466.6__Class: Carboxylic acids and derivatives','CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C__Name: Vexol__Applicant: Alcon__Active moiety: rimexalone__Approval Year: 1994__Route: Ophthalmic__logP: 4.5__MW: 370.5__Class: Steroids and steroid derivatives','COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-]__Name: Sular__Applicant: Miles__Active moiety: nisoldipine__Approval Year: 1995__Route: Oral__logP: 3.2__MW: 388.4__Class: Pyridines and derivatives','COc1cccc(C2(O)CCCCC2CN(C)C)c1__Name: Ultram__Applicant: RW Johnson__Active moiety: tramadol hydrochloride__Approval Year: 1995__Route: Oral__logP: 2.6__MW: 263.4__Class: Phenol ethers','CN(C)C(=N)N=C(N)N__Name: Glucophage__Applicant: Lipha__Active moiety: metformin hydrochloride__Approval Year: 1995__Route: Oral__logP: -1.2__MW: 129.2__Class: Organonitrogen compounds','CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[n-]n2)cc1__Name: Cozaar__Applicant: Merck__Active moiety: losartan potassium__Approval Year: 1995__Route: Oral__logP: 3.9__MW: 421.9__Class: Benzene and substituted derivatives','C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5__Name: Revex__Applicant: Ohmeda__Active moiety: nalmefene hydrochloride__Approval Year: 1995__Route: Injection__logP: 2.5__MW: 339.4__Class: Phenanthrenes and derivatives','CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O__Name: Univasc__Applicant: Schwarz Pharma__Active moiety: moexipril hydrochloride__Approval Year: 1995__Route: Oral__logP: 2.6__MW: 498.6__Class: Carboxylic acids and derivatives','COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2__Name: Cellcept__Applicant: Syntex__Active moiety: mycophenolate mofetil__Approval Year: 1995__Route: Oral__logP: 2.5__MW: 433.5__Class: Isocoumarans','Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1__Name: Prevacid__Applicant: TAP Holdings__Active moiety: lansoprazole__Approval Year: 1995__Route: Oral__logP: 3.5__MW: 369.4__Class: Benzimidazoles','COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I__Name: Ultravist__Applicant: Berlex Laboratories__Active moiety: iopromide__Approval Year: 1995__Route: Injection__logP: -0.4__MW: 791.1__Class: Benzene and substituted derivatives','C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1__Name: Zinecard__Applicant: Pharmacia__Active moiety: dexrazoxane__Approval Year: 1995__Route: Injection__logP: -2.7__MW: 268.3__Class: Carboxylic acids and derivatives','FCOC(C(F)(F)F)C(F)(F)F__Name: Ultane__Applicant: Abbott Laboratories__Active moiety: sevoflurane__Approval Year: 1995__Route: Inhalation__logP: 2.4__MW: 200.1__Class: Organooxygen compounds','CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O__Name: Dynabac__Applicant: Lilly__Active moiety: dirithromycin__Approval Year: 1995__Route: Oral__logP: 2.2__MW: 835.1__Class: Organooxygen compounds','C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O__Name: Precose__Applicant: Bayer__Active moiety: acarbose__Approval Year: 1995__Route: Oral__logP: -8.6__MW: 645.6__Class: Organooxygen compounds','O=C(O)CCCCCCCC(=O)O__Name: Azelex__Applicant: Allergan__Active moiety: azelaic acid__Approval Year: 1995__Route: Topical__logP: 1.9__MW: 188.2__Class: Fatty Acyls','COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12__Name: Coreg__Applicant: SmithKline Beecham__Active moiety: carvedilol__Approval Year: 1995__Route: Oral__logP: 3.7__MW: 406.5__Class: Indoles and derivatives','CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)[O-])C[C@@H]21__Name: Flolan__Applicant: Burroughs Wellcome__Active moiety: epoprostenol sodium__Approval Year: 1995__Route: Injection__logP: 2.1__MW: 351.5__Class: Fatty Acyls','NCCCC(O)(P(=O)([O-])O)P(=O)(O)O__Name: Fosamax__Applicant: Merck__Active moiety: alendronate sodium__Approval Year: 1995__Route: Oral__logP: -1.9__MW: 248.1__Class: Organic phosphonic acids and derivatives','CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1__Name: Casodex__Applicant: Zeneca__Active moiety: bicalutamide__Approval Year: 1995__Route: Oral__logP: 2.9__MW: 430.4__Class: Benzene and substituted derivatives','Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1__Name: Epivir__Applicant: Glaxo Wellcome__Active moiety: lamivudine__Approval Year: 1995__Route: Oral__logP: -0.6__MW: 229.3__Class: Nucleoside and nucleotide analogues','CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O__Name: Amaryl__Applicant: Hoechst-Roussel__Active moiety: glimepiride__Approval Year: 1995__Route: Oral__logP: 3.1__MW: 490.6__Class: Benzene and substituted derivatives','CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1__Name: Invirase__Applicant: Roche__Active moiety: saquinavir__Approval Year: 1995__Route: Oral__logP: 3.1__MW: 670.9__Class: Quinolines and derivatives','NCCCNCCSP(=O)(O)O__Name: Ethyol__Applicant: US Bioscience__Active moiety: amifostine__Approval Year: 1995__Route: Injection__logP: -0.2__MW: 214.2__Class: Organothiophosphorus compounds','O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1__Name: Zyrtec__Applicant: Pfizer__Active moiety: cetirizine__Approval Year: 1995__Route: Oral__logP: 3.1__MW: 388.9__Class: Benzene and substituted derivatives','Nc1nc2ccc(OC(F)(F)F)cc2s1__Name: Rilutek__Applicant: Rhone-Poulenc__Active moiety: riluzole__Approval Year: 1995__Route: Oral__logP: 2.8__MW: 234.2__Class: Benzothiazoles','Nc1nc(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)cs1__Name: Cedax__Applicant: Schering Plough__Active moiety: ceftibuten__Approval Year: 1995__Route: Oral__logP: -0.0__MW: 410.4__Class: Lactams','CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I__Name: Oxilan__Applicant: Cook Imaging__Active moiety: ioxilan__Approval Year: 1995__Route: Injection__logP: -1.0__MW: 791.1__Class: Benzene and substituted derivatives','CC1=C(CCC(=O)O)c2cc3nc(cc4[nH]c(cc5[nH]c(cc1n2)c(C)c5C(C)O)c(C)c4C(C)OC(C)C1=C(C)c2cc4nc(cc5[nH]c(cc6[nH]c(cc1n2)c(C)c6C(C)O)c(C)c5CCC(=O)O)C(CCC(=O)O)=C4C)C(C)=C3CCC(=O)O__Name: Photofrin__Applicant: QLT Phototherapeutics__Active moiety: porfimer sodium__Approval Year: 1995__Route: Injection__logP: 13.8__MW: 1179.4__Class: Tetrapyrroles and derivatives','CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1__Name: Arimidex__Applicant: Zeneca__Active moiety: anastrozole__Approval Year: 1995__Route: Oral__logP: 2.9__MW: 293.4__Class: Benzene and substituted derivatives','CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1__Name: Corvert__Applicant: Upjohn__Active moiety: ibutilide fumurate__Approval Year: 1995__Route: Injection__logP: 8.3__MW: 769.2__Class: Benzene and substituted derivatives','CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1__Name: Maxipime__Applicant: Bristol-Myers Squibb__Active moiety: cefepime hydrochloride__Approval Year: 1996__Route: Injection__logP: 0.1__MW: 481.6__Class: Lactams','CCOCC[PH+](CCOCC)CC[PH+](CCOCC)CCOCC.CCOCC[PH+](CCOCC)CC[PH+](CCOCC)CCOCC.O=[99Tc]=O__Name: Myoview__Applicant: Medi Physics__Active moiety: technetium Tc-99m tetrofosmin__Approval Year: 1996__Route: Injection__logP: 6.9__MW: 899.9__Class: Organic phosphines and derivatives','CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1__Name: Norvir__Applicant: Abbott Laboratories__Active moiety: ritonavir__Approval Year: 1996__Route: Oral__logP: 5.9__MW: 721.0__Class: Carboxylic acids and derivatives','CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O__Name: Crixivan__Applicant: Merck__Active moiety: indinavir sulfate__Approval Year: 1996__Route: Oral__logP: 2.9__MW: 613.8__Class: Carboxylic acids and derivatives','CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I__Name: Visipaque__Applicant: Nycomed__Active moiety: iodixanol__Approval Year: 1996__Route: Injection__logP: -1.6__MW: 1550.2__Class: Benzene and substituted derivatives','CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21__Name: Mavik__Applicant: Knoll__Active moiety: trandolapril__Approval Year: 1996__Route: Oral__logP: 2.8__MW: 430.5__Class: Carboxylic acids and derivatives','O=C([O-])CCCc1ccccc1__Name: Buphenyl__Applicant: Ucyclyd__Active moiety: sodium phenylbutyrate__Approval Year: 1996__Route: Oral__logP: 0.8__MW: 163.2__Class: Benzene and substituted derivatives','CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C__Name: Taxotere__Applicant: Rhone-Poulenc__Active moiety: docetaxel__Approval Year: 1996__Route: Injection__logP: 3.3__MW: 807.9__Class: Prenol lipids','Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1__Name: Gemzar__Applicant: Lilly__Active moiety: gemcitabine hydrochloride__Approval Year: 1996__Route: Injection__logP: -1.3__MW: 263.2__Class: Pyrimidine nucleosides','CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1__Name: Hycamtin__Applicant: SmithKline Beecham__Active moiety: topotecan hydrochloride__Approval Year: 1996__Route: Injection__logP: 1.8__MW: 421.5__Class: Camptothecins','COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2__Name: Differin__Applicant: Galderma__Active moiety: adapalene__Approval Year: 1996__Route: Topical__logP: 6.7__MW: 412.5__Class: Prenol lipids','CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1__Name: Xalatan__Applicant: Pharmacia and Upjohn__Active moiety: latanoprost__Approval Year: 1996__Route: Ophthalmic__logP: 4.2__MW: 432.6__Class: Fatty Acyls','CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1__Name: Albenza__Applicant: SmithKline Beecham__Active moiety: albendazole__Approval Year: 1996__Route: Oral__logP: 3.2__MW: 265.3__Class: Benzimidazoles','CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC__Name: Camptosar__Applicant: Pharmacia and Upjohn__Active moiety: irinotecan hydrochloride__Approval Year: 1996__Route: Injection__logP: 4.1__MW: 586.7__Class: Camptothecins','CN1CCN2c3ncccc3Cc3ccccc3C2C1__Name: Remeron__Applicant: Organon__Active moiety: mirtazapine__Approval Year: 1996__Route: Oral__logP: 2.5__MW: 265.4__Class: Piperazinoazepines','C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12__Name: Merrem__Applicant: Zeneca__Active moiety: meropenem__Approval Year: 1996__Route: Injection__logP: -0.3__MW: 383.5__Class: Lactams','Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1__Name: Viramune__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: nevirapine__Approval Year: 1996__Route: Oral__logP: 2.7__MW: 266.3__Class: Organonitrogen compounds','Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1__Name: Vistide__Applicant: Gilead Sciences__Active moiety: cidofovir__Approval Year: 1996__Route: Injection__logP: -1.7__MW: 279.2__Class: Diazines','CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1__Name: Ultiva__Applicant: Glaxo Wellcome__Active moiety: remifentanil hydrochloride__Approval Year: 1996__Route: Injection__logP: 2.0__MW: 376.5__Class: Carboxylic acids and derivatives','CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1__Name: Allegra__Applicant: Hoechst Marion Roussel__Active moiety: fexofenadine hydrochloride__Approval Year: 1996__Route: Oral__logP: 5.5__MW: 501.7__Class: Benzene and substituted derivatives','O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)([O-])[O-]__Name: Cerebyx__Applicant: Parke-Davis__Active moiety: fosphenytoin sodium__Approval Year: 1996__Route: Injection__logP: 0.3__MW: 360.3__Class: Benzene and substituted derivatives','Brc1c(NC2=NCCN2)ccc2nccnc12__Name: Alphagan__Applicant: Allergan__Active moiety: brimonidine tartrate__Approval Year: 1996__Route: Ophthalmic__logP: 1.8__MW: 292.1__Class: Diazanaphthalenes','COc1ccc(OC)c(C(O)CNC(=O)CN)c1__Name: ProAmatine__Applicant: Roberts__Active moiety: midodrine hydrochloride__Approval Year: 1996__Route: Oral__logP: -0.2__MW: 254.3__Class: Benzene and substituted derivatives','CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O__Name: Nilandron__Applicant: Roussel UCLAF__Active moiety: nilutamide__Approval Year: 1996__Route: Oral__logP: 2.4__MW: 317.2__Class: Azolidines','Nc1nc(O)c2ncn(CCC(CO)CO)c2n1__Name: Denavir__Applicant: SmithKline Beecham__Active moiety: penciclovir__Approval Year: 1996__Route: Topical__logP: -0.9__MW: 253.3__Class: Imidazopyrimidines','CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C__Name: Naropin__Applicant: Astra__Active moiety: ropivacaine hydrochloride monohydrate__Approval Year: 1996__Route: Injection__logP: 3.5__MW: 274.4__Class: Carboxylic acids and derivatives','COC1COC(OC2COC(OC3COC(OC4COC(OC)C(OS(=O)(=O)[O-])C4OS(=O)(=O)[O-])C(OC4OC(C(=O)[O-])C(OC)C(OS(=O)(=O)[O-])C4OS(=O)(=O)[O-])C3OS(=O)(=O)[O-])C(OS(=O)(=O)[O-])C2OS(=O)(=O)[O-])C(OS(=O)(=O)[O-])C1OS(=O)(=O)[O-]__Name: Elmiron__Applicant: Baker Norton__Active moiety: pentosan polysulfate sodium__Approval Year: 1996__Route: Oral__logP: -13.3__MW: 1475.2__Class: Organooxygen compounds','COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12__Name: Accolate__Applicant: Zeneca__Active moiety: zafirlukast__Approval Year: 1996__Route: Oral__logP: 5.7__MW: 575.7__Class: Benzene and substituted derivatives','Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1__Name: Zyprexa__Applicant: Lilly__Active moiety: olanzapine__Approval Year: 1996__Route: Oral__logP: 3.4__MW: 312.4__Class: Benzodiazepines','CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12__Name: Mentax__Applicant: Penederm__Active moiety: butenafine hydrochloride__Approval Year: 1996__Route: Topical__logP: 5.8__MW: 317.5__Class: Naphthalenes','C[N+](C)(C)CC(=O)O__Name: Cystadane__Applicant: Orphan Medical__Active moiety: betaine anhydrous__Approval Year: 1996__Route: Oral__logP: -0.2__MW: 118.2__Class: Carboxylic acids and derivatives','CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1__Name: Astelin__Applicant: Wallace Lab__Active moiety: azelastine hydrochloride__Approval Year: 1996__Route: Nasal__logP: 4.3__MW: 381.9__Class: Diazanaphthalenes','CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O__Name: Stromectol__Applicant: Merck__Active moiety: ivermectin__Approval Year: 1996__Route: Oral__logP: 10.8__MW: 1736.2__Class: Macrolides and analogues','COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2__Name: Aricept__Applicant: Eisai__Active moiety: donepezil hydrochloride__Approval Year: 1996__Route: Oral__logP: 4.4__MW: 379.5__Class: Piperidines','Clc1ccc2nsnc2c1NC1=NCCN1__Name: Zanaflex__Applicant: Athena Neuroscience__Active moiety: tizanidine hydrochloride__Approval Year: 1996__Route: Oral__logP: 1.7__MW: 253.7__Class: Benzothiadiazoles','CC(c1cc2ccccc2s1)N(O)C(N)=O__Name: Zyflo__Applicant: Abbott Laboratories__Active moiety: zileuton__Approval Year: 1996__Route: Oral__logP: 2.7__MW: 236.3__Class: Benzothiophenes','CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1__Name: Aphthasol__Applicant: Block Drug__Active moiety: amlexanox__Approval Year: 1996__Route: Oral__logP: 2.7__MW: 298.3__Class: Benzopyrans','CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-]__Name: Lipitor__Applicant: Parke-Davis__Active moiety: atorvastatin calcium__Approval Year: 1996__Route: Oral__logP: 10.0__MW: 1115.3__Class: Pyrroles','CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21__Name: Patanol__Applicant: Alcon__Active moiety: olopatadine hydrochloride__Approval Year: 1996__Route: Ophthalmic__logP: 3.6__MW: 337.4__Class: Benzoxepines','OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO__Name: Glyset__Applicant: Bayer__Active moiety: miglitol__Approval Year: 1996__Route: Oral__logP: -3.3__MW: 207.2__Class: Piperidines','C[C@@H]1O[C@@H]1P(=O)(O)O.NC(CO)(CO)CO__Name: Monurol__Applicant: Zambon__Active moiety: fosfomycin tromethamine__Approval Year: 1996__Route: Oral__logP: -2.4__MW: 259.2__Class: Organonitrogen compounds','C[C@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@@H](C)N1__Name: Zagam__Applicant: Rhone-Poulenc Rorer__Active moiety: sparfloxacin__Approval Year: 1996__Route: Oral__logP: 2.1__MW: 392.4__Class: Quinolines and derivatives','CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C__Name: Diovan__Applicant: Ciba-Geigy__Active moiety: valsartan__Approval Year: 1996__Route: Oral__logP: 4.2__MW: 435.5__Class: Carboxylic acids and derivatives','C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21__Name: Dostinex__Applicant: Pharmacia and Upjohn__Active moiety: cabergoline__Approval Year: 1996__Route: Oral__logP: 3.2__MW: 451.6__Class: Ergoline and derivatives','CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1__Name: Topamax__Applicant: RW Johnson__Active moiety: topiramate__Approval Year: 1996__Route: Oral__logP: -0.4__MW: 339.4__Class: Dioxolopyrans','Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2__Name: Rezulin__Applicant: Parke-Davis__Active moiety: troglitazone__Approval Year: 1997__Route: Oral__logP: 4.4__MW: 441.5__Class: Benzopyrans','CC(C)Cn1cnc2c(N)nc3ccccc3c21__Name: Aldara__Applicant: 3M__Active moiety: imiquimod__Approval Year: 1997__Route: Topical__logP: 2.8__MW: 240.3__Class: Quinolines and derivatives','O=P([O-])(O)C(Sc1ccc(Cl)cc1)P(=O)([O-])O__Name: Skelid__Applicant: Sanofi Winthrop__Active moiety: tiludronate disodium__Approval Year: 1997__Route: Oral__logP: 0.8__MW: 316.6__Class: Organic phosphonic acids and derivatives','O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1__Name: Agrylin__Applicant: Roberts__Active moiety: anagrelide hydrochloride__Approval Year: 1997__Route: Oral__logP: 1.9__MW: 256.1__Class: Diazanaphthalenes','Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C__Name: Viracept__Applicant: Agouron__Active moiety: nelfinavir mesylate__Approval Year: 1997__Route: Oral__logP: 4.7__MW: 567.8__Class: Carboxylic acids and derivatives','O=P([O-])([O-])CN(CCN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])CP(=O)([O-])[O-].[153Sm+3]__Name: Quadramet__Applicant: Cytogen__Active moiety: samarium Sm 153 lexidronam__Approval Year: 1997__Route: Injection__logP: -6.9__MW: 581.0__Class: Organic phosphonic acids and derivatives','CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1__Name: Rescriptor__Applicant: Pharmacia and Upjohn__Active moiety: delavirdine mesylate__Approval Year: 1997__Route: Oral__logP: 2.7__MW: 456.6__Class: Diazinanes','CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1__Name: Flomax__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: tamsulosin hydrochloride__Approval Year: 1997__Route: Oral__logP: 2.3__MW: 408.5__Class: Benzene and substituted derivatives','CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O__Name: Fareston__Applicant: Orion__Active moiety: toremifene citrate__Approval Year: 1997__Route: Oral__logP: 5.0__MW: 598.1__Class: Stilbenes','CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1__Name: Tazorac__Applicant: Allergan__Active moiety: tazarotene__Approval Year: 1997__Route: Topical__logP: 4.4__MW: 351.5__Class: Prenol lipids','COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C__Name: Posicor__Applicant: Roche__Active moiety: mibefradil dihydrochloride__Approval Year: 1997__Route: Oral__logP: 5.3__MW: 495.6__Class: Tetralins','COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c1-c1ccc(F)cc1__Name: Baycol__Applicant: Bayer__Active moiety: cerivastatin sodium__Approval Year: 1997__Route: Oral__logP: 3.5__MW: 458.6__Class: Pyridines and derivatives','CCCN[C@H]1CCc2nc(N)sc2C1__Name: Mirapex__Applicant: Pharmacia and Upjohn__Active moiety: pramipexole dihydrochloride__Approval Year: 1997__Route: Oral__logP: 1.6__MW: 211.3__Class: Organonitrogen compounds','Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1__Name: Duract__Applicant: Wyeth-Ayerst__Active moiety: bromfenac sodium__Approval Year: 1997__Route: Oral__logP: 1.6__MW: 333.2__Class: Benzene and substituted derivatives','N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1__Name: Femara__Applicant: Novartis Pharmaceuticals__Active moiety: letrozole__Approval Year: 1997__Route: Oral__logP: 2.7__MW: 285.3__Class: Benzene and substituted derivatives','O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12__Name: Anzemet__Applicant: Hoechst Marion Roussel__Active moiety: dolasetron mesylate__Approval Year: 1997__Route: Oral__logP: 2.5__MW: 324.4__Class: Indoles and derivatives','Oc1ccc(CCCCNC[C@H](O)c2ccc(O)c(O)c2)cc1__Name: Genesa__Applicant: Gensia__Active moiety: arbutamine hydrochloride__Approval Year: 1997__Route: Injection__logP: 2.4__MW: 317.4__Class: Benzene and substituted derivatives','CCCN(CCC)CCc1cccc2c1CC(=O)N2__Name: Requip__Applicant: SmithKline Beecham__Active moiety: ropinirole hydrochloride__Approval Year: 1997__Route: Oral__logP: 2.8__MW: 260.4__Class: Indoles and derivatives','Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1__Name: Corlopam__Applicant: Neurex__Active moiety: fenoldopam mesylate__Approval Year: 1997__Route: Injection__logP: 2.7__MW: 305.8__Class: Benzazepines','OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1__Name: Seroquel__Applicant: Zeneca__Active moiety: quetiapine fumarate__Approval Year: 1997__Route: Oral__logP: 2.9__MW: 383.5__Class: Benzothiazepines','Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C__Name: Gabitril__Applicant: Abbott Laboratories__Active moiety: tiagabine hydrochloride__Approval Year: 1997__Route: Oral__logP: 5.0__MW: 375.6__Class: Piperidines','CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1__Name: Avapro__Applicant: Sanofi__Active moiety: irbesartan__Approval Year: 1997__Route: Oral__logP: 4.8__MW: 428.5__Class: Benzene and substituted derivatives','Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1__Name: Raxar__Applicant: Glaxo Wellcome__Active moiety: grepafloxacin hydrochloride__Approval Year: 1997__Route: Oral__logP: 2.3__MW: 359.4__Class: Quinolines and derivatives','COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1__Name: Plavix__Applicant: Sanofi__Active moiety: clopidogrel bisulfate__Approval Year: 1997__Route: Oral__logP: 3.7__MW: 321.8__Class: Carboxylic acids and derivatives','CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1__Name: Meridia__Applicant: Knoll  Pharmacuticals__Active moiety: sibutramine hydrochloride__Approval Year: 1997__Route: Oral__logP: 4.7__MW: 279.9__Class: Benzene and substituted derivatives','CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12__Name: Zomig__Applicant: Zeneca__Active moiety: zolmitriptan__Approval Year: 1997__Route: Oral__logP: 1.9__MW: 287.4__Class: Indoles and derivatives','Cc1[nH+]cc(COP(=O)([O-])[O-])c(CN(CCN(CC(=O)[O-])Cc2c(COP(=O)([O-])O)c[nH+]c(C)c2O)CC(=O)[O-])c1O.[Mn]__Name: Teslascan__Applicant: Nycomed__Active moiety: mangafodipir trisodium__Approval Year: 1997__Route: Injection__logP: -5.5__MW: 690.4__Class: Pyridines and derivatives','C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1__Name: Omnicef__Applicant: Parke-Davis__Active moiety: cefdinir__Approval Year: 1997__Route: Oral__logP: -0.2__MW: 395.4__Class: Lactams','Cc1cn[nH]c1__Name: Antizol__Applicant: Orphan Medical__Active moiety: fomepizole__Approval Year: 1997__Route: Injection__logP: 0.7__MW: 82.1__Class: Azoles','O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12__Name: Evista__Applicant: Lilly__Active moiety: raloxifene hydrochloride__Approval Year: 1997__Route: Oral__logP: 6.1__MW: 473.6__Class: Organooxygen compounds','C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H]1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]21__Name: Trovan__Applicant: Pfizer__Active moiety: alatrofloxacin mesylate__Approval Year: 1997__Route: Injection__logP: 0.9__MW: 558.5__Class: Diazanaphthalenes','N[C@H]1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12__Name: Trovan__Applicant: Pfizer__Active moiety: trovafloxacin mesylate__Approval Year: 1997__Route: Oral__logP: 1.9__MW: 416.4__Class: Diazanaphthalenes','CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1__Name: Teveten__Applicant: SmithKline Beecham__Active moiety: eprosartan mesylate__Approval Year: 1997__Route: Oral__logP: 4.7__MW: 424.5__Class: Benzene and substituted derivatives','CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O__Name: Prandin__Applicant: Novo Nordisk__Active moiety: repaglinide__Approval Year: 1997__Route: Oral__logP: 5.2__MW: 452.6__Class: Piperidines','CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21__Name: Emadine__Applicant: Alcon__Active moiety: emedastine difumarate__Approval Year: 1997__Route: Ophthalmic__logP: 2.2__MW: 302.4__Class: Pyridines and derivatives','Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1__Name: Tasmar__Applicant: Roche__Active moiety: tolcapone__Approval Year: 1998__Route: Oral__logP: 2.5__MW: 273.2__Class: Benzodiazepines','CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1__Name: Amerge__Applicant: Glaxo Wellcome__Active moiety: naratriptan__Approval Year: 1998__Route: Oral__logP: 2.1__MW: 335.5__Class: Indoles and derivatives','CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1__Name: Singulair__Applicant: Merck__Active moiety: montelukast sodium__Approval Year: 1998__Route: Oral__logP: 7.6__MW: 585.2__Class: Linear 13-diarylpropanoids','CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N3)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC1=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2__Name: Refludan__Applicant: Hoechst Marion Roussel__Active moiety: lepirudin__Approval Year: 1998__Route: Injection__logP: -41.7__MW: 6979.5__Class: nan','CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C__Name: Lotemax; Alrex__Applicant: Bausch & Lomb__Active moiety: loteprednol etabonate__Approval Year: 1998__Route: Ophthalmic__logP: 3.9__MW: 467.0__Class: Steroids and steroid derivatives','Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1__Name: Detrol__Applicant: Pharmacia and Upjohn__Active moiety: tolterodine tartrate__Approval Year: 1998__Route: Oral__logP: 5.3__MW: 325.5__Class: Benzene and substituted derivatives','O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O__Name: Actonel__Applicant: Procter & Gamble__Active moiety: risedronate sodium__Approval Year: 1998__Route: Oral__logP: -1.0__MW: 282.1__Class: Organic phosphonic acids and derivatives','CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O__Name: Viagra__Applicant: Pfizer__Active moiety: sildenafil citrate__Approval Year: 1998__Route: Oral__logP: 0.4__MW: 666.7__Class: Benzene and substituted derivatives','CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21__Name: Azopt__Applicant: Alcon__Active moiety: brinzolamide__Approval Year: 1998__Route: Ophthalmic__logP: 0.1__MW: 383.5__Class: Thienothiazines','C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O__Name: Zemplar__Applicant: Abbott Laboratories__Active moiety: paricalcitol__Approval Year: 1998__Route: Intravenous__logP: 5.6__MW: 416.6__Class: Steroids and steroid derivatives','CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F__Name: Xeloda__Applicant: Roche__Active moiety: capecitabine__Approval Year: 1998__Route: Oral__logP: 0.8__MW: 359.4__Class: 5 -deoxyribonucleosides','CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O__Name: Aggrastat__Applicant: Merck__Active moiety: tirofiban hydrochloride__Approval Year: 1998__Route: Injection__logP: 3.0__MW: 440.6__Class: Carboxylic acids and derivatives','N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O__Name: Integrilin__Applicant: COR Therapeutics__Active moiety: eptifibatide__Approval Year: 1998__Route: Injection__logP: -1.8__MW: 832.0__Class: Carboxylic acids and derivatives','CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1__Name: Atacand__Applicant: Astra Merck__Active moiety: candesartan cilexetil__Approval Year: 1998__Route: Oral__logP: 6.3__MW: 610.7__Class: Benzene and substituted derivatives','CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C__Name: Priftin__Applicant: Hoechst Marion Roussel__Active moiety: rifapentine__Approval Year: 1998__Route: Oral__logP: 5.6__MW: 877.0__Class: Prenol lipids','CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.O=C(O)c1ccccc1__Name: Maxalt; Maxalt-MLT__Applicant: Merck__Active moiety: rizatriptan benzoate__Approval Year: 1998__Route: Oral__logP: 3.3__MW: 391.5__Class: Indoles and derivatives','O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1__Name: Thalomid__Applicant: Celgene__Active moiety: thalidomide__Approval Year: 1998__Route: Oral__logP: 0.1__MW: 258.2__Class: Isoindoles and derivatives','CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21__Name: Celexa__Applicant: Forest Laboratories__Active moiety: citalopram hydrobromide__Approval Year: 1998__Route: Oral__logP: 3.8__MW: 324.4__Class: Benzene and substituted derivatives','Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(=O)([S-])OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3O)[C@@H](COP([O-])(=S)O[C@H]3C[C@H](n4ccc(N)nc4=O)O[C@@H]3COP([O-])(=S)O[C@H]3C[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP([O-])(=S)O[C@H]3C[C@H](n4cc(C)c(=O)[nH]c4=O)O[C@@H]3COP([O-])(=S)O[C@H]3C[C@H](n4cc(C)c(=O)[nH]c4=O)O[C@@H]3COP([O-])(=S)O[C@H]3C[C@H](n4cc(C)c(=O)[nH]c4=O)O[C@@H]3COP([O-])(=S)O[C@H]3C[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP([O-])(=S)O[C@H]3C[C@H](n4ccc(N)nc4=O)O[C@@H]3COP([O-])(=S)O[C@H]3C[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O__Name: Vitravene__Applicant: Isis Pharm__Active moiety: fomivirsen sodium__Approval Year: 1998__Route: Injection__logP: -18.6__MW: 6662.3__Class: Phosphorothioate polynucleotides','Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1__Name: Arava__Applicant: Quintiles__Active moiety: leflunomide__Approval Year: 1998__Route: Oral__logP: 3.3__MW: 270.2__Class: Benzene and substituted derivatives','CC(=O)NCSC[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H]1CSCC(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CSCCCN)C(=O)NCC(=O)N[C@@H](CC(=O)[O-])C(=O)N1)C(=O)NCC(=O)N[C@@H](CSCNC(C)=O)C([O-])=NCC([O-])=NCC([O-])=N[C@@H](C[S-])C(N)=O.[99Tc+5]__Name: AcuTect__Applicant: Diatide__Active moiety: technetium Tc-99m apcitide__Approval Year: 1998__Route: Injection__logP: -12.4__MW: 1486.5__Class: Carboxylic acids and derivatives','O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1__Name: Sustiva__Applicant: Dupont Pharmaceuticals__Active moiety: efavirenz__Approval Year: 1998__Route: Oral__logP: 4.1__MW: 315.7__Class: Benzoxazines','CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O__Name: Valstar__Applicant: Anthra Pharm__Active moiety: valrubicin__Approval Year: 1998__Route: Intravesical__logP: 2.5__MW: 723.6__Class: Anthracyclines','C=CCN.ClCC1CO1__Name: Renagel__Applicant: GelTex Pharm__Active moiety: sevelamer hydrochloride__Approval Year: 1998__Route: Oral__logP: 0.8__MW: 149.6__Class: Epoxides','CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1__Name: Micardis__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: telmisartan__Approval Year: 1998__Route: Oral__logP: 7.3__MW: 514.6__Class: Benzene and substituted derivatives','Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1__Name: Ziagen__Applicant: Glaxo Wellcome__Active moiety: abacavir sulfate__Approval Year: 1998__Route: Oral__logP: 1.1__MW: 286.3__Class: Nucleoside and nucleotide analogues','NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1__Name: Provigil__Applicant: Cephalon__Active moiety: modafinil__Approval Year: 1998__Route: Oral__logP: 2.0__MW: 273.4__Class: Benzene and substituted derivatives','Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1__Name: Celebrex__Applicant: Searle__Active moiety: celecoxib__Approval Year: 1998__Route: Oral__logP: 3.5__MW: 381.4__Class: Azoles','O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1__Name: Pletal__Applicant: Otsuka Pharmaceutical__Active moiety: cilostazol__Approval Year: 1999__Route: Oral__logP: 3.5__MW: 369.5__Class: Quinolines and derivatives','CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1__Name: Panretin__Applicant: Ligand Pharm__Active moiety: alitretinoin__Approval Year: 1999__Route: Topical__logP: 5.6__MW: 300.4__Class: Prenol lipids','O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3]__Name: Ferrlecit__Applicant: R&D Labs__Active moiety: sodium ferric gluconate complex__Approval Year: 1999__Route: Injection__logP: -31.8__MW: 2018.3__Class: Hydroxy acids and derivatives','CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1__Name: Agenerase__Applicant: Glaxo Wellcome__Active moiety: amprenavir__Approval Year: 1999__Route: Oral__logP: 2.4__MW: 505.6__Class: Benzene and substituted derivatives','CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O__Name: Xenical__Applicant: Roche__Active moiety: orlistat__Approval Year: 1999__Route: Oral__logP: 6.9__MW: 495.7__Class: Carboxylic acids and derivatives','CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1__Name: Vioxx__Applicant: Merck Research Laboratories__Active moiety: rofecoxib__Approval Year: 1999__Route: Oral__logP: 2.6__MW: 314.4__Class: Stilbenes','CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1__Name: Avandia__Applicant: SKB Pharms__Active moiety: rosiglitazone maleate__Approval Year: 1999__Route: Oral__logP: 2.5__MW: 357.4__Class: Phenol ethers','C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O__Name: Hectorol__Applicant: Bone Care__Active moiety: doxercalciferol__Approval Year: 1999__Route: Oral__logP: 6.6__MW: 412.7__Class: Steroids and steroid derivatives','CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1__Name: Zaditor__Applicant: Ciba Vision__Active moiety: ketotifen fumarate__Approval Year: 1999__Route: Ophthalmic__logP: 4.0__MW: 309.4__Class: Cycloheptathiophenes','CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1__Name: Actos__Applicant: Takeda America__Active moiety: pioglitazone hydrochloride__Approval Year: 1999__Route: Oral__logP: 3.2__MW: 356.4__Class: Phenol ethers','CC(=O)N[C@@H]1[C@@H](NC(=N)N)C=C(C(=O)O)O[C@H]1[C@H](O)[C@H](O)CO__Name: Relenza__Applicant: Glaxo Wellcome__Active moiety: zanamivir__Approval Year: 1999__Route: Inhalation__logP: -3.6__MW: 332.3__Class: Carboxylic acids and derivatives','CC/N=C(\NCC)NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN/C(=N/CC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O__Name: Antagon__Applicant: Organon__Active moiety: ganirelix acetate__Approval Year: 1999__Route: Injection__logP: 2.3__MW: 1570.4__Class: Polypeptides','CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@H](CCSCC(=O)NC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O.[Tc]__Name: NeoTect__Applicant: Diatide__Active moiety: technetium Tc 99m depreotide__Approval Year: 1999__Route: Injection__logP: -1.4__MW: 1455.7__Class: Carboxylic acids and derivatives','Cn1nnc2c(C(N)=O)ncn2c1=O__Name: Temodar__Applicant: Schering__Active moiety: temozolomide__Approval Year: 1999__Route: Oral__logP: -2.1__MW: 194.2__Class: Imidazotetrazines','CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1__Name: Sonata__Applicant: Wyeth-Ayerst__Active moiety: zaleplon__Approval Year: 1999__Route: Oral__logP: 2.6__MW: 305.3__Class: Diazines','C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1__Name: Raplon__Applicant: Organon__Active moiety: rapacuronium bromide__Approval Year: 1999__Route: Injection__logP: 6.9__MW: 597.9__Class: Steroids and steroid derivatives','COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[n-]2)c1C__Name: Aciphex__Applicant: Eisai__Active moiety: rabeprazole sodium__Approval Year: 1999__Route: Oral__logP: 2.6__MW: 358.4__Class: Benzimidazoles','COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1__Name: Ellence__Applicant: Pharmacia and Upjohn__Active moiety: epirubicin hydrochloride__Approval Year: 1999__Route: Injection__logP: 0.0__MW: 543.5__Class: Anthracyclines','CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C__Name: Rapamune__Applicant: Wyeth Ayerst Research__Active moiety: sirolimus__Approval Year: 1999__Route: Oral__logP: 6.2__MW: 914.2__Class: Macrolide lactams','CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)C2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O__Name: Synercid__Applicant: Rhone-Poulenc Rorer__Active moiety: dalfopristin, quinupristin__Approval Year: 1999__Route: Injection__logP: 4.6__MW: 1713.1__Class: Peptidomimetics','Cc1cccn2c(=O)c(-c3nnn[n-]3)cnc12__Name: Alamast__Applicant: Santen__Active moiety: pemirolast potassium__Approval Year: 1999__Route: Ophthalmic__logP: -0.2__MW: 227.2__Class: Pyridopyrimidines','CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1__Name: Tikosyn__Applicant: Pfizer__Active moiety: dofetilide__Approval Year: 1999__Route: Oral__logP: 2.0__MW: 441.6__Class: Benzene and substituted derivatives','CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1__Name: Comtan__Applicant: Orion__Active moiety: entacapone__Approval Year: 1999__Route: Oral__logP: 1.8__MW: 305.3__Class: Cinnamic acids and derivatives','C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12__Name: Aromasin__Applicant: Pharmacia and Upjohn__Active moiety: exemestane__Approval Year: 1999__Route: Oral__logP: 4.0__MW: 296.4__Class: Steroids and steroid derivatives','CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1__Name: Tamiflu__Applicant: Roche__Active moiety: oseltamivir phosphate__Approval Year: 1999__Route: Oral__logP: 1.3__MW: 312.4__Class: Carboxylic acids and derivatives','CC[C@@H](C(N)=O)N1CCCC1=O__Name: Keppra__Applicant: UCP Pharma__Active moiety: levetiracetam__Approval Year: 1999__Route: Oral__logP: -0.1__MW: 170.2__Class: Carboxylic acids and derivatives','NCC(=O)CCC(=O)O__Name: Levulan Kerastick__Applicant: Dusa__Active moiety: aminolevulinic acid hydrochloride__Approval Year: 1999__Route: Topical__logP: -0.6__MW: 131.1__Class: Carboxylic acids and derivatives','COCCNC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-].[Gd+3]__Name: Optimark__Applicant: Mallinckrodt__Active moiety: gadoversetamide__Approval Year: 1999__Route: Injection__logP: -7.3__MW: 661.8__Class: Carboxylic acids and derivatives','CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1__Name: Solage__Applicant: Bristol-Myers Squibb__Active moiety: mequinol, tretinoin__Approval Year: 1999__Route: Topical__logP: 5.6__MW: 300.4__Class: Phenols','COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12__Name: Avelox__Applicant: Bayer__Active moiety: moxifloxacin hydrochloride__Approval Year: 1999__Route: Oral__logP: 2.4__MW: 401.4__Class: Quinolines and derivatives','Cc1cccc([C@H](C)c2c[nH]cn2)c1C__Name: Precedex__Applicant: Abbott Laboratories__Active moiety: dexmedetomidine hydrochloride__Approval Year: 1999__Route: Injection__logP: 3.2__MW: 200.3__Class: Benzene and substituted derivatives','COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12__Name: Tequin__Applicant: Bristol-Myers Squibb__Active moiety: gatifloxacin__Approval Year: 1999__Route: Oral__logP: 2.0__MW: 375.4__Class: Quinolines and derivatives','C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C__Name: Targretin__Applicant: Ligand Pharms__Active moiety: bexarotene__Approval Year: 1999__Route: Oral__logP: 6.1__MW: 348.5__Class: Prenol lipids','CC1OC2(CS1)CN1CCC2CC1__Name: Evoxac__Applicant: Snowbrand Pharmaceuticals__Active moiety: cevimeline hydrochloride__Approval Year: 2000__Route: Oral__logP: 1.6__MW: 199.3__Class: Azaspirodecane derivatives','NC(=O)N1c2ccccc2CC(=O)c2ccccc21__Name: Trileptal__Applicant: Novartis Pharmaceuticals__Active moiety: oxcarbazepine__Approval Year: 2000__Route: Oral__logP: 2.6__MW: 252.3__Class: Benzazepines','COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[n-]2)c1OC__Name: Protonix__Applicant: Wyeth-Ayerst Laboratories__Active moiety: pantoprazole sodium__Approval Year: 2000__Route: Oral__logP: 2.5__MW: 382.4__Class: Benzimidazoles','Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O__Name: Lotronex__Applicant: Glaxo Wellcome__Active moiety: alosetron hydrochloride__Approval Year: 2000__Route: Oral__logP: 2.4__MW: 294.4__Class: Indoles and derivatives','N=S(=O)(O)Cc1noc2ccccc12__Name: Zonegran__Applicant: Elan Pharmaceuticals__Active moiety: zonisamide__Approval Year: 2000__Route: Oral__logP: 1.8__MW: 212.2__Class: Benzisoxazoles','CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC__Name: Septocaine__Applicant: Deproco__Active moiety: articaine hydrochloride, ephinephrine__Approval Year: 2000__Route: Injection__logP: 2.2__MW: 284.4__Class: Thiophenes','C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC.C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)c(CCC(=O)O)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC__Name: Visudyne__Applicant: QLT Phototherapeutics__Active moiety: verteporfin__Approval Year: 2000__Route: Injection__logP: 13.4__MW: 1437.6__Class: Tetrapyrroles and derivatives','Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1__Name: Mobic__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: meloxicam__Approval Year: 2000__Route: Oral__logP: 2.0__MW: 351.4__Class: Benzothiazines','CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1__Name: Zyvox__Applicant: Pharmacia and Upjohn__Active moiety: linezolid__Approval Year: 2000__Route: Oral__logP: 1.1__MW: 337.4__Class: Oxazinanes','CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1__Name: Exelon__Applicant: Novartis Pharmaceuticals__Active moiety: rivastigmine tartrate__Approval Year: 2000__Route: Oral__logP: 2.8__MW: 250.3__Class: Benzene and substituted derivatives','C=CCN.C=CCNCCCCCCCCCC.C=CCNCCCCCC[N+](C)(C)C.ClCC1CO1__Name: Welchol__Applicant: GelTex__Active moiety: colesevelam hydrochloride__Approval Year: 2000__Route: Oral__logP: 6.7__MW: 546.3__Class: Organonitrogen compounds','CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O__Name: Trelstar Depot__Applicant: Debio Recherche__Active moiety: triptorelin pamoate__Approval Year: 2000__Route: Intramuscular__logP: 2.3__MW: 1699.8__Class: Polypeptides','CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1__Name: Acova__Applicant: Texas Biotechnology Corporation__Active moiety: argatroban__Approval Year: 2000__Route: Injection__logP: 0.9__MW: 508.6__Class: Carboxylic acids and derivatives','O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1__Name: Colazal__Applicant: Salix Pharmaceuticals__Active moiety: balsalazide disodium__Approval Year: 2000__Route: Oral__logP: 0.0__MW: 355.3__Class: Carboxylic acids and derivatives','CCCCCCCCCCCCCCCCCCCCCCO__Name: Abreva__Applicant: Avanir Pharmaceuticals__Active moiety: docosanol__Approval Year: 2000__Route: Topical__logP: 7.8__MW: 326.6__Class: Fatty Acyls','CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)OC(C)C__Name: Rescula__Applicant: Ciba Vision__Active moiety: unoprostone isopropyl__Approval Year: 2000__Route: Ophthalmic__logP: 5.1__MW: 424.6__Class: Fatty Acyls','CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O__Name: Cetrotide__Applicant: Asta Medica__Active moiety: cetrorelix acetate__Approval Year: 2000__Route: Injection__logP: -0.5__MW: 1431.1__Class: Polypeptides','Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O__Name: Kaletra__Applicant: Abbott Laboratories__Active moiety: lopinavir, ritonavir__Approval Year: 2000__Route: Oral__logP: 4.3__MW: 628.8__Class: Carboxylic acids and derivatives','CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C__Name: Mifeprex__Applicant: Population Council__Active moiety: mifepristone__Approval Year: 2000__Route: Oral__logP: 5.4__MW: 429.6__Class: Steroids and steroid derivatives','CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O__Name: Angiomax__Applicant: The Medicines Company__Active moiety: bivalirudin__Approval Year: 2000__Route: Intravenous__logP: -8.1__MW: 2180.3__Class: Polypeptides','CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1__Name: Starlix__Applicant: Novartis Pharmaceuticals__Active moiety: nateglinide__Approval Year: 2000__Route: Oral__logP: 3.3__MW: 317.4__Class: Carboxylic acids and derivatives','CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O__Name: Cancidas__Applicant: Merck Research Laboratories__Active moiety: caspofungin acetate__Approval Year: 2001__Route: Intravenous__logP: -3.3__MW: 1093.3__Class: Carboxylic acids and derivatives','O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1__Name: Geodon__Applicant: Pfizer Central Research__Active moiety: ziprasidone hydrochloride__Approval Year: 2001__Route: Oral__logP: 3.8__MW: 412.9__Class: Diazinanes','COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1__Name: Foradil__Applicant: Novartis Pharmaceuticals__Active moiety: formoterol fumarate__Approval Year: 2001__Route: Inhalation__logP: 4.4__MW: 688.8__Class: Benzene and substituted derivatives','COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2__Name: Reminyl__Applicant: Janssen Research Foundation__Active moiety: galantamine hydrobromide__Approval Year: 2001__Route: Oral__logP: 1.9__MW: 287.4__Class: Amaryllidaceae alkaloids','CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1__Name: Travatan__Applicant: Alcon Research__Active moiety: travoprost__Approval Year: 2001__Route: Ophthalmic__logP: 4.4__MW: 500.6__Class: Fatty Acyls','CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1__Name: Lumigan__Applicant: Allergan__Active moiety: bimatoprost__Approval Year: 2001__Route: Ophthalmic__logP: 3.1__MW: 415.6__Class: Fatty Acyls','CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12.O=C(O)CC(O)C(=O)O__Name: Axert__Applicant: Pharmacia and Upjohn__Active moiety: almotriptan malate__Approval Year: 2001__Route: Oral__logP: 1.1__MW: 469.6__Class: Indoles and derivatives','Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1__Name: Gleevec__Applicant: Novartis Pharmaceuticals__Active moiety: imatinib mesylate__Approval Year: 2001__Route: Oral__logP: 4.6__MW: 493.6__Class: Benzene and substituted derivatives','C[C@]12CC[C@H]3[C@H]([C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1C1=CC(=O)CC[C@@]13C__Name: Yasmin__Applicant: Berlex Laboratories__Active moiety: drospirenone,ethinyl estradiol__Approval Year: 2001__Route: Oral__logP: 4.3__MW: 366.5__Class: Steroids and steroid derivatives','FC(F)(F)C(F)(F)C(F)(F)F__Name: Definity__Applicant: Dupont Pharmaceuticals__Active moiety: perflutren lipid microsphere__Approval Year: 2001__Route: Intravenous__logP: 2.7__MW: 188.0__Class: Organofluorides','CCC(C)C1NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(Cc2ccccc2)NC(=O)C(NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C2CCCN2C(=O)C(N)CO)C(C)C)CSSCC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc2cnc[nH]2)C(=O)O)C(C)C)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC1=O__Name: Natrecor__Applicant: Scios__Active moiety: nesiritide__Approval Year: 2001__Route: Intravenous__logP: -20.2__MW: 3464.1__Class: Polypeptides','O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O__Name: Zometa__Applicant: Novartis Pharmaceuticals__Active moiety: zoledronic acid__Approval Year: 2001__Route: Intravenous__logP: -1.1__MW: 272.1__Class: Organic phosphonic acids and derivatives','CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\c3scnc3C)CS[C@H]12)c1csc(N)n1__Name: Spectracef__Applicant: TAP Pharmaceutical Products__Active moiety: cefditoren pivoxil__Approval Year: 2001__Route: Oral__logP: 2.3__MW: 620.7__Class: Lactams','C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC.C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C__Name: NuvaRing__Applicant: Organon__Active moiety: etonogestrel, ethinyl estradiol__Approval Year: 2001__Route: Vaginal__logP: 7.7__MW: 620.9__Class: Steroids and steroid derivatives','CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C__Name: Viread__Applicant: Gilead Sciences__Active moiety: tenofovir disoproxil fumarate__Approval Year: 2001__Route: Oral__logP: 3.0__MW: 519.4__Class: Imidazopyrimidines','CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1__Name: Frova__Applicant: Elan Pharmaceuticals__Active moiety: frovatriptan__Approval Year: 2001__Route: Oral__logP: 1.3__MW: 243.3__Class: Indoles and derivatives','Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1__Name: Bextra__Applicant: GD Searle__Active moiety: valdecoxib__Approval Year: 2001__Route: Oral__logP: 3.0__MW: 314.4__Class: Benzene and substituted derivatives','C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F__Name: Avodart__Applicant: GlaxoSmithKline__Active moiety: dutasteride__Approval Year: 2001__Route: Oral__logP: 6.6__MW: 528.5__Class: Steroids and steroid derivatives','C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC__Name: Ortho Evra__Applicant: RW Johnson Pharmaceutical Research__Active moiety: norelgestromin, ethinyl estradiol__Approval Year: 2001__Route: Transdermal__logP: 4.1__MW: 327.5__Class: Steroids and steroid derivatives','COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO__Name: Tracleer__Applicant: Actelion Pharmaceuticals__Active moiety: bosentan__Approval Year: 2001__Route: Oral__logP: 4.2__MW: 551.6__Class: Diazines','C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)[O-])c4)C3)[C@H](C)[C@H]12__Name: Invanz__Applicant: Merck__Active moiety: ertapenem sodium__Approval Year: 2001__Route: Intramuscular, Intravenous__logP: -0.4__MW: 474.5__Class: Lactams','CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-]__Name: Arixtra__Applicant: Fonda BV__Active moiety: fondaparinux sodium__Approval Year: 2001__Route: Subcutaneous__logP: -19.2__MW: 1498.2__Class: Organooxygen compounds','CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC__Name: Elidel__Applicant: Novartis Pharmaceuticals__Active moiety: pimecrolimus__Approval Year: 2001__Route: Topical__logP: 5.7__MW: 810.5__Class: Macrolide lactams','Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1__Name: Clarinex__Applicant: Schering__Active moiety: desloratadine__Approval Year: 2001__Route: Oral__logP: 4.0__MW: 310.8__Class: Benzocycloheptapyridines','O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-]__Name: Orfadin__Applicant: Swedish Orphan__Active moiety: nitisinone__Approval Year: 2002__Route: Oral__logP: 2.7__MW: 329.2__Class: Organooxygen compounds','C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O__Name: Faslodex__Applicant: AstraZeneca Pharmaceuticals__Active moiety: fulvestrant__Approval Year: 2002__Route: Intramuscular__logP: 8.7__MW: 606.8__Class: Steroids and steroid derivatives','CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1__Name: Benicar__Applicant: Sankyo__Active moiety: olmesartan medoxomil__Approval Year: 2002__Route: Oral__logP: 4.2__MW: 558.6__Class: Benzene and substituted derivatives','CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O__Name: Remodulin__Applicant: United Therapeutics__Active moiety: treprostinil sodium__Approval Year: 2002__Route: Iv (Infusion), Subcutaneous__logP: 3.6__MW: 390.5__Class: Benzene and substituted derivatives','C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F__Name: Vfend__Applicant: Pfizer__Active moiety: voriconazole__Approval Year: 2002__Route: Oral__logP: 2.2__MW: 349.3__Class: Benzene and substituted derivatives','FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br__Name: Imagent__Applicant: Alliance Pharmaceuticals__Active moiety: dimyristoylphosphatidylcholine, perflexane__Approval Year: 2002__Route: Intravenous__logP: 6.3__MW: 499.0__Class: Organofluorides','O=C([O-])CCCO__Name: Xyrem__Applicant: Orphan Medical__Active moiety: sodium oxybate__Approval Year: 2002__Route: Oral__logP: -1.5__MW: 103.1__Class: Fatty Acyls','CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12__Name: Zelnorm__Applicant: Novartis Pharmaceuticals__Active moiety: tegaserod maleate__Approval Year: 2002__Route: Oral__logP: 2.8__MW: 301.4__Class: Indoles and derivatives','[NH-][C@@H]1CCCC[C@H]1[NH-].[Pt+2]__Name: Eloxatin__Applicant: Sanofi-Synthelabo__Active moiety: oxaliplatin__Approval Year: 2002__Route: Intravenous__logP: 2.4__MW: 307.3__Class: Organonitrogen compounds','CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc21)OCOC(=O)C(C)(C)C__Name: Hepsera__Applicant: Gilead Sciences__Active moiety: adefovir dipivoxil__Approval Year: 2002__Route: Oral__logP: 2.7__MW: 501.5__Class: Imidazopyrimidines','COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13__Name: Inspra__Applicant: GD Searle__Active moiety: eplerenone__Approval Year: 2002__Route: Oral__logP: 3.1__MW: 414.5__Class: Steroids and steroid derivatives','O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1__Name: Zetia__Applicant: Schering__Active moiety: ezetimibe__Approval Year: 2002__Route: Oral__logP: 4.9__MW: 409.4__Class: Lactams','O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1__Name: Abilify__Applicant: Otsuka Pharmaceutical__Active moiety: aripiprazole__Approval Year: 2002__Route: Oral__logP: 4.9__MW: 448.4__Class: Diazinanes','CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1__Name: Alinia__Applicant: Romark Laboratories__Active moiety: nitazoxanide__Approval Year: 2002__Route: Oral__logP: 2.2__MW: 307.3__Class: Benzene and substituted derivatives','CNCC[C@@H](Oc1ccccc1C)c1ccccc1__Name: Strattera__Applicant: Eli Lilly__Active moiety: atomoxetine hydrochloride__Approval Year: 2002__Route: Oral__logP: 3.7__MW: 255.4__Class: Phenol ethers','CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12__Name: Relpax__Applicant: Pfizer__Active moiety: eletriptan hydrobromide__Approval Year: 2002__Route: Oral__logP: 3.8__MW: 382.5__Class: Indoles and derivatives','CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O__Name: Fuzeon__Applicant: Hoffmann-La Roche__Active moiety: enfuvirtide__Approval Year: 2003__Route: Subcutaneous__logP: -15.4__MW: 4491.9__Class: Polypeptides','C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1__Name: Emend__Applicant: Merck__Active moiety: aprepitant__Approval Year: 2003__Route: Oral__logP: 5.0__MW: 534.4__Class: Oxazinanes','CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1CN__Name: Factive__Applicant: LG Life Sciences__Active moiety: gemifloxacin mesylate__Approval Year: 2003__Route: Oral__logP: 1.0__MW: 389.4__Class: Diazanaphthalenes','COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1__Name: Iressa__Applicant: AstraZeneca Pharmaceuticals__Active moiety: gefitinib__Approval Year: 2003__Route: Oral__logP: 4.3__MW: 446.9__Class: Diazanaphthalenes','CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O__Name: Velcade__Applicant: Millennium Pharmaceuticals__Active moiety: bortezomib__Approval Year: 2003__Route: Intravenous, Subcutaneous__logP: 0.4__MW: 384.2__Class: Carboxylic acids and derivatives','CCCCCN(C)CCC(O)(P(=O)([O-])O)P(=O)(O)O__Name: Boniva__Applicant: Hoffmann-La Roche__Active moiety: ibandronate sodium__Approval Year: 2003__Route: Oral__logP: -0.1__MW: 318.2__Class: Organic phosphonic acids and derivatives','COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC__Name: Uroxatral__Applicant: Sanofi-Synthelabo__Active moiety: alfuzosin hydrochloride__Approval Year: 2003__Route: Oral__logP: 1.4__MW: 389.5__Class: Diazanaphthalenes','COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C__Name: Reyataz__Applicant: Bristol-Myers Squibb__Active moiety: atazanavir sulfate__Approval Year: 2003__Route: Oral__logP: 4.2__MW: 704.9__Class: Carboxylic acids and derivatives','Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F__Name: Emtriva__Applicant: Gilead Sciences__Active moiety: emtricitabine__Approval Year: 2003__Route: Oral__logP: -0.5__MW: 247.3__Class: Nucleoside and nucleotide analogues','O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2__Name: Aloxi__Applicant: Helsinn Healthcare__Active moiety: palonosetron hydrochloride__Approval Year: 2003__Route: Intravenous__logP: 2.7__MW: 296.4__Class: Isoquinolines and derivatives','CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO__Name: Zavesca__Applicant: Actelion Pharmaceuticals__Active moiety: miglustat__Approval Year: 2003__Route: Oral__logP: -1.5__MW: 219.3__Class: Piperidines','CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-]__Name: Crestor__Applicant: AstraZeneca Pharmaceuticals__Active moiety: rosuvastatin calcium__Approval Year: 2003__Route: Oral__logP: 2.1__MW: 961.1__Class: Diazines','CCCc1nc(C)c2c(O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12__Name: Levitra__Applicant: Bayer__Active moiety: vardenafil hydrochloride__Approval Year: 2003__Route: Oral__logP: 2.5__MW: 488.6__Class: Benzene and substituted derivatives','CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C__Name: Cubicin__Applicant: Cubist Pharmaceuticals__Active moiety: daptomycin__Approval Year: 2003__Route: Intravenous__logP: -5.6__MW: 1620.7__Class: Peptidomimetics','NC1=NCC2c3ccccc3Cc3ccccc3N12__Name: Elestat__Applicant: Allergan__Active moiety: epinastine hydrochloride__Approval Year: 2003__Route: Ophthalmic__logP: 2.5__MW: 249.3__Class: Benzazepines','CC12CC3CC(C)(C1)CC(N)(C3)C2__Name: Namenda__Applicant: Forest Laboratories__Active moiety: memantine hydrochloride__Approval Year: 2003__Route: Oral__logP: 2.7__MW: 179.3__Class: Organonitrogen compounds','CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O__Name: Cialis__Applicant: Lilly Icos__Active moiety: tadalafil__Approval Year: 2003__Route: Oral__logP: 2.2__MW: 389.4__Class: Indoles and derivatives','CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O__Name: Plenaxis__Applicant: Praecis Pharmaceuticals__Active moiety: abarelix__Approval Year: 2003__Route: Intramuscular__logP: 1.2__MW: 1416.1__Class: Carboxylic acids and derivatives','Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1__Name: Ertaczo__Applicant: Mylan Pharmaceuticals__Active moiety: sertaconazole nitrate__Approval Year: 2003__Route: Topical__logP: 7.0__MW: 437.8__Class: Benzothiophenes','C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21__Name: Spiriva Handihaler__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: tiotropium bromide__Approval Year: 2004__Route: Inhalation__logP: 2.3__MW: 392.5__Class: Oxazinanes','Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1__Name: Alimta__Applicant: Eli Lilly__Active moiety: pemetrexed disodium__Approval Year: 2004__Route: Intravenous__logP: -2.0__MW: 425.4__Class: Carboxylic acids and derivatives','C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12__Name: Sensipar__Applicant: Amgen__Active moiety: cinacalcet hydrochloride__Approval Year: 2004__Route: Oral__logP: 6.1__MW: 357.4__Class: Naphthalenes','CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C__Name: Ketek__Applicant: Aventis Pharmaceuticals__Active moiety: telithromycin__Approval Year: 2004__Route: Oral__logP: 4.9__MW: 812.0__Class: Organooxygen compounds','CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C__Name: ChiRhoStim__Applicant: ChiRhoClin__Active moiety: human secretin__Approval Year: 2004__Route: Intravenous__logP: -17.0__MW: 3039.5__Class: Polypeptides','CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3__Name: Apokyn__Applicant: Bertek Pharmaceuticals__Active moiety: apomorphine hydrochloride__Approval Year: 2004__Route: Subcutaneous__logP: 2.8__MW: 267.3__Class: Aporphines','CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C__Name: Tindamax__Applicant: Presutti Laboratories__Active moiety: tinidazole__Approval Year: 2004__Route: Oral__logP: 0.5__MW: 247.3__Class: Azoles','Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1__Name: Vidaza__Applicant: Pharmion__Active moiety: azacitidine__Approval Year: 2004__Route: Intravenous, Subcutaneous__logP: -3.2__MW: 244.2__Class: Organooxygen compounds','CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C__Name: Xifaxan__Applicant: Salix Pharmaceuticals__Active moiety: rifaximin__Approval Year: 2004__Route: Oral__logP: 6.2__MW: 785.9__Class: Macrolactams','O=C(O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1__Name: Sanctura__Applicant: Indevus Pharmaceuticals__Active moiety: trospium chloride__Approval Year: 2004__Route: Oral__logP: 3.8__MW: 392.5__Class: Benzene and substituted derivatives','NC(=O)CC[C@H](N)C(=O)O__Name: NutreStore__Applicant: Nutritional Restart Pharmaceutical__Active moiety: l-glutamine__Approval Year: 2004__Route: Oral__logP: -1.3__MW: 146.1__Class: Carboxylic acids and derivatives','CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-]__Name: Campral__Applicant: Lipha Pharmaceuticals__Active moiety: acamprosate calcium__Approval Year: 2004__Route: Oral__logP: -1.9__MW: 360.4__Class: Organic sulfonic acids and derivatives','CNCC[C@H](Oc1cccc2ccccc12)c1cccs1__Name: Cymbalta__Applicant: Eli Lilly__Active moiety: duloxetine hydrochloride__Approval Year: 2004__Route: Oral__logP: 4.6__MW: 297.4__Class: Naphthalenes','O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CCN(CC(=O)[O-])CC(=O)[O-]__Name: pentetate calcium trisodium__Applicant: Hameln Pharmaceuticals GmbH__Active moiety: pentetate calcium trisodium__Approval Year: 2004__Route: Inhalation, Intravenous__logP: -9.4__MW: 388.3__Class: Carboxylic acids and derivatives','O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CCN(CC(=O)[O-])CC(=O)[O-].[Zn+2]__Name: pentetate zinc trisodium__Applicant: Hameln Pharmaceuticals GmbH__Active moiety: pentetate zinc trisodium__Approval Year: 2004__Route: Inhalation, Intravenous__logP: -9.4__MW: 453.7__Class: Carboxylic acids and derivatives','O=C([O-])[O-].O=C([O-])[O-].O=C([O-])[O-].[La+3].[La+3]__Name: Fosrenol__Applicant: Shire Pharmaceutical Development__Active moiety: lanthanum carbonate hydrate__Approval Year: 2004__Route: Oral__logP: -7.3__MW: 457.8__Class: Organic carbonic acids and derivatives','CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCC.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC__Name: Omacor__Applicant: Abbott Laboratories__Active moiety: omega-3-acid ethyl esters__Approval Year: 2004__Route: Oral__logP: 13.5__MW: 687.1__Class: Fatty Acyls','C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1__Name: Tarceva__Applicant: OSI Pharmaceuticals__Active moiety: erlotinib hydrochloride__Approval Year: 2004__Route: Oral__logP: 3.4__MW: 393.4__Class: Diazanaphthalenes','O=C(O)CCC(=O)O.O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1__Name: Vesicare__Applicant: Yamanouchi Pharma America__Active moiety: solifenacin succinate__Approval Year: 2004__Route: Oral__logP: 3.8__MW: 480.6__Class: Tetrahydroisoquinolines','CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)O)CCN(CC(=O)O)C(COCc1ccccc1)C(=O)[O-].[Gd+3]__Name: Multihance__Applicant: Bracco Diagnostics__Active moiety: gadobenate dimeglumine__Approval Year: 2004__Route: Intravenous__logP: -11.8__MW: 1058.2__Class: Carboxylic acids and derivatives','CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1__Name: Lunesta__Applicant: Sepracor__Active moiety: eszopiclone__Approval Year: 2004__Route: Oral__logP: 1.6__MW: 388.8__Class: Pyrrolopyrazines','Cc1cc(-c2ccc(/N=N/c3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1/N=N/c1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O__Name: VisionBlue__Applicant: Dutch Ophthalmic USA__Active moiety: trypan blue__Approval Year: 2004__Route: Ophthalmic__logP: 5.3__MW: 868.9__Class: Naphthalenes','COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(=O)O__Name: Macugen__Applicant: Eyetech Pharmaceuticals__Active moiety: pegaptanib sodium__Approval Year: 2004__Route: Intravitreal__logP: 2.2__MW: 541.6__Class: Carboxylic acids and derivatives','NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1__Name: Enablex__Applicant: Novartis Pharmaceuticals__Active moiety: darifenacin hydrobromide__Approval Year: 2004__Route: Oral__logP: 4.0__MW: 426.6__Class: Benzene and substituted derivatives','CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@@H](C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC3=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O__Name: Prialt__Applicant: Elan Pharmaceuticals__Active moiety: ziconotide__Approval Year: 2004__Route: Intrathecal__logP: -16.2__MW: 2639.2__Class: Peptidomimetics','Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F__Name: Clolar__Applicant: Genzyme__Active moiety: clofarbine__Approval Year: 2004__Route: Intravenous__logP: -0.3__MW: 303.7__Class: Purine nucleosides','CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O__Name: Ventavis__Applicant: CoTherix__Active moiety: iloprost__Approval Year: 2004__Route: Inhalation__logP: 3.5__MW: 360.5__Class: Fatty Acyls','CC(C)C[C@H](CN)CC(=O)O__Name: Lyrica__Applicant: Pfizer__Active moiety: pregabalin__Approval Year: 2004__Route: Oral__logP: 1.1__MW: 159.2__Class: Carboxylic acids and derivatives','CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O__Name: Symlin__Applicant: Amylin Pharmaceuticals__Active moiety: pramlintide acetate__Approval Year: 2005__Route: Subcutaneous__logP: -23.8__MW: 3949.5__Class: Polypeptides','CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)[O-])c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1__Name: Mycamine__Applicant: Fujisawa Healthcare__Active moiety: micafungin sodium__Approval Year: 2005__Route: Intravenous__logP: -4.2__MW: 1269.3__Class: Carboxylic acids and derivatives','C=C1[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H](O)[C@H]1CO__Name: Baraclude__Applicant: Bristol-Myers Squibb__Active moiety: entecavir__Approval Year: 2005__Route: Oral__logP: -0.8__MW: 277.3__Class: Nucleoside and nucleotide analogues','CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O__Name: Byetta__Applicant: Amylin Pharmaceuticals__Active moiety: exenatide__Approval Year: 2005__Route: Subcutaneous__logP: -20.6__MW: 4186.6__Class: nan','CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O__Name: Tygacil__Applicant: Wyeth Pharmaceuticals__Active moiety: tigecycline__Approval Year: 2005__Route: Intravenous__logP: 0.5__MW: 585.7__Class: Tetracyclines','CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1__Name: Aptivus__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: tipranavir__Approval Year: 2005__Route: Oral__logP: 7.3__MW: 602.7__Class: Diarylheptanoids','CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3__Name: Rozerem__Applicant: Takeda Global Research & Development Center__Active moiety: ramelteon__Approval Year: 2005__Route: Oral__logP: 2.6__MW: 259.3__Class: Indanes','NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N__Name: Nevanac__Applicant: Alcon__Active moiety: nepafenac__Approval Year: 2005__Route: Ophthalmic__logP: 1.5__MW: 254.3__Class: Benzene and substituted derivatives','COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O__Name: Arranon__Applicant: GlaxoSmithKline__Active moiety: nelarabine__Approval Year: 2005__Route: Intravenous__logP: -2.0__MW: 297.3__Class: Purine nucleosides','O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1__Name: Exjade__Applicant: Novartis Pharmaceuticals__Active moiety: deferasirox__Approval Year: 2005__Route: Oral__logP: 3.7__MW: 373.4__Class: Benzene and substituted derivatives','CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1__Name: Nexavar__Applicant: Bayer Pharmaceuticals__Active moiety: sorafenib tosylate__Approval Year: 2005__Route: Oral__logP: 5.5__MW: 464.8__Class: Organooxygen compounds','Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O__Name: Revlimid__Applicant: Celgene__Active moiety: lenalidomide__Approval Year: 2005__Route: Oral__logP: 0.0__MW: 259.3__Class: Isoindoles and derivatives','Cc1nc2c([nH]1)CCN(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)c1ccccc1-2__Name: Vaprisol__Applicant: Astellas Pharma__Active moiety: conivaptan hydrochloride__Approval Year: 2005__Route: Intravenous__logP: 6.5__MW: 498.6__Class: Benzene and substituted derivatives','CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O__Name: Sutent__Applicant: Pfizer__Active moiety: sunitinib malate__Approval Year: 2006__Route: Oral__logP: 2.2__MW: 532.6__Class: Indoles and derivatives','COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1__Name: Ranexa__Applicant: CV Therapeutics__Active moiety: ranolazine__Approval Year: 2006__Route: Oral__logP: 2.3__MW: 427.5__Class: Phenol ethers','CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1__Name: Amitiza__Applicant: Sucampo Pharmaceuticals__Active moiety: lubiprostone__Approval Year: 2006__Route: Oral__logP: 4.3__MW: 390.5__Class: Fatty Acyls','CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1__Name: Eraxis__Applicant: Pfizer__Active moiety: anidulafungin__Approval Year: 2006__Route: Intravenous__logP: -0.9__MW: 1140.3__Class: Carboxylic acids and derivatives','Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1__Name: Dacogen__Applicant: MGI Pharma__Active moiety: decitabine__Approval Year: 2006__Route: Intravenous__logP: -2.1__MW: 228.2__Class: Triazines','c1cnc2cc3c(cc2n1)C1CNCC3C1__Name: Chantix__Applicant: Pfizer__Active moiety: varenicline__Approval Year: 2006__Route: Oral__logP: 1.8__MW: 211.3__Class: Benzazepines','C#CCN[C@@H]1CCc2ccccc21__Name: Azilect__Applicant: Teva Pharmaceuticals__Active moiety: rasagiline mesylate__Approval Year: 2006__Route: Oral__logP: 1.9__MW: 171.2__Class: Indanes','CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1__Name: Prezista__Applicant: Tibotec__Active moiety: darunavir__Approval Year: 2006__Route: Oral__logP: 2.4__MW: 547.7__Class: Benzene and substituted derivatives','Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1__Name: Sprycel__Applicant: Bristol-Myers Squibb__Active moiety: dasatinib__Approval Year: 2006__Route: Oral__logP: 3.3__MW: 488.0__Class: Benzene and substituted derivatives','CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O__Name: Noxafil__Applicant: Schering__Active moiety: posaconazole__Approval Year: 2006__Route: Oral__logP: 4.6__MW: 700.8__Class: Diazinanes','CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)C3C[C@@H]12.Cc1ncc([N+](=O)[O-])n1CCO.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3]__Name: Pylera__Applicant: Axcan Scandipharm__Active moiety: biskalcitrate, metronidazole, tetracycline hydrochloride__Approval Year: 2006__Route: Oral__logP: -11.2__MW: 1202.8__Class: Tetracyclines','O=C(CCCCCCC(=O)Nc1ccccc1)NO__Name: Zolinza__Applicant: Merck__Active moiety: vorinostat__Approval Year: 2006__Route: Oral__logP: 2.5__MW: 264.3__Class: Benzene and substituted derivatives','N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F__Name: Januvia__Applicant: Merck__Active moiety: sitagliptin phosphate__Approval Year: 2006__Route: Oral__logP: 2.0__MW: 407.3__Class: Carboxylic acids and derivatives','CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C__Name: Omnaris__Applicant: Altana Pharma__Active moiety: ciclesonide__Approval Year: 2006__Route: Nasal__logP: 4.7__MW: 540.7__Class: Steroids and steroid derivatives','Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O__Name: Tyzeka__Applicant: Idenix Pharmaceuticals__Active moiety: telbivudine__Approval Year: 2006__Route: Oral__logP: -1.5__MW: 242.2__Class: Pyrimidine nucleosides','Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O__Name: Invega__Applicant: Johnson & Johnson__Active moiety: paliperidone__Approval Year: 2006__Route: Oral__logP: 3.1__MW: 426.5__Class: Pyridopyrimidines','C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN__Name: Vyvanse__Applicant: New River Pharmaceuticals__Active moiety: lisdexamfetamine dimesylate__Approval Year: 2007__Route: Oral__logP: 1.2__MW: 263.4__Class: Carboxylic acids and derivatives','COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC__Name: Tekturna__Applicant: Novartis Pharmaceuticals__Active moiety: aliskiren__Approval Year: 2007__Route: Oral__logP: 3.3__MW: 551.8__Class: Carboxylic acids and derivatives','CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1__Name: Tykerb__Applicant: GlaxoSmithKline__Active moiety: lapatinib__Approval Year: 2007__Route: Oral__logP: 6.1__MW: 581.1__Class: Diazanaphthalenes','C=C[C@]1(C)C[C@@H](OC(=O)CS[C@H]2C[C@@H]3CC[C@H](C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O__Name: Altabax__Applicant: GlaxoSmithKline__Active moiety: retapamulin__Approval Year: 2007__Route: Topical__logP: 5.3__MW: 517.8__Class: Prenol lipids','CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1__Name: Neupro__Applicant: Schwarz BioSciences__Active moiety: rotigotine__Approval Year: 2007__Route: Transdermal__logP: 4.3__MW: 315.5__Class: Tetralins','CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C__Name: Torisel__Applicant: Wyeth__Active moiety: temsirolimus__Approval Year: 2007__Route: Intravenous__logP: 5.7__MW: 1030.3__Class: Macrolide lactams','COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O__Name: Letairis__Applicant: Gilead Sciences__Active moiety: ambrisentan__Approval Year: 2007__Route: Oral__logP: 3.5__MW: 378.4__Class: Benzene and substituted derivatives','Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1__Name: Selzentry__Applicant: Pfizer__Active moiety: maraviroc__Approval Year: 2007__Route: Oral__logP: 6.0__MW: 513.7__Class: Tropane alkaloids','CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O__Name: Somatuline Depot__Applicant: Beaufour Ipsen Pharma__Active moiety: lanreotide__Approval Year: 2007__Route: Subcutaneous__logP: 0.8__MW: 1096.3__Class: Carboxylic acids and derivatives','C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12__Name: Doribax__Applicant: Johnson & Johnson__Active moiety: doripenem__Approval Year: 2007__Route: Intravenous__logP: -1.6__MW: 420.5__Class: Lactams','Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1__Name: Isentress__Applicant: Merck__Active moiety: raltegravir__Approval Year: 2007__Route: Oral__logP: 0.9__MW: 444.4__Class: Diazines','C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1__Name: Ixempra__Applicant: Bristol-Myers Squibb__Active moiety: ixabepilone__Approval Year: 2007__Route: Intravenous__logP: 4.1__MW: 506.7__Class: Macrolides and analogues','Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1__Name: Tasigna__Applicant: Novartis Pharmaceuticals__Active moiety: nilotinib__Approval Year: 2007__Route: Oral__logP: 6.4__MW: 529.5__Class: Benzene and substituted derivatives','C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1__Name: Kuvan__Applicant: Biomarin Pharmaceutical__Active moiety: sapropterin dihydrochloride__Approval Year: 2007__Route: Oral__logP: -1.7__MW: 241.3__Class: Pteridines and derivatives','OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1__Name: Bystolic__Applicant: Mylan Bertek Pharmaceuticals__Active moiety: nebivolol__Approval Year: 2007__Route: Oral__logP: 2.4__MW: 405.4__Class: Benzopyrans','Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br__Name: Intelence__Applicant: Tibotec__Active moiety: etravirine__Approval Year: 2008__Route: Oral__logP: 4.7__MW: 435.3__Class: Organooxygen compounds','CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1__Name: Emend__Applicant: Merck__Active moiety: fosaprepitant dimeglumine__Approval Year: 2008__Route: Intravenous__logP: -2.4__MW: 1004.8__Class: Oxazinanes','CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1__Name: Pristiq__Applicant: Wyeth Pharmaceuticals__Active moiety: desvenlafaxine__Approval Year: 2008__Route: Oral__logP: 2.7__MW: 263.4__Class: Organooxygen compounds','Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21__Name: Treanda__Applicant: Cephalon__Active moiety: bendamustine hydrochloride__Approval Year: 2008__Route: Iv (Infusion)__logP: 3.3__MW: 358.3__Class: Benzimidazoles','CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1__Name: Lexiscan__Applicant: CV Therapeutics__Active moiety: regadenoson__Approval Year: 2008__Route: Intravenous__logP: -2.4__MW: 390.4__Class: Purine nucleosides','C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5__Name: Relistor__Applicant: Progenics Pharmaceuticals__Active moiety: methylnaltrexonebromide__Approval Year: 2008__Route: Subcutaneous__logP: 1.7__MW: 356.4__Class: Phenanthrenes and derivatives','C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1__Name: Entereg__Applicant: Adolor__Active moiety: alvimopan__Approval Year: 2008__Route: Oral__logP: 3.1__MW: 424.5__Class: Peptidomimetics','CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C__Name: Durezol__Applicant: Sirion Therapeutics__Active moiety: difluprednate__Approval Year: 2008__Route: Ophthalmic__logP: 3.5__MW: 508.6__Class: Steroids and steroid derivatives','CCOc1ccc(CC(CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O)cc1.[Gd+3]__Name: Eovist__Applicant: Bayer Healthcare Pharmaceuticals__Active moiety: gadoxetate disodium__Approval Year: 2008__Route: Intravenous__logP: -0.7__MW: 684.8__Class: Carboxylic acids and derivatives','CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl__Name: Cleviprex__Applicant: The Medicines Company__Active moiety: clevidipine__Approval Year: 2008__Route: Intravenous__logP: 4.2__MW: 456.3__Class: Pyridines and derivatives','COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2__Name: Xenazine__Applicant: Prestwick Pharmaceuticals__Active moiety: tetrabenazine__Approval Year: 2008__Route: Oral__logP: 3.2__MW: 317.4__Class: Tetrahydroisoquinolines','N=C(N)NCc1cccc([123I])c1__Name: AdreView__Applicant: GE Healthcare__Active moiety: iobenguane I 123__Approval Year: 2008__Route: Intravenous__logP: 1.3__MW: 271.1__Class: Benzene and substituted derivatives','C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F__Name: Rapaflo__Applicant: Watson Laboratories__Active moiety: silodosin__Approval Year: 2008__Route: Oral__logP: 3.1__MW: 495.5__Class: Indoles and derivatives','COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1__Name: Vimpat__Applicant: Schwarz Biosciences__Active moiety: lacosamide__Approval Year: 2008__Route: Oral__logP: 0.5__MW: 250.3__Class: Carboxylic acids and derivatives','CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1__Name: Toviaz__Applicant: Pfizer__Active moiety: fesoterodine fumarate__Approval Year: 2008__Route: Oral__logP: 5.4__MW: 411.6__Class: Benzene and substituted derivatives','NC(=O)c1cn(Cc2c(F)cccc2F)nn1__Name: Banzel__Applicant: Eisai Medical Research__Active moiety: rufinamide__Approval Year: 2008__Route: Oral__logP: 0.7__MW: 238.2__Class: Carboxylic acids and derivatives','CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O__Name: Promacta__Applicant: GlaxoSmithKline__Active moiety: eltrombopag__Approval Year: 2008__Route: Oral__logP: 4.6__MW: 442.5__Class: Benzene and substituted derivatives','CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C__Name: Nucynta__Applicant: Johnson & Johnson__Active moiety: tapentadol__Approval Year: 2008__Route: Oral__logP: 3.1__MW: 221.3__Class: Benzene and substituted derivatives','CC(C)c1cccc(C(C)C)c1OCOP(=O)([O-])[O-]__Name: Lusedra__Applicant: Eisai Medical Research__Active moiety: fospropofol disodium__Approval Year: 2008__Route: Intravenous__logP: 2.1__MW: 286.3__Class: Benzene and substituted derivatives','c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1__Name: Mozobil__Applicant: Genzyme__Active moiety: plerixafor__Approval Year: 2008__Route: Subcutaneous__logP: 0.4__MW: 502.8__Class: Benzene and substituted derivatives','O=C([O-])CN(CCN(CC(=O)[O-])CC(COP(=O)([O-])OC1CCC(c2ccccc2)(c2ccccc2)CC1)N(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3]__Name: Vasovist__Applicant: Epix Pharmaceuticals__Active moiety: gadofosveset trisodium__Approval Year: 2008__Route: Intravenous__logP: -5.6__MW: 888.9__Class: Carboxylic acids and derivatives','CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O__Name: Firmagon__Applicant: Ferring Pharmaceuticals__Active moiety: degarelix__Approval Year: 2008__Route: Subcutaneous__logP: 1.5__MW: 1632.3__Class: Polypeptides','CCN(CC)C(=O)C1(c2ccccc2)CC1CN__Name: Savella__Applicant: Cypress Bioscience__Active moiety: milnacipran hydrochloride__Approval Year: 2009__Route: Oral__logP: 1.8__MW: 246.4__Class: Benzene and substituted derivatives','Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O__Name: Uloric__Applicant: Takeda Pharmaceuticals__Active moiety: febuxostat__Approval Year: 2009__Route: Oral__logP: 3.7__MW: 316.4__Class: Azoles','CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C__Name: Afinitor__Applicant: Novartis Pharmaceuticals__Active moiety: everolimus__Approval Year: 2009__Route: Oral__logP: 6.2__MW: 958.2__Class: Macrolide lactams','CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1__Name: Coartem__Applicant: Novartis Pharmaceuticals__Active moiety: artemether, lumefantrine__Approval Year: 2009__Route: Oral__logP: 9.2__MW: 529.0__Class: Fluorenes','OCc1ccccc1__Name: Ulesfia__Applicant: Sciele Pharma__Active moiety: benzyl alcohol__Approval Year: 2009__Route: Topical__logP: 1.2__MW: 108.1__Class: Benzene and substituted derivatives','COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1__Name: Fanapt__Applicant: Vanda Pharmaceuticals__Active moiety: iloperidone__Approval Year: 2009__Route: Oral__logP: 4.8__MW: 426.5__Class: Organooxygen compounds','Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1__Name: Samsca__Applicant: Otsuka Pharmaceutical__Active moiety: tolvaptan__Approval Year: 2009__Route: Oral__logP: 5.7__MW: 449.0__Class: Benzene and substituted derivatives','N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1__Name: Besivance__Applicant: Bausch & Lomb__Active moiety: besifloxacin__Approval Year: 2009__Route: Ophthalmic__logP: 3.1__MW: 393.8__Class: Quinolines and derivatives','CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1__Name: Multaq__Applicant: Sanofi-Aventis__Active moiety: dronedarone__Approval Year: 2009__Route: Oral__logP: 7.0__MW: 556.8__Class: Organooxygen compounds','CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2__Name: Effient__Applicant: Eli Lilly__Active moiety: prasugrel__Approval Year: 2009__Route: Oral__logP: 3.9__MW: 373.4__Class: Thienopyridines','N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2__Name: Onglyza__Applicant: Bristol-Myers Squibb__Active moiety: saxagliptin__Approval Year: 2009__Route: Oral__logP: 1.2__MW: 315.4__Class: Carboxylic acids and derivatives','O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1__Name: Livalo__Applicant: Kowa Research Institute__Active moiety: pitavastatin__Approval Year: 2009__Route: Oral__logP: 4.5__MW: 421.5__Class: Quinolines and derivatives','CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1__Name: Saphris__Applicant: Organon__Active moiety: asenapine__Approval Year: 2009__Route: Oral__logP: 4.3__MW: 285.8__Class: Benzoxepines','C=CC(N)CCC(=O)O__Name: Sabril__Applicant: Lundbeck__Active moiety: vigabatrin__Approval Year: 2009__Route: Oral__logP: 0.4__MW: 129.2__Class: Carboxylic acids and derivatives','O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1__Name: Bepreve__Applicant: Ista Pharmaceuticals__Active moiety: bepotastine besilate__Approval Year: 2009__Route: Ophthalmic__logP: 5.1__MW: 547.1__Class: Benzene and substituted derivatives','CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@H]2[C@H](Oc3c4cc5cc3Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]5C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c5cc(O)c(CNCP(=O)(O)O)c(O)c5-c5cc3ccc5O)[C@H](O)c3ccc(c(Cl)c3)O4)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@@H](C)[C@H]1O__Name: Vibativ__Applicant: Theravance__Active moiety: telavancin__Approval Year: 2009__Route: Intravenous__logP: 2.7__MW: 1755.7__Class: Carboxylic acids and derivatives','C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1__Name: Folotyn__Applicant: Allos Therapeutics__Active moiety: pralatrexate__Approval Year: 2009__Route: Intravenous__logP: 1.0__MW: 477.5__Class: Carboxylic acids and derivatives','Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O__Name: Votrient__Applicant: GlaxoSmithKline__Active moiety: pazopanib__Approval Year: 2009__Route: Oral__logP: 3.1__MW: 437.5__Class: Organonitrogen compounds','C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O__Name: Istodax__Applicant: Gloucester Pharmaceuticals__Active moiety: romidepsin__Approval Year: 2009__Route: Intravenous__logP: 1.4__MW: 540.7__Class: Peptidomimetics','COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O__Name: Qutenza__Applicant: Neurogesx__Active moiety: capsaicin__Approval Year: 2009__Route: Topical__logP: 3.8__MW: 305.4__Class: Phenols','Nc1ccncc1__Name: Ampyra__Applicant: Acorda Therapeutics__Active moiety: dalfampridine__Approval Year: 2010__Route: Oral__logP: 0.7__MW: 94.1__Class: Pyridines and derivatives','CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O__Name: Victoza__Applicant: Novo Nordisk__Active moiety: liraglutide__Approval Year: 2010__Route: Subcutaneous__logP: -10.8__MW: 3753.3__Class: Polypeptides','NC(=O)N[C@@H](CCC(=O)O)C(=O)O__Name: Carbaglu__Applicant: Orphan Europe__Active moiety: carglumic acid__Approval Year: 2010__Route: Oral__logP: -1.0__MW: 190.2__Class: Carboxylic acids and derivatives','CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO__Name: Asclera__Applicant: Chemische Fabrik Kreussler & Co., GmbH__Active moiety: polidocanol__Approval Year: 2010__Route: Intravenous__logP: 4.0__MW: 582.8__Class: Organooxygen compounds','C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N__Name: Natazia__Applicant: Bayer HealthCare Pharmaceuticals__Active moiety: estradiol valerate; estradiol valerate and dienogest__Approval Year: 2010__Route: Oral__logP: 3.8__MW: 311.4__Class: Steroids and steroid derivatives','CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C__Name: Jevtana__Applicant: Sanofi-Aventis__Active moiety: cabazitaxel__Approval Year: 2010__Route: Intravenous__logP: 4.6__MW: 835.9__Class: Prenol lipids','CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1__Name: Lastacaft__Applicant: Vistakon Pharmaceuticals__Active moiety: alcaftadine__Approval Year: 2010__Route: Ophthalmic__logP: 2.8__MW: 307.4__Class: Benzazepines','CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C__Name: Ella__Applicant: Laboratoire HRA Pharma__Active moiety: ulipristal acetate__Approval Year: 2010__Route: Oral__logP: 5.5__MW: 475.6__Class: Steroids and steroid derivatives','CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1__Name: Gilenya__Applicant: Novartis Pharmaceuticals__Active moiety: fingolimod__Approval Year: 2010__Route: Oral__logP: 3.2__MW: 307.5__Class: Organonitrogen compounds','CCCCCCOC(=O)/N=C(\N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1__Name: Pradaxa__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: dabigatran etexilate mesylate__Approval Year: 2010__Route: Oral__logP: 5.6__MW: 627.7__Class: Benzimidazoles','O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1__Name: Latuda__Applicant: Sunovion Pharmaceuticals__Active moiety: lurasidone hydrochloride__Approval Year: 2010__Route: Oral__logP: 4.3__MW: 492.7__Class: Diazinanes','CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1__Name: Teflaro__Applicant: Cerexa__Active moiety: ceftaroline fosamil__Approval Year: 2010__Route: Intravenous__logP: -0.1__MW: 684.7__Class: Lactams','C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC__Name: Halaven__Applicant: Eisai__Active moiety: eribulin mesylate__Approval Year: 2010__Route: Intravenous__logP: 3.4__MW: 729.9__Class: Furopyrans','COC(=O)[C@H]1[C@@H](c2ccc([123I])cc2)C[C@@H]2CC[C@H]1N2CCCF__Name: DaTscan__Applicant: GE Healthcare__Active moiety: ioflupane I 123__Approval Year: 2011__Route: Intravenous__logP: 3.8__MW: 427.3__Class: Tropane alkaloids','CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@@H]3[C@@H](C=C[C@@H]4C[C@@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@@H]34)C2CC(=O)O1.CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@H]3[C@@H]4C[C@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@H]4C(C)=C[C@H]3[C@@H]2CC(=O)O1__Name: Natroba__Applicant: Parapro__Active moiety: spinosad__Approval Year: 2011__Route: Topical__logP: 11.4__MW: 1478.0__Class: Organooxygen compounds','N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1__Name: Viibryd__Applicant: Trovis Pharmaceuticals__Active moiety: vilazodone hydrochloride__Approval Year: 2011__Route: Oral__logP: 4.0__MW: 441.5__Class: Diazinanes','CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1__Name: Edarbi__Applicant: Takeda Pharmaceuticals__Active moiety: azilsartan medoxomil__Approval Year: 2011__Route: Oral__logP: 4.7__MW: 568.5__Class: Benzene and substituted derivatives','O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1__Name: Daliresp__Applicant: Forest Research Institute__Active moiety: roflumilast__Approval Year: 2011__Route: Oral__logP: 5.0__MW: 403.2__Class: Benzene and substituted derivatives','O=C([O-])CN1CCN(CC(=O)[O-])CCN(C(CO)C(O)CO)CCN(CC(=O)[O-])CC1.[Gd+3]__Name: Gadavist__Applicant: Bayer HealthCare Pharmaceuticals__Active moiety: gadobutrol__Approval Year: 2011__Route: Intravenous__logP: -7.8__MW: 604.7__Class: Carboxylic acids and derivatives','COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1__Name: Caprelsa__Applicant: AstraZeneca Pharmaceuticals__Active moiety: vandetanib__Approval Year: 2011__Route: Oral__logP: 5.0__MW: 475.4__Class: Diazanaphthalenes','CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C__Name: Horizant__Applicant: GlaxoSmithKline__Active moiety: gabapentin enacarbil__Approval Year: 2011__Route: Oral__logP: 2.7__MW: 329.4__Class: Carboxylic acids and derivatives','CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1__Name: Zytiga__Applicant: Ortho Biotech Oncology Research and Development__Active moiety: abiraterone acetate__Approval Year: 2011__Route: Oral__logP: 6.0__MW: 391.6__Class: Steroids and steroid derivatives','CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C__Name: Tradjenta__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: linagliptin__Approval Year: 2011__Route: Oral__logP: 1.1__MW: 472.6__Class: Imidazopyrimidines','CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C__Name: Victrelis__Applicant: Schering__Active moiety: boceprevir__Approval Year: 2011__Route: Oral__logP: 1.7__MW: 519.7__Class: Peptidomimetics','Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1__Name: Edurant__Applicant: Tibotec__Active moiety: rilpivirine__Approval Year: 2011__Route: Oral__logP: 5.0__MW: 366.4__Class: Benzene and substituted derivatives','CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1__Name: Incivek__Applicant: Vertex Pharmaceuticals__Active moiety: telaprevir__Approval Year: 2011__Route: Oral__logP: 2.4__MW: 679.9__Class: Peptidomimetics','CCc1c(Cl)c(O)c(Cl)c(O)c1C(=O)O[C@H]1[C@H](O)[C@H](OC)[C@H](OC/C2=C\C=C\C[C@H](O)/C(C)=C/[C@H](CC)[C@@H](O[C@@H]3OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]3O)/C(C)=C/C(C)=C/C[C@@H]([C@@H](C)O)OC2=O)O[C@@H]1C__Name: Dificid__Applicant: Optimer Pharmaceuticals__Active moiety: fidaxomicin__Approval Year: 2011__Route: Oral__logP: 6.2__MW: 1058.1__Class: Macrolides and analogues','CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N__Name: Potiga__Applicant: Valeant Pharmaceuticals__Active moiety: ezogabine__Approval Year: 2011__Route: Oral__logP: 3.6__MW: 303.3__Class: Benzene and substituted derivatives','CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2__Name: Arcapta Neohaler__Applicant: Novartis Pharmaceuticals__Active moiety: indacaterol__Approval Year: 2011__Route: Inhalation__logP: 3.1__MW: 392.5__Class: Quinolines and derivatives','O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1__Name: Xarelto__Applicant: Johnson & Johnson__Active moiety: rivaroxaban__Approval Year: 2011__Route: Oral__logP: 2.5__MW: 435.9__Class: Oxazinanes','CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1__Name: Brilinta__Applicant: AstraZeneca Pharmaceuticals__Active moiety: ticagrelor__Approval Year: 2011__Route: Oral__logP: 2.0__MW: 522.6__Class: Triazolopyrimidines','CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F__Name: Zelboraf__Applicant: Hoffmann-La Roche__Active moiety: vemurafenib__Approval Year: 2011__Route: Oral__logP: 5.5__MW: 489.9__Class: Organooxygen compounds','N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O__Name: Firazyr__Applicant: Shire Orphan Therapies__Active moiety: icatibant__Approval Year: 2011__Route: Subcutaneous__logP: -4.4__MW: 1304.5__Class: Carboxylic acids and derivatives','C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl__Name: Xalkori__Applicant: Pfizer__Active moiety: crizotinib__Approval Year: 2011__Route: Oral__logP: 5.0__MW: 450.3__Class: Pyridines and derivatives','Cc1c(O)c(=O)ccn1C__Name: Ferriprox__Applicant: ApoPharma__Active moiety: deferiprone__Approval Year: 2011__Route: Oral__logP: 0.4__MW: 139.2__Class: Pyridines and derivatives','CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21__Name: Onfi__Applicant: Lundbeck__Active moiety: clobazam__Approval Year: 2011__Route: Oral__logP: 3.4__MW: 300.7__Class: Benzodiazepines','N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1__Name: Jakafi__Applicant: Incyte__Active moiety: ruxolitinib__Approval Year: 2011__Route: Oral__logP: 3.5__MW: 306.4__Class: Pyrrolopyrimidines','C/C=C(/C)C(=O)O[C@H]1C(C)=C[C@]23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@]12O)[C@H]1[C@@H](C[C@H]3C)C1(C)C__Name: Picato__Applicant: Leo Pharma__Active moiety: ingenol mebutate__Approval Year: 2012__Route: Topical__logP: 2.3__MW: 430.5__Class: Prenol lipids','CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1__Name: Inlyta__Applicant: Pfizer__Active moiety: axitinib__Approval Year: 2012__Route: Oral__logP: 4.6__MW: 386.5__Class: Thioethers','CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1__Name: Erivedge__Applicant: Genentech__Active moiety: vismodegib__Approval Year: 2012__Route: Oral__logP: 4.7__MW: 421.3__Class: Benzene and substituted derivatives','CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O__Name: Kalydeco__Applicant: Vertex Pharmaceuticals__Active moiety: ivacaftor__Approval Year: 2012__Route: Oral__logP: 5.1__MW: 392.5__Class: Benzene and substituted derivatives','CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1__Name: Zioptan__Applicant: Merck__Active moiety: tafluprost__Approval Year: 2012__Route: Ophthalmic__logP: 4.7__MW: 452.5__Class: Fatty Acyls','CC(C)CC(NC(=O)C(N)CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)O__Name: Surfaxin__Applicant: Discovery Laboratories__Active moiety: lucinactant__Approval Year: 2012__Route: Intratracheal__logP: 6.5__MW: 2469.4__Class: Glycerophospholipids','CNc1ccc(/C=C/c2ccc(OCCOCCOCC[18F])nc2)cc1__Name: Amyvid__Applicant: Avid Radiopharmaceuticals__Active moiety: florbetapir F 18__Approval Year: 2012__Route: Intravenous__logP: 3.7__MW: 359.4__Class: Benzene and substituted derivatives','COc1ccc(C/N=c2\[nH]c(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl__Name: Stendra__Applicant: Vivus__Active moiety: avanafil__Approval Year: 2012__Route: Oral__logP: 1.9__MW: 484.0__Class: Diazines','C[C@H]1CNCCc2ccc(Cl)cc21__Name: Belviq__Applicant: Arena Pharmacueticals__Active moiety: lorcaserin hydrochloride__Approval Year: 2012__Route: Oral__logP: 2.6__MW: 195.7__Class: Benzazepines','Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1__Name: Myrbetriq__Applicant: Astellas Pharma__Active moiety: mirabegron__Approval Year: 2012__Route: Oral__logP: 2.8__MW: 396.5__Class: Benzene and substituted derivatives','O=C(O)CC(O)(CC(=O)O)C(=O)O.O=S(=O)([O-])Oc1ccc(C(c2ccc(OS(=O)(=O)[O-])cc2)c2ccccn2)cc1.O=[Mg]__Name: Prepopik__Applicant: Ferring Pharmaceuticals__Active moiety: sodium picosulfate, magnesium oxide, citric acid__Approval Year: 2012__Route: Oral__logP: 0.2__MW: 667.9__Class: Benzene and substituted derivatives','CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1__Name: Kyprolis__Applicant: Onyx Pharmaceuticals__Active moiety: carfilzomib__Approval Year: 2012__Route: Intravenous__logP: 2.6__MW: 719.9__Class: Carboxylic acids and derivatives','O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1__Name: Tudorza Pressair__Applicant: Forest Laboratories__Active moiety: aclidinium bromide__Approval Year: 2012__Route: Inhalation__logP: 4.7__MW: 484.7__Class: Quinuclidines','CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1.COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C.Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F__Name: Stribild__Applicant: Gilead Sciences__Active moiety: elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate__Approval Year: 2012__Route: Oral__logP: 12.9__MW: 1990.6__Class: Carboxylic acids and derivatives','C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC3=O)C(=O)N2__Name: Linzess__Applicant: Forest Laboratories__Active moiety: linaclotide__Approval Year: 2012__Route: Oral__logP: -5.9__MW: 1526.8__Class: Polypeptides','CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F__Name: Xtandi__Applicant: Medivation__Active moiety: enzalutamide__Approval Year: 2012__Route: Oral__logP: 4.0__MW: 464.4__Class: Azolidines','COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl__Name: Bosulif__Applicant: Wyeth Pharmaceuticals__Active moiety: bosutinib__Approval Year: 2012__Route: Oral__logP: 5.2__MW: 530.5__Class: Quinolines and derivatives','C[N+](C)([11CH3])CCO__Name: [drug marketed without a proprietary name]__Applicant: Mayo Clinic__Active moiety: choline C 11__Approval Year: 2012__Route: Intravenous__logP: -0.3__MW: 103.2__Class: Organonitrogen compounds','C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1__Name: Aubagio__Applicant: Sanofi-Aventis__Active moiety: teriflunomide__Approval Year: 2012__Route: Oral__logP: 3.0__MW: 270.2__Class: Benzene and substituted derivatives','CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1__Name: Stivarga__Applicant: Bayer HealthCare Pharmaceuticals__Active moiety: regorafenib__Approval Year: 2012__Route: Oral__logP: 5.7__MW: 482.8__Class: Organooxygen compounds','N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O__Name: Fycompa__Applicant: Eisai__Active moiety: perampanel__Approval Year: 2012__Route: Oral__logP: 4.4__MW: 349.4__Class: Pyridines and derivatives','COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4__Name: Synribo__Applicant: Ivax International GmbH__Active moiety: omacetaxine mepesuccinate__Approval Year: 2012__Route: Subcutaneous__logP: 2.6__MW: 545.6__Class: Cephalotaxus alkaloids','C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12__Name: Xeljanz__Applicant: Pfizer__Active moiety: tofacitinib__Approval Year: 2012__Route: Oral__logP: 1.5__MW: 312.4__Class: Piperidines','COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC__Name: Cometriq__Applicant: Exelixis__Active moiety: cabozantinib__Approval Year: 2012__Route: Oral__logP: 5.5__MW: 501.5__Class: Organooxygen compounds','NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O__Name: Signifor__Applicant: Novartis Pharmaceuticals__Active moiety: pasireotide__Approval Year: 2012__Route: Subcutaneous__logP: 3.4__MW: 1047.2__Class: Carboxylic acids and derivatives','Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12__Name: Iclusig__Applicant: Ariad Pharmaceuticals__Active moiety: ponatinib__Approval Year: 2012__Route: Oral__logP: 4.5__MW: 532.6__Class: Benzene and substituted derivatives','O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1__Name: Juxtapid__Applicant: Aegerion Pharmaceuticals__Active moiety: lomitapide__Approval Year: 2012__Route: Oral__logP: 8.4__MW: 693.7__Class: Fluorenes','CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC__Name: Gattex__Applicant: NPS Pharmaceuticals__Active moiety: teduglutide(rDNAorigin)__Approval Year: 2012__Route: Subcutaneous__logP: -16.9__MW: 3752.1__Class: Polypeptides','COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1__Name: Eliquis__Applicant: Bristol-Myers Squibb__Active moiety: apixaban__Approval Year: 2012__Route: Oral__logP: 2.7__MW: 459.5__Class: Piperidines','COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12__Name: Sirturo__Applicant: Janssen Research & Development__Active moiety: bedaquiline__Approval Year: 2012__Route: Oral__logP: 7.1__MW: 555.5__Class: Stilbenes','Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O__Name: Nesina__Applicant: Takeda Pharmaceuticals__Active moiety: alogliptin__Approval Year: 2013__Route: Oral__logP: 0.4__MW: 339.4__Class: Benzene and substituted derivatives','COCCO[C@H]1[C@@H](O)[C@H](COP(=O)([O-])S[C@H]2[C@H](COP(=O)([O-])S[C@H]3[C@H](COP(=O)([O-])S[C@H]4[C@H](COP(=O)([O-])S[C@H]5[C@@H](OCCOC)[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5COP(=O)([O-])S[C@H]5C[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)([O-])S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)([O-])S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)([O-])S[C@H]5C[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)([O-])S[C@H]5C[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5COP(=O)([O-])S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)([O-])S[C@H]5C[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)([O-])S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)([O-])S[C@H]5C[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5COP(=O)([O-])S[C@H]5C[C@H](n6cnc7c(N)ncnc76)O[C@@H]5COP(=O)([O-])S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)([O-])S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)([O-])S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)([O-])S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)([O-])S[C@H]5[C@@H](OCCOC)[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5CO)O[C@H](n5cc(C)c(N)nc5=O)[C@H]4OCCOC)O[C@H](n4cnc5c(N)ncnc54)[C@H]3OCCOC)O[C@H](n3cc(C)c(N)nc3=O)[C@H]2OCCOC)O[C@@H]1n1cc(C)c(N)nc1=O__Name: Kynamro__Applicant: Genzyme__Active moiety: mipomersen sodium__Approval Year: 2013__Route: Subcutaneous__logP: -7.0__MW: 7158.1__Class: Purine nucleosides','Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O__Name: Pomalyst__Applicant: Celgene__Active moiety: pomalidomide__Approval Year: 2013__Route: Oral__logP: -0.3__MW: 273.2__Class: Isoindoles and derivatives','OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1__Name: Osphena__Applicant: Shionogi__Active moiety: ospemifene__Approval Year: 2013__Route: Oral__logP: 5.6__MW: 378.9__Class: Stilbenes','CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])CN1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)[O-])CC1.[Gd+3]__Name: Dotarem__Applicant: Guerbet__Active moiety: gadoterate meglumine__Approval Year: 2013__Route: Intravenous__logP: -9.8__MW: 753.9__Class: Carboxylic acids and derivatives','COC(=O)/C=C/C(=O)OC__Name: Tecfidera__Applicant: Biogen Idec__Active moiety: dimethyl fumarate__Approval Year: 2013__Route: Oral__logP: -0.1__MW: 144.1__Class: Fatty Acyls','Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1__Name: Invokana__Applicant: Janssen Research & Development__Active moiety: canagliflozin__Approval Year: 2013__Route: Oral__logP: 3.0__MW: 444.5__Class: Organooxygen compounds','C[C@@H]1C[C@H]2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O__Name: Breo Ellipta__Applicant: GlaxoSmithKline__Active moiety: fluticasone furoate and vilanterol__Approval Year: 2013__Route: Inhalation__logP: 9.5__MW: 1025.0__Class: Steroids and steroid derivatives','CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1__Name: Tafinlar__Applicant: GlaxoSmithKline__Active moiety: dabrafenib__Approval Year: 2013__Route: Oral__logP: 5.4__MW: 519.6__Class: Benzene and substituted derivatives','CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1__Name: Mekinist__Applicant: GlaxoSmithKline__Active moiety: trametinib__Approval Year: 2013__Route: Oral__logP: 3.9__MW: 615.4__Class: Pyridopyrimidines','CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1__Name: Gilotrif__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: afatinib__Approval Year: 2013__Route: Oral__logP: 4.4__MW: 485.9__Class: Diazanaphthalenes','C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21__Name: Tivicay__Applicant: GlaxoSmithKline__Active moiety: dolutegravir__Approval Year: 2013__Route: Oral__logP: 1.4__MW: 419.4__Class: Pyridines and derivatives','Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1__Name: Brintellix__Applicant: Takeda Pharmaceuticals__Active moiety: vortioxetine__Approval Year: 2013__Route: Oral__logP: 3.9__MW: 298.5__Class: Diazinanes','C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O.C[C@]12CC[C@H]3C(=CCc4cc(OS(=O)(=O)O)ccc43)[C@@H]1CCC2=O.C[C@]12CCc3c(ccc4cc(OS(=O)(=O)O)ccc34)[C@@H]1CCC2=O.Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12__Name: Duavee__Applicant: Wyeth Pharmaceuticals__Active moiety: conjugated estrogens and bazedoxifene__Approval Year: 2013__Route: Oral__logP: 16.3__MW: 1515.9__Class: Indoles and derivatives','COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N__Name: Adempas__Applicant: Bayer HealthCare Pharmaceuticals__Active moiety: riociguat__Approval Year: 2013__Route: Oral__logP: 2.4__MW: 422.4__Class: Pyrazolopyridines','CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1__Name: Opsumit__Applicant: Actelion Pharmaceuticals__Active moiety: macitentan__Approval Year: 2013__Route: Oral__logP: 3.6__MW: 588.3__Class: Diazines','CNc1ccc(-c2nc3ccc(O)cc3s2)cc1[18F]__Name: Vizamyl__Applicant: GE Healthcare__Active moiety: flutemetamol F 18__Approval Year: 2013__Route: Intravenous__logP: 3.8__MW: 273.3__Class: Benzothiazoles','CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21__Name: Aptiom__Applicant: Sunovion Pharmaceuticals__Active moiety: eslicarbazepine acetate__Approval Year: 2013__Route: Oral__logP: 3.1__MW: 296.3__Class: Benzazepines','C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1__Name: Imbruvica__Applicant: Pharmacyclics__Active moiety: ibrutinib__Approval Year: 2013__Route: Oral__logP: 4.2__MW: 440.5__Class: Benzene and substituted derivatives','N#C/C(=C1/SC[C@@H](c2ccc(Cl)cc2Cl)S1)n1ccnc1__Name: Luzu__Applicant: Medicis Pharmaceutical__Active moiety: luliconazole__Approval Year: 2013__Route: Topical__logP: 5.1__MW: 354.3__Class: Benzene and substituted derivatives','COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C__Name: Olysio__Applicant: Janssen Research & Development__Active moiety: simeprevir__Approval Year: 2013__Route: Oral__logP: 5.3__MW: 750.0__Class: Macrolactams','CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1__Name: Sovaldi__Applicant: Gilead Sciences__Active moiety: sofosbuvir__Approval Year: 2013__Route: Oral__logP: 1.7__MW: 529.5__Class: Pyrimidine nucleosides','OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2__Name: Anoro Ellipta__Applicant: GlaxoSmithKline__Active moiety: umeclidinium, vilanterol__Approval Year: 2013__Route: Inhalation__logP: 5.1__MW: 428.6__Class: Benzene and substituted derivatives','CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1__Name: Farxiga__Applicant: Bristol-Myers Squibb__Active moiety: dapagliflozin__Approval Year: 2014__Route: Oral__logP: 1.8__MW: 408.9__Class: Organooxygen compounds','CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2__Name: Hetlioz__Applicant: Vanda Pharmaceuticals__Active moiety: tasimelteon__Approval Year: 2014__Route: Oral__logP: 2.3__MW: 245.3__Class: Coumarans','N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1__Name: Northera__Applicant: Chelsea Therapeutics__Active moiety: droxidopa__Approval Year: 2014__Route: Oral__logP: -0.5__MW: 213.2__Class: Carboxylic acids and derivatives','CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C__Name: Impavido__Applicant: Paladin Therapuetics__Active moiety: miltefosine__Approval Year: 2014__Route: Oral__logP: 5.7__MW: 407.6__Class: Organonitrogen compounds','CNc1ccc(/C=C/c2ccc(OCCOCCOCC[18F])cc2)cc1__Name: Neuraceq__Applicant: Piramal Imaging__Active moiety: florbetaben F 18__Approval Year: 2014__Route: Intravenous__logP: 4.3__MW: 358.4__Class: Stilbenes','CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC__Name: Otezla__Applicant: Celgene__Active moiety: apremilast__Approval Year: 2014__Route: Oral__logP: 2.4__MW: 460.5__Class: Isoindoles and derivatives','Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1__Name: Zykadia__Applicant: Novartis Pharmaceuticals__Active moiety: ceritinib__Approval Year: 2014__Route: Oral__logP: 6.4__MW: 558.1__Class: Piperidines','CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1__Name: Zontivity__Applicant: Merck Sharp & Dohme__Active moiety: vorapaxar__Approval Year: 2014__Route: Oral__logP: 5.6__MW: 492.6__Class: Naphthofurans','CN[C@H]1C(=O)N[C@@H]2Cc3ccc(cc3)Oc3cc4cc(c3O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc(O)cc1[C@@H](C(=O)NCCCN(C)C)NC3=O__Name: Dalvance__Applicant: Durata Therapeutics International__Active moiety: dalbavancin__Approval Year: 2014__Route: Intravenous__logP: 4.2__MW: 1816.7__Class: Carboxylic acids and derivatives','C=C1CCN([C@H](C)[C@](O)(Cn2cncn2)c2ccc(F)cc2F)CC1__Name: Jublia__Applicant: Dow Pharmaceutical Sciences__Active moiety: efinaconazole__Approval Year: 2014__Route: Topical__logP: 2.5__MW: 348.4__Class: Benzene and substituted derivatives','Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1__Name: Sivextro__Applicant: Cubist Pharmaceuticals__Active moiety: tedizolid phosphate__Approval Year: 2014__Route: Oral__logP: 1.5__MW: 450.3__Class: Pyridines and derivatives','O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO__Name: Beleodaq__Applicant: Spectrum Pharmaceuticals__Active moiety: belinostat__Approval Year: 2014__Route: Intravenous__logP: 2.0__MW: 318.4__Class: Cinnamic acids and derivatives','OB1OCc2cc(F)ccc21__Name: Kerydin__Applicant: Anacor Pharmaceuticals__Active moiety: tavaborole__Approval Year: 2014__Route: Topical__logP: 0.0__MW: 151.9__Class: Aryl halides','CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1__Name: Zydelig__Applicant: Gilead Sciences__Active moiety: idelalisib__Approval Year: 2014__Route: Oral__logP: 3.8__MW: 415.4__Class: Imidazopyrimidines','COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1__Name: Striverdi Respimat__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: olodaterol__Approval Year: 2014__Route: Inhalation__logP: 2.4__MW: 386.4__Class: Benzoxazines','OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O__Name: Jardiance__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: empagliflozin__Approval Year: 2014__Route: Oral__logP: 1.6__MW: 450.9__Class: Organooxygen compounds','CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O[C@H]3C[C@](C)(N)[C@@H](O)[C@H](C)O3)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(NCc3ccc(-c4ccc(Cl)cc4)cc3)[C@@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O__Name: Orbactiv__Applicant: The Medicines Company__Active moiety: oritavancin diphosphate__Approval Year: 2014__Route: Intravenous__logP: 4.5__MW: 1793.1__Class: Carboxylic acids and derivatives','Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1__Name: Belsomra__Applicant: Merck__Active moiety: suvorexant__Approval Year: 2014__Route: Oral__logP: 4.1__MW: 450.9__Class: Benzene and substituted derivatives','CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2__Name: Cerdelga__Applicant: Genzyme__Active moiety: eliglustat__Approval Year: 2014__Route: Oral__logP: 3.4__MW: 404.6__Class: Benzodioxanes','C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5__Name: Movantik__Applicant: AstraZeneca Pharmaceuticals__Active moiety: naloxegol__Approval Year: 2014__Route: Oral__logP: 1.9__MW: 651.8__Class: Phenanthrenes and derivatives','Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1__Name: Akynzeo__Applicant: Helsinn Healthcare__Active moiety: netupitant, palonosetron__Approval Year: 2014__Route: Oral__logP: 6.8__MW: 578.6__Class: Diazinanes','CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1.COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1ncc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5nc([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c5c4)ccc2-3)[nH]1)C(C)C__Name: Harvoni__Applicant: Gilead Sciences__Active moiety: ledipasvir, sofosbuvir__Approval Year: 2014__Route: Oral__logP: 10.3__MW: 1418.5__Class: Fluorenes','Cc1ccc(=O)n(-c2ccccc2)c1__Name: Esbriet__Applicant: Intermune__Active moiety: pirfenidone__Approval Year: 2014__Route: Oral__logP: 2.1__MW: 185.2__Class: Pyridines and derivatives','COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1__Name: Ofev__Applicant: Boehringer Ingelheim Pharmaceuticals__Active moiety: nintedanib__Approval Year: 2014__Route: Oral__logP: 3.6__MW: 539.6__Class: Indoles and derivatives','N#Cc1c(N2C[C@@H]3NCCO[C@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12__Name: Xtoro__Applicant: Alcon Research__Active moiety: finafloxacin__Approval Year: 2014__Route: Otic__logP: 1.2__MW: 398.4__Class: Quinolines and derivatives','O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1__Name: Lynparza__Applicant: AstraZeneca Pharmaceuticals__Active moiety: olaparib__Approval Year: 2014__Route: Oral__logP: 2.3__MW: 434.5__Class: Diazanaphthalenes','C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)CC2S1(=O)=O.Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)/C(=N/OC(C)(C)C(=O)O)c3nsc(N)n3)[C@H]2SC1__Name: Zerbaxa__Applicant: Cubist Pharmaceuticals__Active moiety: ceftolozane, tazobactam__Approval Year: 2014__Route: Intravenous__logP: -5.4__MW: 967.0__Class: Lactams','CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N__Name: Rapivab__Applicant: BioCryst Pharmaceuticals__Active moiety: peramivir__Approval Year: 2014__Route: Intravenous__logP: -0.1__MW: 328.4__Class: Carboxylic acids and derivatives','CC(C)c1nc(CN(C)C(=O)NC(C(=O)N[C@@H](Cc2ccccc2)CC(O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1.COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc([C@@H]2CC[C@@H](c3ccc(NC(=O)[C@@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C.COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C.Cc1cnc(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](Oc4nc5ccccc5c5ccccc45)CN3C2=O)cn1__Name: Viekira Pak__Applicant: AbbVie__Active moiety: ombitasvir, paritaprevir, ritonavir; dasabuvir (co-packaged)__Approval Year: 2014__Route: Oral__logP: 21.3__MW: 2874.6__Class: Carboxylic acids and derivatives','CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1__Name: Savaysa__Applicant: Daiichi Sankyo__Active moiety: edoxaban tosylate__Approval Year: 2015__Route: Oral__logP: 1.3__MW: 548.1__Class: Carboxylic acids and derivatives','CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O__Name: Ibrance__Applicant: Pfizer__Active moiety: palbociclib__Approval Year: 2015__Route: Oral__logP: 3.0__MW: 447.5__Class: Diazinanes','COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O__Name: Lenvima__Applicant: Eisai__Active moiety: lenvatinib__Approval Year: 2015__Route: Oral__logP: 4.1__MW: 426.9__Class: Quinolines and derivatives','Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1__Name: Farydak__Applicant: Novartis Pharmaceuticals__Active moiety: panobinostat__Approval Year: 2015__Route: Oral__logP: 3.3__MW: 349.4__Class: Indoles and derivatives','CC(C)(O/N=C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O.NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O__Name: Avycaz__Applicant: Forest Research Institute__Active moiety: ceftazidime and avibactam__Approval Year: 2015__Route: Iv (Infusion)__logP: -2.8__MW: 811.8__Class: Lactams','CNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1__Name: Cresemba__Applicant: Astellas Pharma__Active moiety: isavuconazonium sulfate__Approval Year: 2015__Route: Oral__logP: 4.6__MW: 717.8__Class: Carboxylic acids and derivatives','C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O__Name: Cholbam__Applicant: Asklepion Pharmaceuticals__Active moiety: cholic acid__Approval Year: 2015__Route: Oral__logP: 3.4__MW: 408.6__Class: Steroids and steroid derivatives','COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2__Name: Corlanor__Applicant: Amgen__Active moiety: ivabradine__Approval Year: 2015__Route: Oral__logP: 3.3__MW: 468.6__Class: Benzazepines','C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@@]21C__Name: Kybella__Applicant: Kythera Biopharmaceuticals__Active moiety: deoxycholic acid__Approval Year: 2015__Route: Subcutaneous__logP: 4.5__MW: 392.6__Class: Steroids and steroid derivatives','COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O__Name: Viberzi__Applicant: Furiex Pharmaceuticals__Active moiety: eluxadoline__Approval Year: 2015__Route: Oral__logP: 4.2__MW: 569.7__Class: Carboxylic acids and derivatives','CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O__Name: Kengreal__Applicant: The Medicines Company__Active moiety: cangrelor__Approval Year: 2015__Route: Intravenous__logP: 2.9__MW: 776.4__Class: Purine nucleotides','CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O.Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1__Name: Orkambi__Applicant: Vertex Pharmaceuticals__Active moiety: lumacaftor, ivacaftor__Approval Year: 2015__Route: Oral__logP: 9.8__MW: 844.9__Class: Pyridines and derivatives','CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1)[C@H](C(=O)[O-])C(C)C.CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1)[C@H](C(=O)[O-])C(C)C.CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)[O-]__Name: Entresto__Applicant: Novartis Pharmaceuticals__Active moiety: sacubitril, valsartan__Approval Year: 2015__Route: Oral__logP: 9.9__MW: 1688.0__Class: Carboxylic acids and derivatives','O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1__Name: Rexulti__Applicant: Otsuka Pharmaceutical__Active moiety: brexpiprazole__Approval Year: 2015__Route: Oral__logP: 4.7__MW: 433.6__Class: Diazinanes','Cc1c(C(=O)Nc2ccc(N3C[C@H](C)O[C@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1__Name: Odomzo__Applicant: Novartis Pharmaceuticals__Active moiety: sonidegib__Approval Year: 2015__Route: Oral__logP: 5.8__MW: 485.5__Class: Benzene and substituted derivatives','COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C__Name: Daklinza__Applicant: Bristol-Myers Squibb__Active moiety: daclatasvir__Approval Year: 2015__Route: Oral__logP: 6.2__MW: 738.9__Class: Carboxylic acids and derivatives','O=c1[nH]c2ccccc2n1CCN1CCN(c2cccc(C(F)(F)F)c2)CC1__Name: Addyi__Applicant: Sprout Pharmaceuticals__Active moiety: flibanserin__Approval Year: 2015__Route: Oral__logP: 3.2__MW: 390.4__Class: Diazinanes','C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1__Name: Varubi__Applicant: Tesaro__Active moiety: rolapitant__Approval Year: 2015__Route: Oral__logP: 5.7__MW: 500.5__Class: Carboxylic acids and derivatives','CC(=O)OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O__Name: Xuriden__Applicant: Wellstat Therapeutics__Active moiety: uridine triacetate__Approval Year: 2015__Route: Oral__logP: -1.1__MW: 370.3__Class: Pyrimidine nucleosides','CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1__Name: Vraylar__Applicant: Forest Laboratories__Active moiety: cariprazine__Approval Year: 2015__Route: Oral__logP: 4.3__MW: 427.4__Class: Diazinanes','N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl.O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F__Name: Lonsurf__Applicant: Taiho Oncology__Active moiety: trifluridine and tipiracil__Approval Year: 2015__Route: Oral__logP: -0.5__MW: 538.9__Class: Pyrimidine nucleosides','CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21__Name: Aristada__Applicant: Alkermes__Active moiety: aripiprazole lauroxil__Approval Year: 2015__Route: Intramuscular__logP: 8.7__MW: 660.7__Class: Diazinanes','C=C(F)C(=O)[O-].C=C(F)C(=O)[O-].C=CCCCCC=C.C=Cc1ccc(C=C)cc1.C=Cc1cccc(C=C)c1.C=Cc1ccccc1C=C.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO__Name: Veltassa__Applicant: Relypsa__Active moiety: patiromer__Approval Year: 2015__Route: Oral__logP: 6.7__MW: 861.0__Class: Benzene and substituted derivatives','COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4__Name: Yondelis__Applicant: Janssen Products__Active moiety: trabectedin__Approval Year: 2015__Route: Intravenous__logP: 3.4__MW: 761.8__Class: Benzene and substituted derivatives','COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C__Name: Genvoya__Applicant: Gilead Sciences__Active moiety: elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide__Approval Year: 2015__Route: Oral__logP: 4.3__MW: 447.9__Class: Nucleoside and nucleotide analogues','O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1__Name: Cotellic__Applicant: Genentech__Active moiety: cobimetinib__Approval Year: 2015__Route: Oral__logP: 3.8__MW: 531.3__Class: Benzene and substituted derivatives','C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C__Name: Tagrisso__Applicant: AstraZeneca Pharmaceuticals__Active moiety: osimertinib__Approval Year: 2015__Route: Oral__logP: 4.5__MW: 499.6__Class: Indoles and derivatives','CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O__Name: Ninlaro__Applicant: Millenium Pharmaceuticals__Active moiety: ixazomib__Approval Year: 2015__Route: Oral__logP: 1.3__MW: 361.0__Class: Benzene and substituted derivatives','CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O__Name: Alecensa__Applicant: Hoffmann-La Roche__Active moiety: alectinib__Approval Year: 2015__Route: Oral__logP: 4.8__MW: 482.6__Class: Indoles and derivatives','O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O__Name: Bridion__Applicant: Merck__Active moiety: sugammadex__Approval Year: 2015__Route: Intravenous__logP: -7.7__MW: 2002.2__Class: Organooxygen compounds','CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1__Name: Uptravi__Applicant: Actelion Pharmaceuticals__Active moiety: selexipag__Approval Year: 2015__Route: Oral__logP: 3.9__MW: 496.6__Class: Organonitrogen compounds','O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12__Name: Zurampic__Applicant: Ardea Biosciences__Active moiety: lesinurad__Approval Year: 2015__Route: Oral__logP: 4.2__MW: 404.3__Class: Azoles','C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1.COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc3c(c2)cc2n3[C@H](c3ccccc3)Oc3cc(C4=NC([C@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)N=C4)ccc3-2)[nH]1)C(C)C__Name: Zepatier__Applicant: Merck__Active moiety: elbasvir and grazoprevir__Approval Year: 2016__Route: Oral__logP: 10.6__MW: 1649.0__Class: Carboxylic acids and derivatives','CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1__Name: Briviact__Applicant: UCB__Active moiety: brivaracetam__Approval Year: 2016__Route: Oral__logP: 0.9__MW: 212.3__Class: Carboxylic acids and derivatives','CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1__Name: Venclexta__Applicant: AbbVie__Active moiety: venetoclax__Approval Year: 2016__Route: Oral__logP: 8.7__MW: 868.5__Class: Diazinanes','CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1__Name: Nuplazid__Applicant: Acadia Pharmaceuticals__Active moiety: pimavanserin__Approval Year: 2016__Route: Oral__logP: 4.7__MW: 427.6__Class: Phenol ethers','C[C@]1([18F])C[C@@](N)(C(=O)O)C1__Name: Axumin__Applicant: Blue Earth Diagnostics__Active moiety: fluciclovine F 18__Approval Year: 2016__Route: Intravenous__logP: 0.3__MW: 146.2__Class: Carboxylic acids and derivatives','CC[C@@H]1[C@@H]2C[C@H](O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@H]3[C@H](C)CCC(=O)O)[C@@H]2[C@@H]1O__Name: Ocaliva__Applicant: Intercept Pharmaceuticals__Active moiety: obeticholic acid__Approval Year: 2016__Route: Oral__logP: 5.1__MW: 420.6__Class: Steroids and steroid derivatives','C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O.[68Ga+3]__Name: Netspot__Applicant: Advanced Accelerator Applications__Active moiety: gallium Ga 68 dotatate__Approval Year: 2016__Route: Intravenous__logP: -7.9__MW: 1486.6__Class: Carboxylic acids and derivatives','CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1.COC[C@H]1C[C@@H](c2ncc(-c3ccc4c(c3)COc3cc5c(ccc6[nH]c([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)nc65)cc3-4)[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1__Name: Epclusa__Applicant: Gilead Sciences__Active moiety: sofosbuvir and velpatasvir__Approval Year: 2016__Route: Oral__logP: 9.4__MW: 1412.5__Class: Naphthopyrans','CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1__Name: Xiidra__Applicant: Shire Development__Active moiety: lifitegrast__Approval Year: 2016__Route: Ophthalmic__logP: 4.8__MW: 615.5__Class: Carboxylic acids and derivatives','N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1__Name: Eucrisa__Applicant: Anacor Pharmacueticals__Active moiety: crisaborole__Approval Year: 2016__Route: Topical__logP: 1.6__MW: 251.0__Class: Organooxygen compounds','CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1__Name: Rubraca__Applicant: Clovis Oncology__Active moiety: rucaparib__Approval Year: 2016__Route: Oral__logP: 3.0__MW: 323.4__Class: Indoles and derivatives','CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CC(N)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)O__Name: Trulance__Applicant: Synergy Pharmaceuticals__Active moiety: plecanatide__Approval Year: 2017__Route: Oral__logP: -8.1__MW: 1681.9__Class: Polypeptides','CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O__Name: Parsabiv__Applicant: Amgen__Active moiety: etelcalcetide__Approval Year: 2017__Route: Intravenous__logP: -7.2__MW: 1048.3__Class: Carboxylic acids and derivatives','CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C__Name: Emflaza__Applicant: Marathon Pharmaceuticals__Active moiety: deflazacort__Approval Year: 2017__Route: Oral__logP: 2.6__MW: 441.5__Class: Steroids and steroid derivatives','CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1__Name: Xermelo__Applicant: Lexicon Pharmaceuticals__Active moiety: telotristat ethyl__Approval Year: 2017__Route: Oral__logP: 5.0__MW: 575.0__Class: Carboxylic acids and derivatives','CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1__Name: Kisqali__Applicant: Novartis Pharmaceuticals__Active moiety: ribociclib__Approval Year: 2017__Route: Oral__logP: 2.8__MW: 434.5__Class: Diazinanes','C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O__Name: Xadago__Applicant: Newron Pharmaceuticals__Active moiety: safinamide__Approval Year: 2017__Route: Oral__logP: 2.4__MW: 302.3__Class: Carboxylic acids and derivatives','CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1__Name: Symproic__Applicant: Shionogi__Active moiety: naldemedine__Approval Year: 2017__Route: Oral__logP: 3.5__MW: 570.6__Class: Morphinans','NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12__Name: Zejula__Applicant: Tesaro__Active moiety: niraparib__Approval Year: 2017__Route: Oral__logP: 2.6__MW: 320.4__Class: Piperidines','[2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])C1CC(=O)C(CC(C)C)CN1CC2__Name: Austedo__Applicant: Teva Pharmaceuticals__Active moiety: deutetrabenazine__Approval Year: 2017__Route: Oral__logP: 3.2__MW: 323.5__Class: Tetrahydroisoquinolines','COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2__Name: Ingrezza__Applicant: Neurocrine Biosciences__Active moiety: valbenazine__Approval Year: 2017__Route: Oral__logP: 3.6__MW: 418.6__Class: Carboxylic acids and derivatives','CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4__Name: Rydapt__Applicant: Novartis Pharmaceuticals__Active moiety: midostaurin__Approval Year: 2017__Route: Oral__logP: 5.9__MW: 570.6__Class: Indoles and derivatives','CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](C(=O)N[C@@H](C)C(N)=O)[C@@H](C)O__Name: Tymlos__Applicant: Radius Health__Active moiety: abaloparatide__Approval Year: 2017__Route: Subcutaneous__logP: -15.4__MW: 3960.7__Class: Polypeptides','COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1__Name: Alunbrig__Applicant: Ariad Pharmaceuticals__Active moiety: brigatinib__Approval Year: 2017__Route: Oral__logP: 5.1__MW: 584.1__Class: Piperidines','CC1=NN(c2ccccc2)C(=O)C1__Name: Radicava__Applicant: Mitsubishi Tanabe Pharma Development__Active moiety: edaravone__Approval Year: 2017__Route: Intravenous__logP: 1.8__MW: 174.2__Class: Azolines','Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F__Name: Baxdela__Applicant: Melinta Therapeutics__Active moiety: delafloxacin__Approval Year: 2017__Route: Oral__logP: 1.9__MW: 440.8__Class: Quinolines and derivatives','COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1__Name: Bevyxxa__Applicant: Portola Pharmaceuticals__Active moiety: betrixaban__Approval Year: 2017__Route: Oral__logP: 4.1__MW: 451.9__Class: Benzene and substituted derivatives','CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C__Name: Nerlynx__Applicant: Puma Biotechnology__Active moiety: neratinib__Approval Year: 2017__Route: Oral__logP: 5.9__MW: 557.1__Class: Quinolines and derivatives','CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1.CC[C@H]1[C@@H](C(=O)N[C@]2(C(=O)NS(=O)(=O)C3(C)CC3)C[C@H]2C(F)F)N2C[C@@H]1Oc1nc3cc(OC)ccc3nc1C(F)(F)CCCC[C@@H]1C[C@H]1OC(=O)N[C@@H](C(C)(C)C)C2=O.COC[C@H]1C[C@@H](c2ncc(-c3ccc4c(c3)COc3cc5c(ccc6[nH]c([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)nc65)cc3-4)[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1__Name: Vosevi__Applicant: Gilead Sciences__Active moiety: sofosbuvir, velpatasvir, voxilaprevir__Approval Year: 2017__Route: Oral__logP: 14.3__MW: 2281.4__Class: Naphthopyrans','CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1__Name: Idhifa__Applicant: Celgene__Active moiety: enasidenib__Approval Year: 2017__Route: Oral__logP: 4.3__MW: 473.4__Class: Triazines','CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC/C=C/C(F)(F)c2nc3ccccc3nc2O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4(C)CC4)C[C@H]3C(F)F)N(C2)C1=O__Name: Mavyret__Applicant: AbbVie__Active moiety: glecaprevir, pibrentasvir__Approval Year: 2017__Route: Oral__logP: 3.9__MW: 838.9__Class: Carboxylic acids and derivatives','C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12.O=C(O)C[C@@H]1CC[C@H](NC(=O)Cc2cccs2)B(O)O1__Name: Vabomere__Applicant: The Medicines Company__Active moiety: meropenem and vaborbactam__Approval Year: 2017__Route: Intravenous__logP: 0.1__MW: 680.6__Class: Lactams','O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1__Name: [drug marketed without a proprietary name]__Applicant: Chemo Research, S.L.__Active moiety: benznidazole__Approval Year: 2017__Route: Oral__logP: 1.1__MW: 260.3__Class: Allyl-type 1,3-dipolar organic compounds','COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21__Name: Aliqopa__Applicant: Bayer HealthCare Pharmaceuticals__Active moiety: copanlisib__Approval Year: 2017__Route: Intravenous__logP: 0.7__MW: 480.5__Class: Diazanaphthalenes','Cc1ncc([N+](=O)[O-])n1CC(C)O__Name: Solosec__Applicant: Symbiomix Therapeutics__Active moiety: secnidazole__Approval Year: 2017__Route: Oral__logP: 0.5__MW: 185.2__Class: Azoles','CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1__Name: Verzenio__Applicant: Eli Lilly__Active moiety: abemaciclib__Approval Year: 2017__Route: Oral__logP: 4.9__MW: 506.6__Class: Benzimidazoles','CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12__Name: Calquence__Applicant: Acerta Pharma B.V.__Active moiety: acalabrutinib__Approval Year: 2017__Route: Oral__logP: 3.3__MW: 465.5__Class: Azoles','O=C(CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1)OCCCCO[N+](=O)[O-]__Name: Vyzulta__Applicant: Bausch & Lomb__Active moiety: latanoprostene bunod__Approval Year: 2017__Route: Ophthalmic__logP: 3.8__MW: 507.6__Class: Fatty Acyls','COc1cccc(N2CCN(C3=Nc4c(F)cccc4[C@H](CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1__Name: Prevymis__Applicant: Merck__Active moiety: letermovir__Approval Year: 2017__Route: Oral__logP: 5.7__MW: 572.6__Class: Diazinanes','CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C__Name: Ozempic__Applicant: Novo Nordisk__Active moiety: semaglutide__Approval Year: 2017__Route: Subcutaneous__logP: -11.6__MW: 4113.6__Class: nan','CNc1ncc(-c2ccc3c(=O)c(C(=O)O)cn(C4CC4)c3c2C)cc1C__Name: Xepi__Applicant: Ferrer Internacional S.A.__Active moiety: ozenoxacin__Approval Year: 2017__Route: Topical__logP: 3.8__MW: 363.4__Class: Quinolines and derivatives','Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1__Name: Rhopressa__Applicant: Aerie Pharmaceuticals__Active moiety: netarsudil__Approval Year: 2017__Route: Ophthalmic__logP: 4.9__MW: 453.5__Class: Carboxylic acids and derivatives','CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1__Name: Steglatro__Applicant: Merck Sharp & Dohme__Active moiety: ertugliflozin__Approval Year: 2017__Route: Oral__logP: 1.4__MW: 436.9__Class: Benzene and substituted derivatives','CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]c2ccccc12)NC=O__Name: Macrilen__Applicant: Aeterna Zentaris GmBH__Active moiety: macimorelin__Approval Year: 2017__Route: Oral__logP: 1.8__MW: 474.6__Class: Carboxylic acids and derivatives','CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O__Name: Giapreza__Applicant: La Jolla Pharmaceuticals__Active moiety: angiotensin II__Approval Year: 2017__Route: Intravenous__logP: -1.1__MW: 1046.2__Class: Carboxylic acids and derivatives','C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O.[177Lu+3]__Name: Lutathera__Applicant: Advanced Accelerator Applications__Active moiety: lutetium Lu 177 dotatate__Approval Year: 2018__Route: Intravenous__logP: -7.4__MW: 1609.6__Class: Carboxylic acids and derivatives','CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1.Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F.O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2__Name: Biktarvy__Applicant: Gilead Sciences__Active moiety: bictegravir, emtricitabine, tenofovir alafenamide__Approval Year: 2018__Route: Oral__logP: 4.2__MW: 1173.1__Class: Carboxylic acids and derivatives','CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO__Name: Symdeko__Applicant: Vertex Pharmaceuticals__Active moiety: tezacaftor, ivacaftor; ivacaftor (co-packaged)__Approval Year: 2018__Route: Oral__logP: 3.4__MW: 520.5__Class: Indoles and derivatives','CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F__Name: Erleada__Applicant: Janssen Biotech__Active moiety: apalutamide__Approval Year: 2018__Route: Oral__logP: 3.5__MW: 477.4__Class: Azolidines','COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC__Name: Tavalisse__Applicant: Rigel Pharmaceuticals__Active moiety: fostamatinib disodium hexahydrate__Approval Year: 2018__Route: Oral__logP: 3.1__MW: 580.5__Class: Benzene and substituted derivatives','Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1__Name: Akynzeo__Applicant: Helsinn Healthcare__Active moiety: fosnetupitant and palonosetron__Approval Year: 2018__Route: Intravenous__logP: 6.8__MW: 578.6__Class: Diazinanes','CC(Oc1c(Cl)cccc1Cl)C1=NCCN1__Name: Lucemyra__Applicant: US World Meds__Active moiety: lofexidine__Approval Year: 2018__Route: Oral__logP: 2.8__MW: 259.1__Class: Benzene and substituted derivatives','O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1__Name: Doptelet__Applicant: Dova Pharmaceuticals__Active moiety: avatrombopag__Approval Year: 2018__Route: Oral__logP: 6.6__MW: 649.7__Class: Diazinanes','CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1__Name: Olumiant__Applicant: Eli Lilly__Active moiety: baricitinib__Approval Year: 2018__Route: Oral__logP: 1.1__MW: 371.4__Class: Pyrrolopyrimidines','CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C__Name: [drug marketed without a proprietary name]__Applicant: Medicines Development Limited__Active moiety: moxidectin__Approval Year: 2018__Route: Oral__logP: 5.7__MW: 639.8__Class: Macrolides and analogues','CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O__Name: Zemdri__Applicant: Achaogen__Active moiety: plazomicin__Approval Year: 2018__Route: Intravenous__logP: -5.4__MW: 592.7__Class: Carboxylic acids and derivatives','C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O__Name: Epidiolex__Applicant: GW Pharmaceuticals__Active moiety: cannabidiol__Approval Year: 2018__Route: Oral__logP: 5.8__MW: 314.5__Class: Prenol lipids','COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1__Name: Braftovi__Applicant: Array Biopharma__Active moiety: encorafenib__Approval Year: 2018__Route: Oral__logP: 3.9__MW: 540.0__Class: Azoles','Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21__Name: Mektovi__Applicant: Array Biopharma__Active moiety: binimetinib__Approval Year: 2018__Route: Oral__logP: 3.0__MW: 441.2__Class: Benzene and substituted derivatives','O=C(NN1C(=O)[C@H]2[C@H]3C=C[C@H]([C@@H]4C[C@H]34)[C@H]2C1=O)c1ccc(C(F)(F)F)cc1__Name: Tpoxx__Applicant: SIGA Technologies__Active moiety: tecovirimat__Approval Year: 2018__Route: Oral__logP: 2.4__MW: 376.3__Class: Isoindoles and derivatives','COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(NC(C)CCCN)c2n1__Name: Krintafel__Applicant: GlaxoSmithKline__Active moiety: tafenoquine__Approval Year: 2018__Route: Oral__logP: 5.9__MW: 463.5__Class: Quinolines and derivatives','N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1__Name: Tibsovo__Applicant: Agios Pharmaceuticals__Active moiety: ivosidenib__Approval Year: 2018__Route: Oral__logP: 4.3__MW: 583.0__Class: Carboxylic acids and derivatives','COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F__Name: Orilissa__Applicant: AbbVie__Active moiety: elagolix__Approval Year: 2018__Route: Oral__logP: 5.5__MW: 631.6__Class: Carboxylic acids and derivatives','CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O.CCC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CCCC(=O)O__Name: Omegaven__Applicant: Fresenius Kabi__Active moiety: fish oil triglycerides__Approval Year: 2018__Route: Intravenous__logP: 12.9__MW: 645.0__Class: Fatty Acyls','CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC__Name: Mulpleta__Applicant: Shionogi__Active moiety: lusutrombopag__Approval Year: 2018__Route: Oral__logP: 8.5__MW: 591.6__Class: Cinnamic acids and derivatives','OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O__Name: Galafold__Applicant: Amicus Therapeutics__Active moiety: migalastat__Approval Year: 2018__Route: Oral__logP: -3.0__MW: 163.2__Class: Piperidines','C=C1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O__Name: Annovera__Applicant: The Population Council__Active moiety: segesterone acetate, ethinyl estradiol__Approval Year: 2018__Route: Vaginal__logP: 4.2__MW: 370.5__Class: Steroids and steroid derivatives','CC(C)(C)C(O)/C=C/c1ccc2c(c1)OCO2__Name: Diacomit__Applicant: Biocodex SA__Active moiety: stiripentol__Approval Year: 2018__Route: Oral__logP: 2.8__MW: 234.3__Class: Benzodioxoles','CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12__Name: Xerava__Applicant: Tetraphase Pharmaceuticals__Active moiety: eravacycline__Approval Year: 2018__Route: Intravenous__logP: 0.3__MW: 558.6__Class: Tetracyclines','Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O__Name: Pifeltro__Applicant: Merck Sharp & Dohme__Active moiety: doravirine__Approval Year: 2018__Route: Oral__logP: 2.7__MW: 425.8__Class: Organooxygen compounds','C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1__Name: Copiktra__Applicant: Verastem__Active moiety: duvelisib__Approval Year: 2018__Route: Oral__logP: 4.5__MW: 416.9__Class: Isoquinolines and derivatives','COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1__Name: Vizimpro__Applicant: Pfizer__Active moiety: dacomitinib__Approval Year: 2018__Route: Oral__logP: 5.2__MW: 469.9__Class: Diazanaphthalenes','CON(C)Cc1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O__Name: Seysara__Applicant: Allergan__Active moiety: sarecycline__Approval Year: 2018__Route: Oral__logP: 0.1__MW: 487.5__Class: Tetracyclines','CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O__Name: Nuzyra__Applicant: Paratek Pharmacueticals__Active moiety: omadacycline__Approval Year: 2018__Route: Oral__logP: 1.3__MW: 556.7__Class: Tetracyclines','COCCO[C@@H]1[C@H](O)[C@@H](COP(O)(=S)O[C@@H]2[C@@H](COP(O)(=S)O[C@@H]3[C@@H](COP(O)(=S)O[C@@H]4[C@@H](COP(O)(=S)O[C@@H]5[C@@H](COP(O)(=S)O[C@H]6C[C@H](n7cnc8c(N)ncnc87)O[C@@H]6COP(O)(=S)O[C@H]6C[C@H](n7cnc8c(N)ncnc87)O[C@@H]6COP(O)(=S)O[C@H]6C[C@H](n7cnc8c(=O)[nH]c(N)nc87)O[C@@H]6COP(O)(=S)O[C@H]6C[C@H](n7cc(C)c(=O)[nH]c7=O)O[C@@H]6COP(O)(=S)O[C@H]6C[C@H](n7cnc8c(N)ncnc87)O[C@@H]6COP(O)(=S)O[C@H]6C[C@H](n7cc(C)c(N)nc7=O)O[C@@H]6COP(O)(=S)O[C@H]6C[C@H](n7cnc8c(N)ncnc87)O[C@@H]6COP(O)(=S)O[C@H]6C[C@H](n7cc(C)c(=O)[nH]c7=O)O[C@@H]6COP(O)(=S)O[C@H]6C[C@H](n7cc(C)c(=O)[nH]c7=O)O[C@@H]6COP(O)(=S)O[C@H]6C[C@H](n7cnc8c(=O)[nH]c(N)nc87)O[C@@H]6COP(O)(=S)O[C@@H]6[C@@H](COP(O)(=S)O[C@@H]7[C@@H](COP(O)(=S)O[C@@H]8[C@@H](COP(=O)(S)O[C@@H]9[C@@H](COP(O)(=S)O[C@@H]%10[C@@H](CO)O[C@@H](n%11cc(C)c(=O)[nH]c%11=O)[C@@H]%10OCCOC)O[C@@H](n%10cc(C)c(N)nc%10=O)[C@@H]9OCCOC)O[C@@H](n9cc(C)c(=O)[nH]c9=O)[C@@H]8OCCOC)O[C@@H](n8cc(C)c(=O)[nH]c8=O)[C@@H]7OCCOC)O[C@@H](n7cnc8c(=O)[nH]c(N)nc87)[C@@H]6OCCOC)O[C@@H](n6cnc7c(N)ncnc76)[C@@H]5OCCOC)O[C@@H](n5cc(C)c(=O)[nH]c5=O)[C@@H]4OCCOC)O[C@@H](n4cc(C)c(N)nc4=O)[C@@H]3OCCOC)O[C@@H](n3cc(C)c(N)nc3=O)[C@@H]2OCCOC)O[C@H]1n1cc(C)c(N)nc1=O__Name: Tegsedi__Applicant: Ionis Pharmaceuticals__Active moiety: inotersen__Approval Year: 2018__Route: Subcutaneous__logP: -4.9__MW: 7183.2__Class: nan','Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1__Name: Talzenna__Applicant: Pfizer__Active moiety: talazoparib__Approval Year: 2018__Route: Oral__logP: 2.6__MW: 380.4__Class: Quinolines and derivatives','COC(=O)OCOc1c2n(ccc1=O)N([C@@H]1c3ccccc3SCc3c1ccc(F)c3F)[C@@H]1COCCN1C2=O__Name: Xofluza__Applicant: Shionogi__Active moiety: baloxavir marboxil__Approval Year: 2018__Route: Oral__logP: 3.4__MW: 571.6__Class: Benzothiepins','C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21__Name: Lorbrena__Applicant: Pfizer__Active moiety: lorlatinib__Approval Year: 2018__Route: Oral__logP: 2.8__MW: 406.4__Class: Macrolactams','CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1__Name: Yupelri__Applicant: Theravance Biopharma__Active moiety: revefenacin__Approval Year: 2018__Route: Inhalation__logP: 4.8__MW: 597.8__Class: Piperidines','CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C__Name: Aemcolo__Applicant: Cosmo Technologies__Active moiety: rifamycin__Approval Year: 2018__Route: Oral__logP: 4.8__MW: 697.8__Class: Macrolactams','CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1__Name: Daurismo__Applicant: Pfizer__Active moiety: glasdegib__Approval Year: 2018__Route: Oral__logP: 3.4__MW: 374.4__Class: Benzene and substituted derivatives','O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1__Name: Vitrakvi__Applicant: Loxo Oncology__Active moiety: larotrectinib__Approval Year: 2018__Route: Oral__logP: 2.9__MW: 428.4__Class: Pyrrolidines','Nc1ccncc1N__Name: Firdapse__Applicant: Catalyst Pharmaceuticals__Active moiety: amifampridine__Approval Year: 2018__Route: Oral__logP: 0.2__MW: 109.1__Class: Pyridines and derivatives','CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1__Name: Xospata__Applicant: Astellas Pharma__Active moiety: gilteritinib__Approval Year: 2018__Route: Oral__logP: 2.7__MW: 552.7__Class: Piperidines','COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1__Name: Motegrity__Applicant: Shire Development__Active moiety: prucalopride__Approval Year: 2018__Route: Oral__logP: 2.1__MW: 367.9__Class: Benzene and substituted derivatives','CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1__Name: Egaten__Applicant: Novartis Pharmaceuticals__Active moiety: triclabendazole__Approval Year: 2019__Route: Oral__logP: 6.0__MW: 359.7__Class: Organooxygen compounds','CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C__Name: Zulresso__Applicant: Sage Therapeutics__Active moiety: brexanolone__Approval Year: 2019__Route: Intravenous__logP: 4.6__MW: 318.5__Class: Steroids and steroid derivatives','NC(=O)OC[C@H](N)Cc1ccccc1__Name: Sunosi__Applicant: Jazz Pharmaceuticals__Active moiety: solriamfetol__Approval Year: 2019__Route: Oral__logP: 0.7__MW: 194.2__Class: Benzene and substituted derivatives','CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1__Name: Mayzent__Applicant: Novartis Pharmaceuticals__Active moiety: siponimod__Approval Year: 2019__Route: Oral__logP: 6.8__MW: 516.6__Class: Benzene and substituted derivatives','COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1__Name: Balversa__Applicant: Janssen Biotech__Active moiety: erdafitinib__Approval Year: 2019__Route: Oral__logP: 4.2__MW: 446.6__Class: Organonitrogen compounds','CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1__Name: Vyndaqel__Applicant: Pfizer__Active moiety: tafamidis meglumine__Approval Year: 2019__Route: Oral__logP: 1.1__MW: 503.3__Class: Azoles','Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1__Name: Piqray__Applicant: Novartis Pharmaceuticals__Active moiety: alpelisib__Approval Year: 2019__Route: Oral__logP: 3.8__MW: 441.5__Class: Carboxylic acids and derivatives','CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O__Name: Vyleesi__Applicant: AMAG Pharmaceuticals__Active moiety: bremelanotide__Approval Year: 2019__Route: Subcutaneous__logP: -0.4__MW: 1025.2__Class: Carboxylic acids and derivatives','O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1__Name: Xpovio__Applicant: Karyopharm Therapeutics__Active moiety: selinexor__Approval Year: 2019__Route: Oral__logP: 3.4__MW: 443.3__Class: Azoles','C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCN=CN)C[C@H]12__Name: Recarbrio__Applicant: Merck Sharp & Dohme__Active moiety: imipenem, cilastatin, and relebactam__Approval Year: 2019__Route: Intravenous__logP: -0.4__MW: 299.4__Class: Lactams','Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].[Fe+3]__Name: Accrufer__Applicant: Sheild Therapeutics__Active moiety: ferric maltol__Approval Year: 2019__Route: Oral__logP: 0.1__MW: 431.2__Class: Pyrans','CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1__Name: Nubeqa__Applicant: Bayer HealthCare Pharmaceuticals__Active moiety: darolutamide__Approval Year: 2019__Route: Oral__logP: 2.7__MW: 398.9__Class: Azoles','FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1__Name: Turalio__Applicant: Daiichi Sankyo__Active moiety: pexidartinib__Approval Year: 2019__Route: Oral__logP: 5.2__MW: 417.8__Class: Pyrrolopyridines','Clc1ccc(CCCOCCCN2CCCCC2)cc1__Name: Wakix__Applicant: Bioprojet Pharma__Active moiety: pitolisant__Approval Year: 2019__Route: Oral__logP: 4.2__MW: 295.9__Class: Benzene and substituted derivatives','O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(OC(F)(F)F)cc1)C2__Name: [drug marketed without a proprietary name]__Applicant: Global Alliance for TB Drug Development__Active moiety: pretomanid__Approval Year: 2019__Route: Oral__logP: 2.7__MW: 359.3__Class: Benzene and substituted derivatives','CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1__Name: Rozlytrek__Applicant: Genentech__Active moiety: entrectinib__Approval Year: 2019__Route: Oral__logP: 5.0__MW: 560.6__Class: Diazinanes','Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1__Name: Inrebic__Applicant: Celgene__Active moiety: fedratinib__Approval Year: 2019__Route: Oral__logP: 4.8__MW: 524.7__Class: Benzene and substituted derivatives','CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12__Name: Rinvoq__Applicant: Abbvie__Active moiety: upadacitinib__Approval Year: 2019__Route: Oral__logP: 2.9__MW: 380.4__Class: Pyrrolopyrazines','C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O__Name: Xenleta__Applicant: Nabriva Therapeutics__Active moiety: lefamulin__Approval Year: 2019__Route: Oral__logP: 3.9__MW: 507.7__Class: Prenol lipids','C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O.[68Ga+3]__Name: [drug marketed without a proprietary name]__Applicant: University of Iowa Health Care__Active moiety: Ga 68 DOTATOC__Approval Year: 2019__Route: Intravenous__logP: -7.9__MW: 1486.6__Class: Carboxylic acids and derivatives','CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O__Name: Nourianz__Applicant: Kyowa Kirin__Active moiety: istradefylline__Approval Year: 2019__Route: Oral__logP: 2.1__MW: 384.4__Class: Imidazopyrimidines','CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1__Name: Ibsrela__Applicant: Ardelyx__Active moiety: tenapanor__Approval Year: 2019__Route: Oral__logP: 6.2__MW: 1145.1__Class: Tetrahydroisoquinolines','CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1__Name: Aklief__Applicant: Galderma Research and Development__Active moiety: trifarotene__Approval Year: 2019__Route: Topical__logP: 6.0__MW: 459.6__Class: Benzene and substituted derivatives','CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C__Name: Scenesse__Applicant: Clunuvel__Active moiety: afamelanotide__Approval Year: 2019__Route: Subcutaneous__logP: -4.1__MW: 1646.9__Class: Polypeptides','N[C@@H](Cc1cc(O)c(O)cc1[18F])C(=O)O__Name: [drug marketed without a proprietary name]__Applicant: Feinstein Institute__Active moiety: fluorodopa F 18__Approval Year: 2019__Route: Intravenous__logP: 0.2__MW: 214.2__Class: Carboxylic acids and derivatives','CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1__Name: Reyvow__Applicant: Eli Lilly__Active moiety: lasmiditan__Approval Year: 2019__Route: Oral__logP: 3.3__MW: 377.4__Class: Benzene and substituted derivatives','CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O.CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO.CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO__Name: Trikafta__Applicant: Vertex Pharmaceuticals__Active moiety: elexacaftor, ivacaftor, tezacaftor; ivacaftor (co-packaged)__Approval Year: 2019__Route: Oral__logP: 11.9__MW: 1433.5__Class: Indoles and derivatives','C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1__Name: Brukinsa__Applicant: BeiGene USA__Active moiety: zanubrutinib__Approval Year: 2019__Route: Oral__logP: 4.2__MW: 471.6__Class: Benzene and substituted derivatives','CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)CS[C@H]12)c1csc(N)n1)C(=O)O__Name: Fetroja__Applicant: Shionogi__Active moiety: cefiderocol__Approval Year: 2019__Route: Intravenous__logP: -0.2__MW: 752.2__Class: Lactams','NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl__Name: Xcopri__Applicant: SK Life Science__Active moiety: cenobamate__Approval Year: 2019__Route: Oral__logP: 1.2__MW: 267.7__Class: Benzene and substituted derivatives','CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O__Name: Oxbryta__Applicant: Global Blood Therapeutics__Active moiety: voxelotor__Approval Year: 2019__Route: Oral__logP: 3.6__MW: 337.4__Class: Organooxygen compounds','CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12__Name: Caplyta__Applicant: Intra-Cellular Therapies__Active moiety: lumateperone__Approval Year: 2019__Route: Oral__logP: 3.9__MW: 393.5__Class: Organooxygen compounds','CCOc1ccc(Nc2ccc(C(=C3C=CC(=[N+](CC)Cc4cccc(S(=O)(=O)[O-])c4)C=C3C)c3ccc(N(CC)Cc4cccc(S(=O)(=O)[O-])c4)cc3C)cc2)cc1__Name: TissueBlue__Applicant: D.O.R.C International b.v__Active moiety: Brilliant Blue G Ophthalmic Solution__Approval Year: 2019__Route: Ophthalmic__logP: 9.0__MW: 831.0__Class: Benzene and substituted derivatives','Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1__Name: Dayvigo__Applicant: Eisai__Active moiety: lemborexant__Approval Year: 2019__Route: Oral__logP: 3.7__MW: 410.4__Class: Organonitrogen compounds','C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F__Name: Ubrelvy__Applicant: Allergan__Active moiety: ubrogepant__Approval Year: 2019__Route: Oral__logP: 3.5__MW: 549.6__Class: Carboxylic acids and derivatives','Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1__Name: Ayvakit__Applicant: Blueprint Medicines Corporation__Active moiety: avapritinib__Approval Year: 2020__Route: Oral__logP: 2.6__MW: 498.6__Class: Diazinanes','CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1__Name: Tazverik__Applicant: Epizyme, Inc.__Active moiety: tazemetostat__Approval Year: 2020__Route: Oral__logP: 4.7__MW: 572.8__Class: Benzene and substituted derivatives','OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO__Name: Pizensy__Applicant: Braintree Laboratories, Inc.__Active moiety: lactitol__Approval Year: 2020__Route: Oral__logP: -5.8__MW: 344.3__Class: Fatty Acyls','CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O__Name: Nexletol__Applicant: Esperion Therapeutics, Inc.__Active moiety: bempedoic acid__Approval Year: 2020__Route: Oral__logP: 4.5__MW: 344.5__Class: Fatty Acyls','CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC__Name: Barhemsys__Applicant: Acacia Pharma Ltd.__Active moiety: amisulpride__Approval Year: 2020__Route: Injection__logP: 1.3__MW: 369.5__Class: Benzene and substituted derivatives','N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F__Name: Nurtec ODT__Applicant: Biohaven Pharmaceuticals__Active moiety: rimegepant__Approval Year: 2020__Route: Oral__logP: 4.5__MW: 534.6__Class: Imidazopyridines','N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1__Name: Isturisa__Applicant: Novartis Pharmaceuticals Corporation__Active moiety: osilodrostat__Approval Year: 2020__Route: Oral__logP: 2.4__MW: 227.2__Class: Benzene and substituted derivatives','CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N__Name: Zeposia__Applicant: Celgene Corporation__Active moiety: ozanimod__Approval Year: 2020__Route: Oral__logP: 3.6__MW: 404.5__Class: Azoles','Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21__Name: Koselugo__Applicant: AstraZeneca Pharmaceuticals LP__Active moiety: selumetinib__Approval Year: 2020__Route: Oral__logP: 3.5__MW: 457.7__Class: Benzimidazoles','CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21__Name: Pemazyre__Applicant: Incyte Corporation__Active moiety: pemigatinib__Approval Year: 2020__Route: Oral__logP: 3.7__MW: 487.5__Class: Benzene and substituted derivatives','Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1__Name: Tukysa__Applicant: Seattle Genetics, Inc.__Active moiety: tucatinib__Approval Year: 2020__Route: Oral__logP: 5.1__MW: 480.5__Class: Diazanaphthalenes','Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1__Name: Ongentys__Applicant: Neurocrine Biosciences, Inc.__Active moiety: opicapone__Approval Year: 2020__Route: Oral__logP: 3.3__MW: 413.2__Class: Azoles','CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F__Name: Tabrecta__Applicant: Novartis Pharmaceuticals Corporation__Active moiety: capmatinib__Approval Year: 2020__Route: Oral__logP: 3.4__MW: 412.4__Class: Quinolines and derivatives','COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1__Name: Retevmo__Applicant: Loxo Oncology, Inc.__Active moiety: selpercatinib__Approval Year: 2020__Route: Oral__logP: 3.3__MW: 525.6__Class: Diazinanes','CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21__Name: Qinlock__Applicant: Deciphera Pharmaceuticals, LLC__Active moiety: ripretinib__Approval Year: 2020__Route: Oral__logP: 5.7__MW: 510.4__Class: Pyridines and derivatives','C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H]([18F])[C@@H]2O__Name: Cerianna__Applicant: Zionexa-US Corporation__Active moiety: fluoroestradiol F 18__Approval Year: 2020__Route: Injection__logP: 3.6__MW: 289.4__Class: Steroids and steroid derivatives','C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4__Name: [drug marketed without a proprietary name]__Applicant: Amivas, LLC__Active moiety: artesunate__Approval Year: 2020__Route: Injection__logP: 2.6__MW: 384.4__Class: Prenol lipids','[18F]c1ccc(-c2ccc3c(c2)[nH]c2ccncc23)cn1__Name: Tauvid__Applicant: Avid Radiopharmaceuticals, Inc.__Active moiety: flortaucipir F 18__Approval Year: 2020__Route: Injection__logP: 3.9__MW: 262.3__Class: Indoles and derivatives','COc1ccc2[nH]c3c(c2c1)CCN[C@]31CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4__Name: Zepzelca__Applicant: Pharma Mar USA, Inc.__Active moiety: lurbinectedin__Approval Year: 2020__Route: Injection__logP: 4.2__MW: 784.9__Class: Harmala alkaloids','CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC__Name: Dojolvi__Applicant: Ultragenyx Pharmaceutical Inc.__Active moiety: triheptanoin__Approval Year: 2020__Route: Oral__logP: 5.9__MW: 428.6__Class: Glycerolipids','COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21__Name: Byfavo__Applicant: Cosmo Technologies, Ltd.__Active moiety: remimazolam__Approval Year: 2020__Route: Injection__logP: 4.2__MW: 439.3__Class: Benzodiazepines','COc1cnc(-n2cnc(C)n2)c2c1c(C(=O)C(=O)N1CCN(C(=O)c3ccccc3)CC1)cn2COP(=O)(O)O__Name: Rukobia__Applicant: ViiV Healthcare Company__Active moiety: fostemsavir__Approval Year: 2020__Route: Oral__logP: 1.2__MW: 583.5__Class: Pyridines and derivatives','O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F__Name: Inqovi__Applicant: Astex Pharmaceuticals, Inc.__Active moiety: decitabine and cedazuridine__Approval Year: 2020__Route: Oral__logP: -1.6__MW: 268.2__Class: Organooxygen compounds','Cc1ccc(-c2ccc(C)cn2)nc1__Name: Xeglyze__Applicant: Dr. Reddys Laboratories__Active moiety: abametapir__Approval Year: 2020__Route: Topical__logP: 2.8__MW: 184.2__Class: Pyridines and derivatives','CC1CS(=O)(=O)CCN1/N=C/c1ccc([N+](=O)[O-])o1__Name: Lampit__Applicant: Bayer HealthCare Pharmaceuticals, Inc.__Active moiety: nifurtimox__Approval Year: 2020__Route: Oral__logP: 0.6__MW: 287.3__Class: Furans','Cc1cn2nc(-c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1__Name: Evrysdi__Applicant: Genentech, Inc.__Active moiety: risdiplam__Approval Year: 2020__Route: Intravenous__logP: 2.0__MW: 401.5__Class: Diazinanes','COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1__Name: Olinvyk__Applicant: Trevena, Inc.__Active moiety: oliceridine__Approval Year: 2020__Route: Injection__logP: 4.7__MW: 386.6__Class: Organooxygen compounds','Cc1cn([C@H]2CN(P(=O)(OC[C@@H]3CNC[C@H](n4ccc(N)nc4=O)O3)N(C)C)C[C@@H](COP(=O)(N(C)C)N3C[C@@H](COP(=O)(N(C)C)N4C[C@@H](COP(=O)(N(C)C)N5C[C@@H](COP(=O)(N(C)C)N6C[C@@H](COP(=O)(N(C)C)N7C[C@@H](COP(=O)(N(C)C)N8C[C@@H](COP(=O)(N(C)C)N9C[C@@H](COP(=O)(N(C)C)N%10C[C@@H](COP(=O)(N(C)C)N%11C[C@@H](COP(=O)(N(C)C)N%12C[C@@H](COP(=O)(N(C)C)N%13C[C@@H](COP(=O)(N(C)C)N%14C[C@@H](COP(=O)(N(C)C)N%15C[C@@H](COP(=O)(N(C)C)N%16C[C@@H](COP(=O)(N(C)C)N%17C[C@@H](COP(=O)(N(C)C)N%18C[C@@H](COP(=O)(N(C)C)N%19C[C@@H](COP(=O)(N(C)C)N%20C[C@@H](COP(=O)(N(C)C)N%21C[C@@H](CO)O[C@@H](n%22ccc(N)nc%22=O)C%21)O[C@@H](n%21ccc(N)nc%21=O)C%20)O[C@@H](n%20cc(C)c(=O)[nH]c%20=O)C%19)O[C@@H](n%19ccc(N)nc%19=O)C%18)O[C@@H](n%18ccc(N)nc%18=O)C%17)O[C@@H](n%17cnc%18c(=O)[nH]c(N)nc%18%17)C%16)O[C@@H](n%16cnc%17c(=O)[nH]c(N)nc%17%16)C%15)O[C@@H](n%15cc(C)c(=O)[nH]c%15=O)C%14)O[C@@H](n%14cc(C)c(=O)[nH]c%14=O)C%13)O[C@@H](n%13ccc(N)nc%13=O)C%12)O[C@@H](n%12cc(C)c(=O)[nH]c%12=O)C%11)O[C@@H](n%11cnc%12c(=O)[nH]c(N)nc%12%11)C%10)O[C@@H](n%10cnc%11c(N)ncnc%11%10)C9)O[C@@H](n9cnc%10c(N)ncnc%109)C8)O[C@@H](n8cnc9c(=O)[nH]c(N)nc98)C7)O[C@@H](n7cnc8c(=O)[nH]c(N)nc87)C6)O[C@@H](n6cc(C)c(=O)[nH]c6=O)C5)O[C@@H](n5cnc6c(=O)[nH]c(N)nc65)C4)O[C@@H](n4cc(C)c(=O)[nH]c4=O)C3)O2)c(=O)[nH]c1=O__Name: Viltepso__Applicant: Nippon Shinyaku Co., Ltd.__Active moiety: viltolarsen__Approval Year: 2020__Route: Injection__logP: -6.6__MW: 6924.9__Class: nan','CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C__Name: Winlevi__Applicant: Cassiopea SpA__Active moiety: clascoterone__Approval Year: 2020__Route: Topical__logP: 3.8__MW: 402.5__Class: Steroids and steroid derivatives','C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)[O-])CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O.[64Cu+2]__Name: Detectnet__Applicant: RadioMedix, Inc.__Active moiety: copper Cu 64 dotatate__Approval Year: 2020__Route: Injection__logP: -6.0__MW: 1497.6__Class: Carboxylic acids and derivatives','CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1__Name: Gavreto__Applicant: Blueprint Medicines Corporation__Active moiety: pralsetinib__Approval Year: 2020__Route: Oral__logP: 4.2__MW: 533.6__Class: Pyridines and derivatives','CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1__Name: Veklury__Applicant: Gilead Sciences, Inc.__Active moiety: remdesivir__Approval Year: 2020__Route: Injection__logP: 2.3__MW: 602.6__Class: Carboxylic acids and derivatives','NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1__Name: Zokinvy__Applicant: Eiger BioPharmaceuticals, Inc.__Active moiety: lonafarnib__Approval Year: 2020__Route: Oral__logP: 5.9__MW: 638.8__Class: Benzocycloheptapyridines','CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](C)NC1=O__Name: Imcivree__Applicant: Rhythm Pharmaceuticals, Inc.__Active moiety: setmelanotide__Approval Year: 2020__Route: Injection__logP: -2.8__MW: 1117.3__Class: Carboxylic acids and derivatives','N#Cc1cccc(C(NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1__Name: Orladeyo__Applicant: BioCryst Pharmaceuticals, Inc.__Active moiety: berotralstat__Approval Year: 2020__Route: Oral__logP: 5.7__MW: 562.6__Class: Benzene and substituted derivatives','O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1__Name: Klisyri__Applicant: Athenex, Inc.__Active moiety: tirbanibulin__Approval Year: 2020__Route: Topical__logP: 3.3__MW: 431.5__Class: Pyridines and derivatives','CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1__Name: Orgovyx__Applicant: Myovant Sciences GmbH__Active moiety: relugolix__Approval Year: 2020__Route: Oral__logP: 3.8__MW: 623.6__Class: Benzene and substituted derivatives','O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21__Name: Gemtesa__Applicant: Urovant Sciences GmbH__Active moiety: vibegron__Approval Year: 2020__Route: Oral__logP: 2.8__MW: 444.5__Class: Pyrrolopyrimidines','COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N__Name: Verquvo__Applicant: Merck Sharp and Dohme Corp.__Active moiety: vericiguat__Approval Year: 2021__Route: Oral__logP: 2.6__MW: 426.4__Class: Pyrazolopyridines','C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12__Name: Cabenuva__Applicant: ViiV Healthcare Company__Active moiety: cabotegravir; rilpivirine (co-packaged)__Approval Year: 2021__Route: Injection__logP: 1.0__MW: 405.4__Class: Pyridines and derivatives','C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C__Name: Lupkynis__Applicant: Aurinia Pharmaceuticals, Inc.__Active moiety: voclosporin__Approval Year: 2021__Route: Oral__logP: 3.4__MW: 1214.6__Class: Peptidomimetics','CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1__Name: Tepmetko__Applicant: EMD Serono, Inc.__Active moiety: tepotinib__Approval Year: 2021__Route: Oral__logP: 4.0__MW: 492.6__Class: Diazines','CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F__Name: Ukoniq__Applicant: TG Therapeutics, Inc.__Active moiety: umbralisib__Approval Year: 2021__Route: Injection__logP: 6.7__MW: 571.6__Class: Isoflavonoids','CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1__Name: Cosela__Applicant: G1 Therapeutics, Inc.__Active moiety: trilaciclib__Approval Year: 2021__Route: Injection__logP: 2.7__MW: 446.6__Class: Diazinanes','Nc1nc2c(c(=O)[nH]1)N[C@@H]1[C@H](N2)O[C@@H]2COP(=O)(O)O[C@@H]2C1(O)O__Name: Nulibry__Applicant: Origin Biosciences, Inc.__Active moiety: fosdenopterin__Approval Year: 2021__Route: Injection__logP: -2.5__MW: 363.2__Class: Pteridines and derivatives','CCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(N(CCCl)CCCl)cc1__Name: Pepaxto__Applicant: Oncopeptides AB__Active moiety: melphalan flufenamide__Approval Year: 2021__Route: Injection__logP: 3.3__MW: 498.4__Class: Carboxylic acids and derivatives','COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1C(=O)OC[n+]1cccc(C(=O)N[C@@H](CO)C(=O)[O-])c1__Name: Azstarys__Applicant: Commave Therapeutics SA__Active moiety: serdexmethylphenidate and dexmethylphenidate__Approval Year: 2021__Route: Oral__logP: -0.3__MW: 499.5__Class: Organonitrogen compounds','COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC__Name: Fotivda__Applicant: Aveo Pharmaceuticals, Inc.__Active moiety: tivozanib__Approval Year: 2021__Route: Oral__logP: 5.6__MW: 454.9__Class: Quinolines and derivatives','CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C__Name: Ponvory__Applicant: Janssen Pharmaceuticals, Inc.__Active moiety: ponesimod__Approval Year: 2021__Route: Oral__logP: 4.3__MW: 461.0__Class: Phenol ethers','CC(C)C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)[C@@H](C)O__Name: Zegalogue__Applicant: Zealand Pharma A/S__Active moiety: dasiglucagon__Approval Year: 2021__Route: Injection__logP: -14.7__MW: 3381.7__Class: Polypeptides','CCOc1ccccc1OCC1CNCCO1__Name: Qelbree__Applicant: Supernus Pharmaceuticals, Inc.__Active moiety: viloxazine__Approval Year: 2021__Route: Oral__logP: 1.5__MW: 237.3__Class: Phenol ethers','C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O__Name: Nextstellis__Applicant: Mayne Pharma, LLC__Active moiety: drospirenone and estetrol__Approval Year: 2021__Route: Oral__logP: 1.6__MW: 304.4__Class: Steroids and steroid derivatives','O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc([18F])nc1)C(=O)O)C(=O)O__Name: Pylarify__Applicant: Progenics Pharmaceuticals, Inc.__Active moiety: piflufolastat F 18__Approval Year: 2021__Route: Injection__logP: 0.2__MW: 441.4__Class: Carboxylic acids and derivatives','C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1__Name: Lumakras__Applicant: Amgen, Inc.__Active moiety: sotorasib__Approval Year: 2021__Route: Oral__logP: 4.5__MW: 560.6__Class: Pyridines and derivatives','Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1__Name: Lybalvi__Applicant: Alkermes, Inc.__Active moiety: olanzapine and samidorphan__Approval Year: 2021__Route: Oral__logP: 3.4__MW: 312.4__Class: Benzodiazepines','CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1__Name: Truseltiq__Applicant: QED Therapeutics, Inc.__Active moiety: infigratinib__Approval Year: 2021__Route: Oral__logP: 5.4__MW: 560.5__Class: Diazinanes','CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@@H](n4ncnc4-c4ccncc4)[C@@H]5OC[C@](C)(N)C(C)(C)C)C3=CC[C@@]2(C)[C@@H]1C(=O)O__Name: Brexafemme__Applicant: Scynexis, Inc.__Active moiety: ibrexafungerp__Approval Year: 2021__Route: Oral__logP: 8.6__MW: 730.1__Class: Prenol lipids','CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2__Name: Kerendia__Applicant: Bayer HealthCare Pharmaceuticals, Inc.__Active moiety: finerenone__Approval Year: 2021__Route: Injection__logP: 3.0__MW: 378.4__Class: Diazanaphthalenes','CSc1ccc(OCc2ncc([N+](=O)[O-])n2C)cc1__Name: [drug marketed without a proprietary name]__Applicant: Drugs for Neglected Diseases initiative__Active moiety: fexinidazole__Approval Year: 2021__Route: Oral__logP: 2.6__MW: 279.3__Class: Azoles','CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1__Name: Rezurock__Applicant: Kadmon Pharmaceuticals, LLC__Active moiety: belumosudil__Approval Year: 2021__Route: Oral__logP: 4.8__MW: 452.5__Class: Diazanaphthalenes','CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c3ccc(O)cc3)cc2S(=O)(=O)N1__Name: Bylvay__Applicant: Albireo AB__Active moiety: odevixibat__Approval Year: 2021__Route: Oral__logP: 5.9__MW: 740.9__Class: Carboxylic acids and derivatives','CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F__Name: Welireg__Applicant: Merck Sharp and Dohme Corp.__Active moiety: belzutifan__Approval Year: 2021__Route: Oral__logP: 3.3__MW: 383.3__Class: Organooxygen compounds','CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1__Name: Korsuva__Applicant: Cara Therapeutics, Inc.__Active moiety: difelikefalin__Approval Year: 2021__Route: Injection__logP: 0.8__MW: 679.9__Class: Carboxylic acids and derivatives','C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C__Name: Exkivity__Applicant: Takeda Pharmaceuticals U.S.A., Inc.__Active moiety: mobocertinib__Approval Year: 2021__Route: Oral__logP: 5.1__MW: 585.7__Class: Benzene and substituted derivatives','C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F__Name: Qulipta__Applicant: AbbVie, Inc.__Active moiety: atogepant__Approval Year: 2021__Route: Oral__logP: 3.9__MW: 603.5__Class: Carboxylic acids and derivatives','CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O__Name: Livmarli__Applicant: Mirum Pharmaceuticals, Inc.__Active moiety: maralixibat__Approval Year: 2021__Route: Injection__logP: 6.6__MW: 675.0__Class: Benzothiepins','Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F__Name: Tavneos__Applicant: ChemoCentryx, Inc.__Active moiety: avacopan__Approval Year: 2021__Route: Oral__logP: 8.0__MW: 581.7__Class: Benzene and substituted derivatives','O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1__Name: Scemblix__Applicant: Novartis Pharmaceuticals Corporation__Active moiety: asciminib__Approval Year: 2021__Route: Oral__logP: 3.5__MW: 449.8__Class: Benzene and substituted derivatives','CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H]2CCCN2)CSSC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)CNC1=O__Name: Voxzogo__Applicant: BioMarin Pharmaceutical, Inc.__Active moiety: vosoritide__Approval Year: 2021__Route: Injection__logP: -21.0__MW: 4102.8__Class: Peptidomimetics','CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O__Name: Livtencity__Applicant: Takeda Pharmaceuticals U.S.A., Inc.__Active moiety: maribavir__Approval Year: 2021__Route: Oral__logP: 1.8__MW: 376.2__Class: Benzimidazole ribonucleosides and ribonucleotides','CC1(C)C(/C=C/C2=C(Oc3ccc(C[C@H](NC(=O)c4ccc(NCc5cnc6nc(N)[nH]c(=O)c6n5)cc4)C(=O)O)cc3)/C(=C/C=C3/N(CCCCS(=O)(=O)O)c4ccc(S(=O)(=O)O)cc4C3(C)C)CCC2)=[N+](CCCCS(=O)(=O)O)c2ccc(S(=O)(=O)[O-])cc21__Name: Cytalux__Applicant: On Target Laboratories, Inc.__Active moiety: pafolacianine__Approval Year: 2021__Route: Injection__logP: 6.9__MW: 1326.5__Class: Carboxylic acids and derivatives','C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O__Name: Rezlidhea__Applicant: Rigel Pharmaceuticals__Active moiety: olutasidenib__Approval Year: 2022__Route: Oral__logP: 2.9__MW: 354.8__Class: Quinolines and derivatives','C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1__Name: Lytgobi__Applicant: Otsuka Holdings__Active moiety: futibatinib__Approval Year: 2022__Route: Oral__logP: 1.8__MW: 418.5__Class: Benzene and substituted derivatives','O=C(O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1__Name: Omlonti__Applicant: Santen Pharmaceutical/UBE Corporation__Active moiety: oomidenepag isopropyl ophthalmic solution__Approval Year: 2022__Route: Ophthalmic__logP: 2.5__MW: 478.5__Class: Azoles','NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O__Name: Terlivaz__Applicant: Mallinckrodt Pharmaceuticals__Active moiety: terlipressin__Approval Year: 2022__Route: Injection__logP: -7.0__MW: 1227.4__Class: Polypeptdies','[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC__Name: Sotyktu__Applicant: Bristol Myers Squibb__Active moiety: deucravacitinib__Approval Year: 2022__Route: Oral__logP: 1.7__MW: 425.5__Class: Azoles','CC(C)c1c(O)cc(/C=C/c2ccccc2)cc1O__Name: Vtama__Applicant: Dermavant Sciences/Hebei Wenfeng Industrial Group__Active moiety: tapinarof__Approval Year: 2022__Route: Topical__logP: 4.4__MW: 254.3__Class: Stilbenes','CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1__Name: Voquezna__Applicant: Takeda/Phathom Pharmaceuticals__Active moiety: vonoprazan, amoxicillin, and clarithromycin__Approval Year: 2022__Route: Oral__logP: 2.6__MW: 345.4__Class: Pyrroles','CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O__Name: Camzyos__Applicant: Bristol Myers Squibb__Active moiety: mavacamten__Approval Year: 2022__Route: Oral__logP: 2.3__MW: 273.3__Class: Diazines','O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1__Name: Vivjoa__Applicant: Gedeon Richter/Mycovia Pharmaceuticals__Active moiety: oteseconazole__Approval Year: 2022__Route: Oral__logP: 4.6__MW: 527.4__Class: Pyridines and derivatives','O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)C1CCC(CNC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)CC1)C(=O)O)C(=O)O__Name: Pluvicto__Applicant: Novartis__Active moiety: lutetium (177Lu) vipivotide tetraxetan__Approval Year: 2022__Route: Injection__logP: -0.4__MW: 1042.2__Class: Carboxylic acids and derivatives','CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C__Name: Ztalmy__Applicant: Marinus Pharmaceuticals__Active moiety: ganaxolone__Approval Year: 2022__Route: Oral__logP: 5.0__MW: 332.5__Class: Steroids and steroid derivatives','C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1__Name: Vonjo__Applicant: CTI BioPharma__Active moiety: pacritinib__Approval Year: 2022__Route: Oral__logP: 5.0__MW: 472.6__Class: Phenol ethers','O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1__Name: Pyrukynd__Applicant: Agios Pharmaceuticals__Active moiety: mitapivat__Approval Year: 2022__Route: Oral__logP: 3.2__MW: 450.6__Class: Quinolines and derivatives','CCCS(=O)(=O)NC1CC(N(C)c2ncnc3[nH]ccc23)C1__Name: Cibinqo__Applicant: Pfizer__Active moiety: abrocitinib__Approval Year: 2022__Route: Oral__logP: 1.3__MW: 323.4__Class: Pyrrolopyrimidines','COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1__Name: Quviviq__Applicant: Idorsia__Active moiety: daridorexant__Approval Year: 2022__Route: Oral__logP: 4.3__MW: 450.9__Class: Azoles','C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N__Name: Krazati__Applicant: Mirati Therapeutics__Active moiety: adagrasib__Approval Year: 2022__Route: Oral__logP: 4.7__MW: 604.1__Class: Diazinanes'],
colors: [
{
r: [68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,70,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,65,65,65,65,65,65,65,65,65,65,65,65,65,65,65,65,65,65,65,65,65,65,65,62,62,62,62,62,62,62,62,62,62,62,62,62,62,62,62,62,62,62,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,59,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,54,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,49,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,45,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,42,39,39,39,39,39,39,39,39,39,39,39,39,39,39,39,39,39,39,39,39,39,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,35,35,35,35,35,35,35,35,35,35,35,35,35,35,35,35,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,32,31,31,31,31,31,31,31,31,31,31,31,31,31,30,30,30,30,30,30,30,30,30,30,30,30,30,30,30,30,31,31,31,31,31,31,31,31,31,31,31,31,31,31,31,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,41,41,41,41,41,41,41,41,41,41,41,41,41,47,47,47,47,47,47,47,47,47,47,47,47,47,47,47,47,47,47,47,47,47,47,47,47,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,72,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,86,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,117,117,117,117,117,117,117,117,117,117,117,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,160,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,213,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,239,253,253,253,253,253,253,253,253,253,253,253,253,253,253,253,253],
g: [1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,10,10,10,10,10,10,10,10,10,10,10,10,10,10,10,10,10,10,10,10,19,19,19,19,19,19,19,19,19,19,19,19,19,19,19,19,19,19,19,19,19,27,27,27,27,27,27,27,27,27,27,27,27,27,27,27,27,27,27,27,27,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,41,41,41,41,41,41,41,41,41,41,41,41,41,41,41,41,41,41,41,41,41,41,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,50,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,58,66,66,66,66,66,66,66,66,66,66,66,66,66,66,66,66,66,66,66,66,66,66,66,73,73,73,73,73,73,73,73,73,73,73,73,73,73,73,73,73,73,73,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,81,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,112,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,119,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,132,137,137,137,137,137,137,137,137,137,137,137,137,137,137,137,137,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,147,153,153,153,153,153,153,153,153,153,153,153,153,153,157,157,157,157,157,157,157,157,157,157,157,157,157,157,157,157,161,161,161,161,161,161,161,161,161,161,161,161,161,161,161,165,165,165,165,165,165,165,165,165,165,165,165,165,165,165,165,165,165,165,165,165,165,171,171,171,171,171,171,171,171,171,171,171,171,171,171,171,171,171,171,171,171,175,175,175,175,175,175,175,175,175,175,175,175,175,180,180,180,180,180,180,180,180,180,180,180,180,180,180,180,180,180,180,180,180,180,180,180,180,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,186,193,193,193,193,193,193,193,193,193,193,193,193,193,193,193,193,193,193,193,193,193,193,193,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,198,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,204,208,208,208,208,208,208,208,208,208,208,208,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,218,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,222,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,226,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,231,231,231,231,231,231,231,231,231,231,231,231,231,231,231,231],
b: [84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,84,93,93,93,93,93,93,93,93,93,93,93,93,93,93,93,93,93,93,93,93,101,101,101,101,101,101,101,101,101,101,101,101,101,101,101,101,101,101,101,101,101,109,109,109,109,109,109,109,109,109,109,109,109,109,109,109,109,109,109,109,109,115,115,115,115,115,115,115,115,115,115,115,115,115,115,115,115,115,115,115,115,115,115,121,121,121,121,121,121,121,121,121,121,121,121,121,121,121,121,121,121,121,121,121,121,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,126,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,131,135,135,135,135,135,135,135,135,135,135,135,135,135,135,135,135,135,135,135,135,135,135,135,137,137,137,137,137,137,137,137,137,137,137,137,137,137,137,137,137,137,137,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,142,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,141,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,140,138,138,138,138,138,138,138,138,138,138,138,138,138,137,137,137,137,137,137,137,137,137,137,137,137,137,137,137,137,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,133,133,133,133,133,133,133,133,133,133,133,133,133,133,133,133,133,133,133,133,133,133,130,130,130,130,130,130,130,130,130,130,130,130,130,130,130,130,130,130,130,130,127,127,127,127,127,127,127,127,127,127,127,127,127,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,118,110,110,110,110,110,110,110,110,110,110,110,110,110,110,110,110,110,110,110,110,110,110,110,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,103,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,92,84,84,84,84,84,84,84,84,84,84,84,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,75,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,57,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,40,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,28,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37,37],
},
{
r: [179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,179,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,124,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,68,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,26,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235,235],
g: [0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,17,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,83,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,136,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,183,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,212,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220,220],
b: [0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,88,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,175,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,255,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,230,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,199,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,90,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120,120],
},
{
r: [178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34],
g: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139,139],
b: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34],
},
{
r: [178,34,34,34,178,178,178,178,178,34,34,178,178,178,178,34,178,34,34,34,178,178,178,34,34,34,34,178,178,34,178,34,34,34,34,178,178,178,34,34,34,178,178,178,34,178,178,178,178,178,34,178,34,34,34,178,178,34,178,178,34,34,178,34,34,178,178,178,178,34,178,34,178,34,34,178,178,34,178,34,34,34,34,178,178,178,178,178,178,34,34,178,178,34,34,34,178,34,34,178,178,34,178,178,178,34,34,178,178,178,34,34,34,178,178,34,34,178,34,178,178,34,178,178,178,178,34,178,34,34,178,34,34,178,178,34,34,34,178,178,34,34,34,178,34,178,178,34,34,34,34,34,178,34,34,178,34,34,34,34,34,178,34,34,34,34,178,34,34,34,34,178,34,178,34,34,178,34,34,34,34,178,178,34,178,178,34,178,178,178,34,34,34,34,34,34,34,34,178,178,178,178,34,178,178,34,34,34,34,34,178,178,178,34,178,34,178,34,34,34,178,178,34,178,34,178,34,34,178,34,34,34,34,178,34,34,34,178,178,178,34,34,178,34,178,34,34,34,34,34,178,34,34,34,178,178,34,178,178,178,34,34,178,34,34,178,178,178,178,178,34,178,34,178,34,178,178,34,178,178,34,34,178,178,34,34,34,178,34,178,34,34,34,34,34,34,178,34,34,34,34,34,34,34,178,34,34,34,178,34,34,34,178,34,34,34,34,34,34,178,34,178,34,34,34,34,34,34,34,178,34,178,34,178,34,34,34,178,34,34,34,178,178,34,34,34,178,178,34,178,178,34,34,34,34,34,178,34,178,34,178,34,34,34,34,34,34,178,178,34,34,34,34,34,178,34,178,178,178,34,34,178,34,178,34,178,178,34,34,34,34,34,178,178,178,34,178,34,34,34,34,34,34,34,178,178,34,34,34,34,178,178,34,178,178,178,34,34,178,34,178,34,178,34,178,178,34,34,34,178,178,178,34,178,34,34,34,34,178,34,178,178,178,34,34,178,34,178,34,178,34,34,178,34,34,34,34,34,34,34,178,34,34,34,178,34,34,34,34,178,34,34,34,178,178,34,34,178,178,178,178,34,34,178,178,34,178,34,34,34,34,34,178,178,34,34,34,34,178,34,178,178,34,178,178,178,34,178,178,34,178,178,34,34,178,178,34,34,34,178,34,34,34,178,178,34,34,34,34,34,34,34,34,178,34,34,34,34,34,178,178,178,34,34,178,178,34,178,34,34,34,34,178,34,178,178,178,34,178,178,178,34,178,34,34,34,34,34,34,178,178,178,178,34,34,34,34,178,34,34,178,34,34,34,34,34,34,178,178,178,34,178,178,34,178,34,178,34,178,178,34,34,34,34,178,178,178,178,34,34,34,178,34,34,34,34,34,34,34,34,34,178,34,34,34,178,34,34,34,34,178,34,34,34,178,178,178,34,34,34,34,178,178,34,34,34,34,178,34,34,34,178,34,34,178,34,34,178,34,34,34,178,34,34,178,34,34,178,34,34,34,34,34,34,34,34,178,34,34,178,34,34,178,34,34,34,34,178,34,34,34,178,178,34,178,178,34,178,34,178,34,34,34,34,34,34,34,178,34,178,178,34,34,34,34,34,178,34,34,34,178,34,178,34,34,34,34,34,34,34,34,34,34,178,34,178,34,34,34,34,34,178,34,34,34,34,34,34,178,34,178,34,178,178,34,34,178,34,34,34,34,34,34,34,34,34,178,34,178,34,34,34,34,34,34,178,34,178,34,34,34,178,34,178,178,178,34,34,178,178,34,34,34,34,178,34,34,34,34,178,34,34,34,34,34,34,34,178,34,34,178,34,178,34,34,34,34,34,178,34,34,34,178,34,34,34,34,34,34,34,178,34,34,34,34,34,178,34,178,34,34,34,34,34,34,34,34,34,178,34,34,178,178,178,34,34,34,178,34,34,34,178,34,34,34,34,34,34,178,34,34,34,34,34,34,34,34,34,34,178,178,178,178,34,178,34,34,178,34,178,178,178,178,178,34,178,34,178,34,178,34,34,34,178,34,34,178,178,178,178,34,34,34,178,34,34,178,34,34,34,34,178,34,34,34,34,178,34,34,178,34,34,178,34,178,34,34,178,178,34,178,34,34,34,178,34,34,34,34,34,34],
g: [34,139,139,139,34,34,34,34,34,139,139,34,34,34,34,139,34,139,139,139,34,34,34,139,139,139,139,34,34,139,34,139,139,139,139,34,34,34,139,139,139,34,34,34,139,34,34,34,34,34,139,34,139,139,139,34,34,139,34,34,139,139,34,139,139,34,34,34,34,139,34,139,34,139,139,34,34,139,34,139,139,139,139,34,34,34,34,34,34,139,139,34,34,139,139,139,34,139,139,34,34,139,34,34,34,139,139,34,34,34,139,139,139,34,34,139,139,34,139,34,34,139,34,34,34,34,139,34,139,139,34,139,139,34,34,139,139,139,34,34,139,139,139,34,139,34,34,139,139,139,139,139,34,139,139,34,139,139,139,139,139,34,139,139,139,139,34,139,139,139,139,34,139,34,139,139,34,139,139,139,139,34,34,139,34,34,139,34,34,34,139,139,139,139,139,139,139,139,34,34,34,34,139,34,34,139,139,139,139,139,34,34,34,139,34,139,34,139,139,139,34,34,139,34,139,34,139,139,34,139,139,139,139,34,139,139,139,34,34,34,139,139,34,139,34,139,139,139,139,139,34,139,139,139,34,34,139,34,34,34,139,139,34,139,139,34,34,34,34,34,139,34,139,34,139,34,34,139,34,34,139,139,34,34,139,139,139,34,139,34,139,139,139,139,139,139,34,139,139,139,139,139,139,139,34,139,139,139,34,139,139,139,34,139,139,139,139,139,139,34,139,34,139,139,139,139,139,139,139,34,139,34,139,34,139,139,139,34,139,139,139,34,34,139,139,139,34,34,139,34,34,139,139,139,139,139,34,139,34,139,34,139,139,139,139,139,139,34,34,139,139,139,139,139,34,139,34,34,34,139,139,34,139,34,139,34,34,139,139,139,139,139,34,34,34,139,34,139,139,139,139,139,139,139,34,34,139,139,139,139,34,34,139,34,34,34,139,139,34,139,34,139,34,139,34,34,139,139,139,34,34,34,139,34,139,139,139,139,34,139,34,34,34,139,139,34,139,34,139,34,139,139,34,139,139,139,139,139,139,139,34,139,139,139,34,139,139,139,139,34,139,139,139,34,34,139,139,34,34,34,34,139,139,34,34,139,34,139,139,139,139,139,34,34,139,139,139,139,34,139,34,34,139,34,34,34,139,34,34,139,34,34,139,139,34,34,139,139,139,34,139,139,139,34,34,139,139,139,139,139,139,139,139,34,139,139,139,139,139,34,34,34,139,139,34,34,139,34,139,139,139,139,34,139,34,34,34,139,34,34,34,139,34,139,139,139,139,139,139,34,34,34,34,139,139,139,139,34,139,139,34,139,139,139,139,139,139,34,34,34,139,34,34,139,34,139,34,139,34,34,139,139,139,139,34,34,34,34,139,139,139,34,139,139,139,139,139,139,139,139,139,34,139,139,139,34,139,139,139,139,34,139,139,139,34,34,34,139,139,139,139,34,34,139,139,139,139,34,139,139,139,34,139,139,34,139,139,34,139,139,139,34,139,139,34,139,139,34,139,139,139,139,139,139,139,139,34,139,139,34,139,139,34,139,139,139,139,34,139,139,139,34,34,139,34,34,139,34,139,34,139,139,139,139,139,139,139,34,139,34,34,139,139,139,139,139,34,139,139,139,34,139,34,139,139,139,139,139,139,139,139,139,139,34,139,34,139,139,139,139,139,34,139,139,139,139,139,139,34,139,34,139,34,34,139,139,34,139,139,139,139,139,139,139,139,139,34,139,34,139,139,139,139,139,139,34,139,34,139,139,139,34,139,34,34,34,139,139,34,34,139,139,139,139,34,139,139,139,139,34,139,139,139,139,139,139,139,34,139,139,34,139,34,139,139,139,139,139,34,139,139,139,34,139,139,139,139,139,139,139,34,139,139,139,139,139,34,139,34,139,139,139,139,139,139,139,139,139,34,139,139,34,34,34,139,139,139,34,139,139,139,34,139,139,139,139,139,139,34,139,139,139,139,139,139,139,139,139,139,34,34,34,34,139,34,139,139,34,139,34,34,34,34,34,139,34,139,34,139,34,139,139,139,34,139,139,34,34,34,34,139,139,139,34,139,139,34,139,139,139,139,34,139,139,139,139,34,139,139,34,139,139,34,139,34,139,139,34,34,139,34,139,139,139,34,139,139,139,139,139,139],
b: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34],
},
{
r: [71,210,48,184,72,65,213,41,189,34,72,216,68,42,86,31,37,226,52,208,72,68,72,144,72,46,31,72,71,31,200,45,176,71,53,62,68,72,55,231,94,32,54,62,60,53,71,70,42,49,68,137,58,76,52,67,69,55,62,31,94,56,71,226,101,101,58,37,49,76,144,55,70,31,70,68,71,45,144,61,31,50,165,200,72,48,62,70,70,86,31,71,72,70,94,44,72,32,45,41,72,31,66,72,72,41,101,72,31,42,119,31,62,72,72,45,68,41,64,248,59,50,68,94,68,49,37,234,65,31,70,129,53,42,31,41,68,34,231,72,129,37,61,72,68,71,72,58,61,41,48,37,49,110,62,71,34,72,157,62,62,241,32,49,50,70,33,239,31,41,60,41,176,45,61,58,71,168,137,31,110,55,45,31,68,137,54,71,69,70,137,119,59,34,208,39,34,37,72,72,137,69,31,42,152,41,54,34,119,31,210,34,94,61,39,110,71,70,63,67,72,68,31,62,41,129,46,41,101,31,37,71,56,39,37,39,37,69,72,41,44,70,48,45,45,72,32,70,31,31,68,31,33,66,71,253,32,236,65,226,192,32,72,33,60,31,72,49,218,76,31,68,39,69,34,72,46,168,64,49,68,41,71,37,70,184,34,189,68,86,248,94,50,34,34,246,41,72,72,45,76,31,69,94,33,60,48,119,71,34,42,144,94,160,37,52,52,34,39,41,33,34,32,144,129,42,45,119,48,72,68,62,200,59,48,119,157,44,39,45,231,68,56,160,71,63,65,176,60,31,72,208,176,31,65,50,69,31,70,68,39,60,229,58,46,37,37,176,68,41,226,37,39,216,61,31,72,42,72,72,37,226,37,66,205,110,68,46,49,61,55,67,70,71,176,41,31,46,200,52,37,39,41,49,44,251,46,58,33,218,42,59,66,234,152,70,86,165,70,31,72,50,94,48,94,31,58,110,86,34,68,71,42,231,31,55,31,216,68,76,69,68,184,61,34,239,76,41,44,208,72,33,41,34,31,137,137,44,45,50,69,144,59,86,63,67,54,76,70,34,72,45,39,72,39,34,44,56,229,42,72,200,137,69,33,63,72,205,50,72,72,110,70,70,71,251,34,50,70,52,160,44,61,69,69,37,58,68,72,71,68,63,229,37,53,72,45,168,66,213,44,42,86,71,72,49,48,41,31,110,70,39,46,119,72,31,56,31,200,160,86,184,37,197,60,72,59,68,210,72,41,119,72,34,31,72,50,31,37,70,76,31,55,31,63,165,62,110,31,45,63,72,53,49,45,205,241,56,129,184,31,229,56,56,101,86,63,152,34,59,31,54,50,62,70,71,61,50,110,33,168,31,176,86,67,34,50,248,61,119,144,71,144,34,197,58,50,144,41,205,41,31,39,46,168,72,144,63,34,37,42,110,119,152,119,213,45,48,37,33,64,37,119,251,71,61,157,69,31,184,94,37,53,168,34,101,236,69,34,229,63,71,69,176,70,67,31,244,165,56,94,54,56,253,41,41,50,31,76,152,160,50,152,49,42,70,184,86,41,210,176,76,39,53,46,66,50,41,52,101,68,34,48,221,246,45,41,56,42,72,67,253,55,31,68,31,72,110,34,31,101,76,32,244,244,119,189,205,31,184,71,86,70,239,218,34,86,50,101,55,129,71,56,76,246,59,239,119,64,152,71,244,129,52,31,70,71,37,144,33,41,37,37,31,41,192,69,152,49,48,68,192,253,86,56,65,58,62,63,137,31,50,184,70,50,137,54,49,71,71,76,34,37,31,221,33,216,58,184,72,189,56,31,41,192,86,168,251,236,72,76,33,64,34,101,157,65,55,72,37,34,33,129,129,34,32,64,34,45,197,110,62,221,76,58,50,69,34,69,65,34,157,76,34,144,129,32,56,71,45,205,197,72,64,31,248,76,68,56,41,56,241,45,37,37,119,71,101,55,101,41,41,37,45,152,31,34,31,184,41,37,56,76,192,76,56,72,33,62,46,119,71,50,71,76,42,192,72,184,31,50,33,37,59,34,61,218,34,72,31,69,176,86,70,53,52,64,101,34,165,239,31,37,129,192,31,60,152,56,216,234,37,68,49,226,32,49,39,71,50,94,37,42,110,69,144,144,31,55,86,119],
g: [42,226,106,222,41,66,226,123,223,168,35,226,58,118,198,158,172,228,97,225,37,191,24,215,36,110,162,27,45,153,224,113,221,47,95,73,1,33,91,228,201,146,93,76,79,95,42,50,118,103,58,213,84,194,97,62,5,91,76,158,201,88,46,228,203,203,84,132,103,194,215,91,7,150,51,191,47,178,215,188,150,100,219,224,33,106,76,51,48,198,158,45,31,51,201,114,31,146,178,175,33,158,64,24,32,123,203,27,153,118,209,158,76,40,22,113,191,175,69,230,82,100,58,201,191,103,132,229,66,162,7,211,95,118,153,123,58,168,228,36,211,132,188,28,58,42,27,84,188,123,106,132,103,206,76,47,168,41,217,76,76,229,146,103,182,51,144,229,158,123,79,175,221,113,188,84,19,219,213,158,206,91,178,162,58,213,93,14,56,10,213,209,82,168,225,128,139,132,23,26,213,53,150,118,216,175,93,139,209,162,226,139,201,188,128,206,14,48,72,62,31,58,158,73,175,211,110,123,203,158,132,42,185,128,132,128,172,53,28,123,114,11,106,178,113,35,146,50,153,153,58,153,144,64,45,231,146,229,66,228,223,146,37,144,79,162,41,103,227,194,158,191,128,56,139,36,110,219,70,103,58,123,46,172,7,222,168,223,58,198,230,201,100,139,139,230,175,26,29,113,194,158,53,201,144,79,106,209,17,139,118,215,201,218,172,97,97,139,128,123,144,139,146,215,211,118,178,209,106,20,58,76,224,81,106,209,217,114,128,113,228,1,185,218,45,71,66,221,79,150,36,225,221,162,66,182,4,162,8,191,128,79,228,84,110,172,172,221,1,123,228,132,128,226,188,158,24,118,40,32,132,228,132,64,225,206,58,110,103,188,91,62,50,16,221,123,158,110,224,97,132,128,123,103,114,231,110,84,144,227,118,81,64,229,216,51,198,219,11,162,26,182,201,106,201,153,84,206,198,139,2,44,118,228,150,91,150,226,191,194,53,2,222,188,139,229,194,175,114,225,38,144,123,139,153,213,213,114,178,182,5,215,82,198,71,62,93,194,51,139,38,113,128,20,128,139,114,88,228,118,33,224,213,4,144,72,26,225,182,41,35,206,11,11,16,231,168,182,8,97,218,114,188,4,56,172,84,1,23,47,2,72,228,132,95,33,178,219,64,226,114,118,198,46,32,103,106,123,162,206,8,128,110,209,38,153,88,162,224,218,198,222,172,224,79,37,81,191,226,36,123,209,29,139,162,29,100,153,172,48,194,158,91,153,72,219,76,206,153,113,71,20,95,103,178,225,229,88,211,222,153,228,185,88,203,198,71,216,139,82,153,93,182,76,10,45,188,182,206,144,219,158,221,198,62,168,182,230,188,209,215,14,215,139,224,84,100,215,123,225,175,153,128,110,219,23,215,71,168,172,118,206,209,216,209,226,178,106,132,144,69,132,209,231,19,188,217,56,150,222,201,132,95,219,168,203,229,4,139,228,71,17,56,221,10,62,150,230,219,185,201,93,185,231,123,175,182,153,194,216,218,100,216,103,118,51,222,198,123,226,221,194,128,95,110,64,182,123,97,203,191,168,106,227,230,113,175,88,118,22,62,231,91,150,191,162,28,206,168,162,203,194,146,230,230,209,223,225,158,222,44,198,51,229,227,168,198,182,203,91,211,14,185,194,230,81,229,209,70,216,13,230,211,97,150,11,16,132,215,144,123,172,132,158,175,223,5,216,103,106,191,223,231,198,185,66,84,76,72,213,162,182,222,8,182,213,93,103,44,14,194,168,172,153,227,144,226,84,222,22,223,185,150,123,223,198,219,231,229,27,194,144,70,139,203,217,66,91,22,132,168,144,211,211,168,146,69,139,113,224,206,76,227,194,84,182,53,168,53,66,139,217,194,139,215,211,146,185,13,113,225,224,24,69,162,230,194,58,88,175,185,229,178,172,132,209,19,203,91,203,123,175,172,178,216,162,168,162,222,175,132,185,194,223,194,88,37,144,73,110,209,17,182,19,194,118,223,28,222,162,182,144,132,82,168,188,227,139,29,162,56,221,198,7,95,97,69,203,168,219,229,150,132,211,223,162,79,216,185,226,229,172,2,103,228,146,103,128,17,100,201,132,118,206,53,215,215,158,91,198,209],
b: [122,27,142,41,121,135,26,142,38,132,116,25,131,142,103,137,130,24,141,28,118,112,106,67,117,142,135,109,123,138,32,142,47,125,141,137,84,115,141,25,98,140,141,138,138,141,122,126,142,142,131,72,140,108,141,133,89,141,138,137,98,140,124,24,94,94,140,142,142,108,67,141,90,139,127,112,125,125,67,116,139,142,54,32,115,142,138,127,126,103,137,123,112,127,98,142,112,140,125,127,115,137,134,106,113,142,94,109,138,142,83,137,138,120,104,142,112,127,136,33,139,142,131,98,112,142,142,26,135,135,90,77,141,142,138,142,131,132,25,117,77,142,116,110,131,122,109,140,116,142,142,142,142,88,138,125,132,121,59,138,138,29,140,142,122,127,141,28,137,142,138,127,47,142,116,140,101,52,72,137,88,141,125,135,131,72,141,97,130,93,72,83,139,132,28,142,141,142,105,108,72,129,139,142,62,127,141,141,83,135,27,141,98,116,142,88,97,126,137,133,112,131,137,137,127,77,142,142,94,137,142,122,119,142,142,142,130,129,110,142,142,94,142,125,142,116,140,126,138,138,131,138,141,134,123,37,140,27,135,24,37,140,118,141,138,135,121,142,25,108,137,112,142,130,141,117,142,52,136,142,131,142,124,130,90,41,132,38,131,103,33,98,142,141,141,32,127,108,111,142,108,137,129,98,141,138,142,83,100,141,142,67,98,57,130,141,141,141,142,142,141,141,140,67,77,142,125,83,142,103,131,138,32,139,142,83,59,142,142,142,25,84,119,57,123,136,135,47,138,139,117,28,47,135,135,122,87,135,92,112,142,138,25,140,142,130,130,47,84,142,24,142,142,25,116,137,106,142,120,113,142,24,142,134,29,88,131,142,142,116,141,133,126,99,47,142,137,142,32,141,142,142,142,142,142,35,142,140,141,25,142,139,134,26,62,127,103,54,94,135,108,122,98,142,98,138,140,88,103,141,86,122,142,25,139,141,139,25,112,108,129,86,41,116,141,28,108,127,142,28,119,141,142,141,138,72,72,142,125,122,89,67,139,103,136,133,141,108,127,141,119,142,142,103,142,141,142,140,25,142,115,32,72,87,141,137,108,29,122,121,116,88,94,94,99,35,132,122,92,141,57,142,116,87,130,130,140,84,105,125,86,137,25,142,141,115,125,52,134,26,142,142,103,124,113,142,142,142,135,88,92,142,142,83,119,138,140,135,32,57,103,41,130,33,138,118,139,112,27,117,142,83,111,141,135,111,142,138,130,126,108,137,141,138,137,54,138,88,138,142,136,103,141,142,125,29,29,140,77,41,138,25,119,140,94,103,136,62,141,139,138,141,122,138,93,123,116,122,88,141,52,137,47,103,133,132,122,33,116,83,67,97,67,141,33,140,142,67,142,29,127,138,142,142,52,105,67,136,132,130,142,88,83,62,83,26,125,142,142,141,136,142,83,35,101,116,59,130,139,41,98,142,141,52,132,94,27,87,141,25,136,100,130,47,93,133,139,30,54,119,98,141,119,37,142,127,122,138,108,62,57,142,62,142,142,127,41,103,142,27,47,108,142,141,142,134,122,142,141,94,112,132,142,24,32,142,127,140,142,104,133,37,141,139,112,135,110,88,132,135,94,108,140,30,30,83,38,29,137,41,122,103,127,28,25,132,103,122,94,141,77,97,119,108,32,139,28,83,136,62,96,30,77,141,139,94,99,142,67,141,142,130,142,137,127,37,89,62,142,142,112,37,37,103,119,135,140,138,137,72,135,122,41,92,122,72,141,142,122,97,108,132,130,138,24,141,25,140,41,104,38,119,139,142,37,103,52,35,27,109,108,141,136,141,94,59,135,141,104,142,132,141,77,77,132,140,136,141,142,33,88,138,24,108,140,122,129,132,129,135,141,59,108,141,67,77,140,119,96,142,29,33,106,136,135,33,108,131,140,127,119,29,125,130,142,83,101,94,141,94,142,127,130,125,62,135,132,135,41,127,142,119,108,37,108,140,118,141,137,142,83,100,122,101,108,142,37,110,41,135,122,141,142,139,132,116,25,141,111,135,130,47,103,90,141,141,136,94,132,54,28,139,142,77,37,135,138,62,119,25,26,130,86,142,24,140,142,142,100,142,98,142,142,88,129,67,67,137,141,103,83],
},
{
r: [253,229,254,81,250,253,160,73,254,174,2,171,61,52,93,30,250,254,134,129,254,227,253,145,3,4,17,19,254,26,152,144,112,101,21,2,252,150,87,231,110,98,178,18,2,57,200,254,19,145,36,247,147,163,96,211,252,1,2,61,74,165,246,253,156,249,64,243,20,42,51,98,254,56,3,44,254,234,104,139,179,54,223,196,254,30,156,1,247,81,44,254,100,220,134,6,25,106,95,4,36,103,132,253,229,20,81,253,21,76,126,74,71,253,114,9,192,254,63,254,241,217,5,243,236,2,128,254,9,56,252,123,121,93,54,178,5,51,254,123,252,186,142,1,16,37,14,186,33,254,254,204,66,181,148,253,13,7,69,109,89,254,179,109,129,10,254,242,252,92,251,66,254,3,54,39,252,124,76,73,254,174,254,96,124,52,17,253,47,254,140,112,17,227,242,106,8,4,251,254,183,252,44,78,173,170,3,208,120,170,254,197,248,106,251,254,253,12,89,0,5,202,87,92,228,254,28,227,128,147,33,1,184,103,242,199,124,254,37,8,254,254,6,166,110,22,196,14,238,254,11,148,14,170,254,253,54,254,235,254,254,254,253,197,3,254,32,184,173,199,34,253,34,140,34,45,134,244,118,52,26,84,25,42,253,253,78,86,1,139,252,136,25,16,61,254,101,9,29,153,202,217,103,208,18,84,28,252,253,222,168,254,110,240,223,10,100,47,92,86,30,69,140,132,194,118,90,45,51,254,158,0,232,252,176,186,219,66,41,100,253,252,227,93,45,254,140,178,118,205,254,254,254,153,28,92,252,37,253,82,254,2,246,49,42,137,126,63,252,244,240,79,115,173,76,114,98,253,253,7,68,254,117,250,254,252,13,208,68,59,78,3,1,254,63,161,9,131,107,8,24,139,56,10,47,253,109,101,24,250,252,245,114,95,188,253,254,196,252,86,254,173,254,51,243,176,228,239,123,6,252,39,254,254,246,19,79,248,95,251,232,253,254,76,96,254,252,152,107,242,0,64,71,244,174,168,214,71,26,139,252,249,148,213,142,86,150,254,22,59,12,254,238,253,22,4,148,253,204,155,188,115,254,252,36,22,19,254,155,2,120,59,147,220,223,254,156,235,254,147,254,250,191,252,68,120,2,252,253,44,252,253,254,29,26,59,131,226,29,242,249,192,152,253,13,10,3,250,238,254,253,33,166,250,18,189,33,251,253,246,82,254,136,246,254,183,210,244,248,18,165,200,254,33,115,152,114,186,245,254,222,86,39,240,24,171,17,210,12,49,244,254,252,21,84,254,248,1,189,214,158,251,131,82,184,49,1,250,252,233,204,250,69,0,252,6,253,76,254,73,233,74,254,239,254,254,191,253,208,252,161,254,232,96,153,231,247,123,254,254,66,155,202,247,238,253,216,1,64,71,197,145,183,155,219,252,118,236,8,158,254,254,236,252,253,226,248,1,37,235,109,250,78,244,254,249,254,252,223,251,103,252,41,136,254,2,211,254,247,254,237,181,61,253,184,253,41,57,205,112,254,248,194,168,20,11,166,117,224,251,239,252,106,216,87,2,176,144,217,252,217,163,254,253,253,6,249,160,200,254,95,252,250,213,191,109,254,254,168,228,156,252,254,254,252,199,236,254,152,243,128,191,249,254,254,254,213,249,242,121,235,252,241,163,252,11,254,192,2,183,253,253,254,24,90,252,254,208,253,200,64,252,89,90,181,252,252,253,4,205,219,251,252,231,254,254,30,234,6,244,226,245,252,252,121,220,202,232,254,253,253,247,233,253,253,29,254,128,254,254,81,249,207,132,226,253,254,254,253,3,128,16,252,189,178,228,237,251,252,137,252,166,254,254,131,194,1,251,124,118,87,7,246,211,244,208,254,210,61,197,160,179,57,117,252,247,137,245,253,144,253,224,252,11,134,253,229,254,36,101,158,254,170,250,242,253,104,104,126,249,13,163,222,237,234,174,171,247,246,52,144,32,254,194,205,253,36,6,49,161,145,252,161,253,249,254,254,254,252,197,254,211,189,165,253,239,252,211,121,241,242,222,224,252,16,68,207,252,78,252,254,136,45,219,254,140,254,253,254,254,253,214,252,132,253,112,179,234,253,188,26,106,41,248,254,98,231,216,90,217,254],
g: [220,80,176,18,127,227,47,16,205,52,1,51,15,16,23,17,125,170,39,37,198,78,146,43,3,4,12,13,193,16,45,42,31,26,14,2,246,44,21,82,30,25,53,13,2,15,62,157,13,43,18,114,43,48,24,67,251,1,2,15,16,49,108,152,46,120,15,101,14,17,16,25,207,16,3,17,209,86,28,41,54,16,74,60,194,17,46,1,114,18,17,163,26,72,39,5,16,28,24,4,18,27,38,235,80,14,18,222,14,17,36,16,16,224,31,7,58,161,15,185,96,70,4,101,88,1,37,191,7,16,246,35,34,23,16,53,4,16,211,35,140,56,42,1,11,18,11,56,17,187,187,63,15,54,44,224,10,6,16,29,21,211,54,29,37,8,172,100,140,22,135,15,182,3,16,18,137,35,17,16,202,52,202,24,35,16,12,146,17,216,41,31,12,78,98,28,7,4,131,198,55,140,17,17,52,51,3,65,34,51,161,60,118,28,135,194,231,9,21,0,4,62,21,22,79,193,16,78,37,43,17,1,55,27,98,61,35,194,18,7,200,170,5,49,30,15,60,11,91,174,9,44,11,51,194,218,16,191,87,205,183,165,233,60,3,196,17,55,52,61,17,155,17,41,17,17,39,103,33,16,16,19,16,17,227,148,17,20,0,41,238,39,16,11,15,216,26,7,17,45,62,70,27,65,13,19,16,142,150,73,50,159,30,95,74,8,26,17,22,20,17,16,41,38,59,33,22,17,16,180,47,0,83,137,53,56,71,15,17,26,154,253,78,23,17,174,41,53,33,64,200,163,204,45,16,22,251,18,229,19,185,2,110,17,17,40,36,15,242,105,95,18,32,52,17,31,25,233,227,6,15,157,33,127,205,238,10,65,15,15,17,3,1,174,15,48,7,38,29,7,15,41,16,8,17,227,29,26,15,127,238,107,31,24,57,226,169,60,242,20,215,52,180,16,101,53,79,93,35,5,247,18,167,167,110,13,18,116,24,131,83,231,196,17,24,163,137,45,29,98,0,15,16,103,52,50,69,16,16,41,251,121,44,68,42,20,44,182,15,15,9,207,91,235,15,4,44,226,63,46,57,32,198,246,18,15,13,193,46,1,34,15,43,72,74,180,46,87,215,43,204,125,58,244,15,34,2,249,222,17,251,154,159,17,16,15,38,77,17,98,120,58,45,218,10,8,3,129,91,182,220,17,49,125,13,57,17,131,150,110,19,211,39,108,215,55,66,105,118,13,49,62,209,17,32,45,31,56,107,178,73,20,18,95,15,51,12,66,9,17,103,205,236,14,19,207,116,0,57,69,47,133,38,19,55,17,1,129,240,84,63,125,16,0,247,5,152,17,200,16,84,16,167,93,178,185,58,229,65,142,48,163,83,24,45,82,112,35,176,215,15,46,62,114,91,222,69,1,15,16,60,43,55,46,71,244,33,88,7,47,174,183,88,240,233,77,118,0,18,87,29,127,17,103,213,120,180,247,74,133,27,253,17,39,189,1,67,209,112,165,90,54,15,233,55,155,17,15,64,31,189,118,59,50,14,9,49,33,76,135,93,240,28,69,21,2,53,42,70,240,70,48,172,148,226,5,123,47,62,207,24,244,129,68,58,29,196,183,50,79,46,142,191,202,238,61,88,187,45,101,37,58,123,172,202,189,68,120,100,34,87,242,96,48,236,9,204,58,1,55,229,224,165,15,22,236,213,65,148,62,15,144,21,22,54,144,249,154,4,64,71,135,244,82,200,178,17,86,5,105,77,107,144,249,34,72,62,83,213,235,218,112,84,150,148,17,170,37,169,157,18,123,64,38,77,152,169,170,155,3,37,11,137,57,53,79,90,133,253,40,144,49,157,182,38,59,0,131,35,33,21,6,110,67,105,65,211,66,15,60,47,54,15,33,138,114,40,107,229,42,218,76,236,9,39,226,80,189,18,26,47,198,51,129,98,146,28,28,36,121,10,48,73,90,86,52,51,114,108,16,42,17,193,59,64,154,18,5,17,48,43,253,48,231,121,159,169,216,140,60,167,67,57,49,220,93,144,67,34,96,100,73,76,246,11,15,64,138,17,138,185,39,17,71,187,41,176,154,161,176,150,69,249,38,224,31,54,86,220,57,16,28,17,116,213,25,82,69,22,70,161],
b: [158,100,120,124,94,165,127,120,144,123,9,124,113,105,127,73,94,116,129,129,138,101,102,129,15,20,47,52,133,66,128,129,129,128,56,13,184,128,126,99,129,128,123,49,13,110,115,108,52,129,83,92,128,126,128,110,189,8,11,113,121,126,92,105,127,93,116,92,54,92,103,128,146,108,15,95,148,97,129,129,122,107,104,117,135,73,127,8,92,124,95,111,128,105,129,26,63,129,127,20,83,128,129,172,100,54,124,160,56,122,130,121,120,161,129,32,118,110,114,127,93,107,22,92,96,9,130,132,32,108,184,130,130,127,107,123,22,103,149,130,99,120,129,6,45,85,43,120,78,129,129,113,117,122,128,161,41,28,119,129,126,149,122,129,129,34,118,92,99,127,97,117,124,18,107,88,97,130,122,120,141,123,141,128,130,105,47,102,99,154,129,129,47,101,93,129,30,20,95,138,121,99,95,123,124,125,18,111,129,125,110,116,92,129,97,135,169,38,126,4,22,114,126,127,100,133,68,101,130,128,78,6,121,128,93,115,130,135,85,30,140,116,26,125,129,59,117,43,94,119,36,128,43,125,135,156,107,132,96,144,126,113,170,116,15,136,75,121,124,115,80,107,80,129,80,97,129,92,129,105,66,125,63,92,165,103,123,125,5,129,176,129,63,45,113,154,128,32,71,128,114,107,128,111,49,125,68,100,104,104,125,109,129,94,104,34,128,99,127,125,73,119,129,129,117,129,126,97,103,123,127,4,98,97,123,120,106,117,90,128,106,191,101,127,97,119,129,123,129,113,140,111,143,128,68,127,189,85,167,124,127,11,92,101,92,129,130,114,180,92,94,123,129,124,122,129,128,170,165,28,118,108,129,94,144,176,41,111,118,112,123,18,6,119,114,126,32,129,129,30,61,129,108,34,99,165,129,128,61,94,176,92,129,127,120,163,115,117,180,125,153,124,123,103,92,123,100,94,130,26,185,88,114,114,92,52,123,92,127,95,98,169,136,122,128,111,97,128,129,93,4,116,120,92,123,125,108,120,66,129,189,93,128,109,129,125,128,124,59,112,38,146,94,172,59,20,128,163,113,127,120,129,138,184,83,59,52,133,127,9,129,112,128,105,104,123,127,96,153,128,143,94,119,182,118,129,13,187,160,95,189,106,109,71,66,112,129,102,71,93,93,118,128,156,41,34,18,95,94,124,158,78,125,94,49,119,78,95,104,92,124,149,129,92,153,121,111,92,92,49,126,115,148,78,129,128,129,120,92,122,104,125,88,94,61,124,47,111,38,101,92,144,174,56,125,146,92,5,119,108,127,96,129,124,121,101,6,95,178,98,113,94,119,4,185,26,105,122,140,120,98,121,114,94,122,127,119,167,111,100,126,111,98,128,128,99,92,130,120,153,117,127,114,92,94,160,108,8,116,120,116,129,121,127,106,182,129,96,30,127,119,126,96,178,170,102,92,5,85,96,129,94,123,92,151,93,123,185,104,96,128,191,90,129,130,9,110,148,92,113,95,122,113,170,121,107,90,110,113,129,130,92,117,125,54,36,125,129,103,97,94,178,129,108,126,11,123,129,107,178,107,126,118,103,163,24,93,127,115,146,127,182,95,109,119,129,136,126,125,100,127,100,132,141,176,115,96,129,128,92,130,119,93,118,141,130,109,93,92,130,96,180,93,126,174,36,143,118,9,121,167,161,113,61,126,174,151,111,103,115,116,101,126,126,122,101,187,106,20,113,106,97,182,99,140,122,73,97,24,92,102,92,101,187,130,105,114,98,151,172,156,92,98,104,103,71,116,130,115,108,124,93,112,129,102,105,115,116,107,15,130,45,97,119,123,100,95,96,191,129,101,125,108,124,129,117,5,95,130,129,126,28,92,110,92,111,149,111,113,116,127,122,110,129,98,92,129,92,167,129,156,103,174,36,129,163,100,130,83,128,127,138,125,95,93,102,129,129,130,93,41,126,104,95,97,123,124,92,92,105,129,75,133,117,113,106,83,24,101,126,129,191,126,169,93,109,115,154,99,116,114,110,119,126,158,94,101,110,130,93,92,104,103,184,45,118,112,98,123,98,127,129,97,106,129,129,120,106,110,120,104,108,187,129,161,129,122,97,158,120,66,129,90,92,151,128,99,108,126,107,110],
},
{
r: [178,34,178,178,178,34,34,178,178,34,178,34,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,34,34,178,178,178,178,34,178,178,178,178,178,34,178,34,34,178,178,178,178,34,178,178,178,178,178,178,178,178,34,34,34,34,178,178,178,178,178,178,178,34,178,178,178,178,34,178,34,178,178,178,178,178,178,178,34,34,178,178,178,178,178,34,178,178,178,178,34,178,178,178,34,178,178,178,34,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,34,178,178,34,34,178,178,178,178,178,178,178,34,178,178,178,34,178,178,178,178,178,34,178,178,178,178,34,178,178,178,178,178,178,178,178,34,178,34,178,178,34,178,178,34,178,34,34,178,178,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,34,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,34,34,178,34,178,178,178,178,34,178,178,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,34,178,34,178,178,178,178,178,34,178,178,178,34,178,34,178,178,178,178,34,178,34,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,34,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,34,34,34,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,34,178,178,34,178,178,178,178,178,178,178,34,34,178,178,34,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,34,178,34,34,34,34,178,178,34,178,178,178,34,178,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,178,178,178,178,178,34,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,34,178,178,34,178,178,34,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,34,178,178,178,178,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,34,34,178,178,34,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,34,34,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,34,178,34,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,34,178,178,34,34,178,178,178,178,178,178,178,178,178,34,34,178,34,178,178,178,178,178,34,178,178,34,178,34,178,34,178,178,34,178,178,178,34,178,178,34,178,34,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,34,34,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178],
g: [34,139,34,34,34,139,139,34,34,139,34,139,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,139,139,34,34,34,34,139,34,34,34,34,34,139,34,139,139,34,34,34,34,139,34,34,34,34,34,34,34,34,139,139,139,139,34,34,34,34,34,34,34,139,34,34,34,34,139,34,139,34,34,34,34,34,34,34,139,139,34,34,34,34,34,139,34,34,34,34,139,34,34,34,139,34,34,34,139,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,139,34,34,139,139,34,34,34,34,34,34,34,139,34,34,34,139,34,34,34,34,34,139,34,34,34,34,139,34,34,34,34,34,34,34,34,139,34,139,34,34,139,34,34,139,34,139,139,34,34,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,139,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,139,139,34,139,34,34,34,34,139,34,34,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,139,34,139,34,34,34,34,34,139,34,34,34,139,34,139,34,34,34,34,139,34,139,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,139,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,139,139,139,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,139,34,34,139,34,34,34,34,34,34,34,139,139,34,34,139,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,139,34,139,139,139,139,34,34,139,34,34,34,139,34,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,34,34,34,34,34,139,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,139,34,34,139,34,34,139,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,139,34,34,34,34,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,139,139,34,34,139,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,139,139,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,139,34,139,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,139,34,34,139,139,34,34,34,34,34,34,34,34,34,139,139,34,139,34,34,34,34,34,139,34,34,139,34,139,34,139,34,34,139,34,34,34,139,34,34,139,34,139,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,139,139,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34],
b: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34],
},
{
r: [34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,34,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,34,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,34,178,178,178,178,178,178,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,34,34,178,178,178,178,178,178,178,178,178,34,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,34,34,178,178,178,178,178,178,34,34,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,34,178,178,178,178,178,178,34,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,34,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,34,34,34,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,178,178,34,178,178,34,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,34,178,178,178,178,178,178,178,178,178,34,178,178,34,178,178,178,178,178,178,178,178,34,178,178,34,34,178,178,178,178,34,178,178,34,178,178,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,34,178,178,178,34,34,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,34,178,34,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,34,178,34,34,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,34,34,34,178,178,178,178,34,178,178,178,34,178,178,34,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,178,34,178,34,178,34,178,178,178,34,178,34,178,34,178,178,178,34,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,34,178,34,34,34,34,178,178,178,178,178,178,178,178,34,178,178,178,178,178,34,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,34,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,34,178,178,178,178,178,178,178,34,178,34,178,34,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178],
g: [139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,139,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,139,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,139,34,34,34,34,34,34,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,139,139,34,34,34,34,34,34,34,34,34,139,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,139,139,34,34,34,34,34,34,139,139,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,139,34,34,34,34,34,34,139,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,139,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,139,139,139,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,34,34,139,34,34,139,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,139,34,34,34,34,34,34,34,34,34,139,34,34,139,34,34,34,34,34,34,34,34,139,34,34,139,139,34,34,34,34,139,34,34,139,34,34,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,139,34,34,34,139,139,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,139,34,139,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,139,34,139,139,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,139,139,139,34,34,34,34,139,34,34,34,139,34,34,139,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,34,139,34,139,34,139,34,34,34,139,34,139,34,139,34,34,34,139,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,139,34,139,139,139,139,34,34,34,34,34,34,34,34,139,34,34,34,34,34,139,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,139,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,139,34,34,34,34,34,34,34,139,34,139,34,139,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34],
b: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34],
},
{
r: [178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,34,178,178,178,178,178,34,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,34,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,34,178,178,178,34,34,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178],
g: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,139,34,34,34,34,34,139,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,139,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,139,34,34,34,139,139,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34],
b: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34],
},
{
r: [178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,34,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178],
g: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,139,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34],
b: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34],
},
{
r: [178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,34,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,34,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,178,34],
g: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,139,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,139,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,139],
b: [34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34],
},
]},
Drugs_tree: {
x: [652.393,649.79,652.393,667.007,652.393,635.919,652.393,654.684,190.902,196.29,190.902,187.721,521.164,515.66,521.164,524.362,473.851,475.204,473.851,471.252,473.851,475.601,237.009,234.276,237.009,238.606,237.009,228.094,237.009,246.724,237.009,235.707,237.009,240.904,502.704,511.071,502.704,493.492,285.285,284.838,285.285,271.141,285.285,288.264,285.285,289.111,285.285,297.967,416.956,418.53,607.271,605.617,144.586,144.705,144.586,144.492,298.015,296.379,298.015,300.885,271.141,255.217,243.194,235.865,243.194,249.876,366.797,353.539,366.797,380.866,366.797,365.372,326.692,316.411,326.692,333.686,326.692,328.812,326.692,325.223,429.371,450.835,429.371,411.981,92.198,94.245,234.329,236.919,234.329,232.7,399.227,402.104,399.227,406.695,399.227,389.367,399.227,431.081,399.227,368.187,399.227,397.478,519.446,511.071,519.446,527.195,519.446,522.911,519.446,518.046,72.579,84.064,72.579,71.696,72.579,62.378,206.809,211.161,526.477,519.517,526.477,532.031,478.092,448.696,478.092,508.274,478.092,477.096,478.092,481.324,572.777,568.604,535.986,532.777,450.835,439.565,450.835,447.067,450.835,445.467,450.835,481.909,450.835,449.245,450.835,456.287,173.687,179.941,173.687,167.311,451.606,449.107,451.606,457.08,451.606,448.696,451.606,448.471,218.055,213.97,218.055,224.375,493.076,501.329,493.076,485.316,535.724,532.031,535.724,537.612,688.17,690.887,382.924,358.563,382.924,408.927,667.496,641.153,667.496,670.277,667.496,671.63,91.329,87.418,91.329,117.71,456.287,459.662,139.944,139.849,139.944,140.662,283.365,286.198,687.968,678.067,418.53,431.736,418.53,448.696,418.53,384.312,246.724,253.164,234.464,234.875,479.061,493.409,355.58,358.563,529.675,523.24,529.675,531.146,529.675,538.091,269.107,296.882,269.107,268.108,269.107,274.042,640.856,644.586,640.856,632.862,640.856,644.723,641.153,613.329,641.153,643.506,641.153,637.546,659.336,682.525,659.336,635.919,481.909,479.738,481.909,493.409,481.909,492.807,481.909,490.919,481.909,478.713,615.028,616.436,615.028,606.595,615.028,612.115,615.028,617.717,615.028,624.136,328.553,341.005,328.553,328.129,328.553,318.396,328.553,325.139,431.081,463.358,212.148,219.781,212.148,208.148,353.539,341.005,82.364,80.014,82.364,84.303,389.288,388.141,389.288,390.11,515.803,519.088,636.162,632.858,403.415,393.577,403.415,414.675,439.565,435.045,310.643,307.175,310.643,304.993,310.643,318.396,483.047,481.779,483.047,485.618,483.047,459.281,483.047,493.492,483.047,503.463,439.043,441.231,355.431,358.563,145.282,136.857,145.282,150.999,540.838,550.99,540.838,574.136,242.355,236.67,242.355,249.239,615.456,617.194,236.67,233.709,380.866,384.312,380.866,388.782,117.71,144.751,562.552,562.565,358.563,324.914,358.563,365.022,358.563,368.187,358.563,360.906,428.384,428.07,262.441,262.243,262.441,271.043,262.441,249.239,218.473,211.161,218.473,227.978,515.676,519.517,515.676,512.477,228.094,224.375,228.094,219.781,461.676,460.607,461.676,463.358,528.436,530.444,220.286,217.824,293.305,294.154,293.305,288.155,293.305,305.397,477.096,475.246,477.096,475.601,557.113,555.515,557.113,564.82,557.113,568.604,557.113,563.17,557.113,543.492,557.113,558.166,557.113,547.044,384.312,356.389,384.312,381.188,447.067,443.288,447.067,447.019,532.777,527.195,432.366,438.744,432.366,424.204,285.071,293.305,285.071,281.271,285.071,281.257,689.474,679.387,689.474,697.02,212.899,216.124,140.396,153.837,140.396,127.018,449.575,458.411,449.575,438.171,375.076,374.943,375.076,387.195,375.076,364.098,375.076,375.014,679.387,667.007,405.61,408.927,494.997,490.919,305.854,323.488,114.229,112.839,616.436,617.404,583.857,605.617,583.857,563.109,588.615,591.887,296.882,324.914,79.38,84.064,79.38,75.888,84.064,96.816,648.842,647.817,648.842,650.657,408.842,412.684,172.444,175.559,316.411,305.397,679.556,676.101,679.556,682.525,679.556,676.869,609.728,613.329,393.969,390.11,395.123,392.186,395.123,385.623,406.695,409.304,406.695,413.769,652.744,653.066,319.807,318.87,319.807,321.125,372.908,375.362,544.162,543.492,496.689,492.807,368.187,346.077,241.0,242.354,241.0,232.575,241.0,249.239,510.071,508.763,510.071,512.477,574.012,576.589,574.012,577.265,574.012,570.403,580.395,576.33,321.041,316.181,321.041,322.646,632.862,623.713,227.991,228.282,159.461,163.843,159.461,158.519,159.461,162.249,159.461,153.184,389.367,380.759,389.367,389.499,315.563,307.495,315.563,323.488,227.978,227.145,227.978,224.375,227.978,233.211,585.877,588.942,612.506,614.123,314.18,310.323,671.63,674.423,375.362,380.759,672.315,670.277,672.315,673.658,81.509,78.176,81.509,86.632,576.589,583.037,576.589,575.073,576.589,572.834,277.772,274.134,245.743,248.129,245.743,241.709,232.575,227.578,232.575,228.282,232.575,235.772,216.434,219.781,276.113,264.573,276.113,279.869,276.113,276.719,276.113,284.933,388.141,387.195,162.928,158.616,162.928,169.761,656.841,653.066,241.977,241.709,241.977,239.634,241.977,263.721,241.977,221.208,431.382,434.321,270.176,271.663,167.545,153.837,167.545,181.41,22.184,19.957,22.184,24.956,355.014,353.313,318.87,317.711,121.829,118.014,121.829,127.018,124.126,116.075,672.292,667.496,639.195,641.153,639.195,638.16,459.281,459.344,459.281,434.321,459.281,456.201,570.403,564.82,610.384,609.458,216.681,217.717,216.681,227.578,216.681,213.828,216.681,208.343,216.681,212.855,478.183,471.293,144.751,140.662,144.751,152.455,144.751,144.705,144.751,175.555,166.709,164.266,166.709,169.761,424.204,414.689,407.045,395.123,422.801,425.161,422.801,419.239,234.875,235.707,351.189,352.929,274.134,269.107,235.675,238.461,235.675,233.915,440.597,443.593,69.709,69.615,158.511,160.089,158.511,152.455,666.522,668.222,666.522,678.067,413.769,419.239,421.053,420.836,53.745,62.378,53.745,47.028,99.692,112.839,501.572,501.329,137.512,145.762,137.512,142.828,137.512,135.644,552.77,550.99,523.24,519.088,523.24,515.66,526.671,530.444,539.373,541.176,325.139,321.645,319.124,321.645,390.11,388.782,355.273,356.389,355.273,354.361,227.55,223.743,47.028,42.561,47.028,46.028,233.915,234.157,233.915,230.339,504.493,501.329,397.672,411.981,397.672,385.197,284.933,289.607,284.933,289.089,284.933,285.895,380.759,377.259,217.824,210.998,217.824,223.743,545.1,541.176,545.1,547.373,653.066,625.334,653.066,655.884,653.066,650.657,653.066,666.522,653.066,670.273,653.066,649.678,356.389,324.914,623.713,614.012,316.181,319.968,124.618,134.059,124.618,117.384,124.618,121.225,572.834,569.088,414.689,403.097,443.593,446.524,443.593,443.771,271.663,274.814,237.776,238.195,226.98,224.375,424.374,422.008,348.107,364.098,348.107,333.076,219.781,219.292,276.998,274.042,535.994,508.274,535.994,562.484,535.994,535.543,493.409,519.517,493.409,496.218,118.014,115.843,583.037,587.07,115.199,116.225,115.199,114.585,588.942,598.031,588.942,587.75,588.942,579.587,615.951,614.123,615.951,609.308,615.951,614.012,615.951,614.383,615.951,622.001,327.45,325.134,116.225,117.71,468.828,468.835,249.876,253.81,249.876,250.03,249.876,253.845,69.925,68.69,196.29,203.756,385.055,393.577,265.891,263.721,530.444,520.848,530.444,543.492,380.466,382.924,380.466,378.763,545.781,543.932,516.61,515.648,294.154,295.037,304.993,300.885,153.184,154.112,153.184,145.762,393.577,391.059,328.101,328.129,465.572,449.939,465.572,466.689,465.572,479.061,479.738,474.805,479.738,482.761,478.355,474.744,478.355,478.559,478.355,483.047,378.393,385.197,378.393,374.887,314.605,311.026,314.605,317.711,314.605,314.895,291.932,297.723,291.932,286.198,404.37,407.045,250.106,253.232,369.921,363.217,369.921,373.809,369.921,374.014,482.761,484.395,435.161,449.939,435.161,420.836,253.164,256.573,441.231,445.467,364.098,360.408,543.46,542.16,264.573,286.198,264.573,261.583,264.573,238.461,264.573,267.665,374.89,380.923,374.89,375.124,312.413,310.323,288.155,271.663,288.155,305.854,288.155,284.635,695.337,687.968,695.337,699.142,373.442,374.988,610.239,613.329,228.282,224.427,253.232,255.217,253.232,254.358,317.711,333.076,317.711,300.604,408.51,408.927,25.092,24.956,674.43,673.658,597.464,598.031,277.933,283.021,277.933,271.043,296.628,300.604,491.403,493.409,674.929,676.869,472.09,474.805,308.084,316.181,308.084,297.967,236.073,239.222,236.073,231.77,65.963,69.615,569.169,568.604,626.066,628.222,627.295,629.371,374.988,378.768,175.182,165.747,175.182,187.535,538.091,537.064,538.091,547.044,46.631,55.711,46.631,43.641,602.786,605.815,337.348,333.686,597.71,591.887,597.71,605.617,562.565,562.522,384.617,385.197,520.848,514.512,444.925,445.467,19.957,17.904,381.961,380.866,460.595,457.08,541.176,522.387,541.176,543.932,541.176,554.656,512.652,515.697,512.652,508.274,603.112,605.617,482.963,481.909,302.844,297.723,302.844,306.491,69.615,73.774,204.345,208.343,609.458,613.494,609.458,606.793,656.271,654.684,656.271,657.355,605.815,574.136,605.815,607.704,186.6,187.543,240.96,238.628,112.839,111.493,112.839,125.495,210.998,203.595,142.828,144.106,142.828,146.89,655.412,652.393,471.42,469.936,693.631,698.092,615.014,613.329,408.502,411.981,281.271,280.053,203.595,195.262,162.583,158.511,422.008,418.53,515.648,512.652,427.364,430.425,427.364,424.806,427.364,428.07,427.364,425.796,495.719,492.807,543.207,547.59,543.207,563.109,543.207,542.592,543.207,519.517,614.012,605.617,138.774,136.857,138.774,139.764,700.152,694.365,700.152,699.383,700.152,704.41,492.807,501.001,574.662,571.831,574.662,574.136,380.923,377.345,380.923,388.782,263.721,286.198,321.373,324.914,605.559,609.308,319.107,318.87,67.485,68.69,67.485,55.711,67.485,67.617,67.485,64.858,67.485,52.618,67.485,91.329,105.609,111.493,105.609,101.658,169.761,178.575,690.887,694.365,181.41,195.126,567.203,563.17,314.392,317.711,314.392,311.426,271.043,272.948,178.575,187.159,385.197,378.768,622.001,626.066,374.943,374.99,233.211,238.461,205.051,200.096,205.051,206.533,444.056,427.703,444.056,437.969,444.056,463.358,444.056,443.593,443.903,443.771,569.088,564.243,187.535,203.756,729.37,717.155,109.121,103.391,657.355,658.023,328.617,328.257,704.586,701.696,464.96,462.099,464.96,467.065,568.604,576.33,350.311,353.313,683.5,670.273,683.5,693.631,328.129,328.257,408.927,434.321,408.927,412.116,434.321,435.616,627.284,627.976,232.489,236.885,232.489,229.461,203.756,227.578,617.373,615.028,466.797,463.358,361.847,365.372,632.858,627.976,569.294,571.831,689.143,682.525,689.143,694.365,482.442,487.383,482.442,476.298,273.146,268.984,365.044,365.372,606.595,598.031,173.372,159.745,173.372,185.702,158.875,165.747,158.875,154.929,367.182,370.131,324.914,286.198,324.914,328.075,617.194,625.334,617.194,612.818,380.286,385.055,469.3,462.099,469.3,476.298,95.008,98.407,459.746,463.358,62.378,62.737,463.358,462.789,463.358,469.936,125.495,127.883,125.495,137.512,550.763,555.529,550.763,548.136,609.42,613.163,62.606,63.112,480.659,479.74,480.659,481.779,238.461,216.124,238.461,238.195,352.929,355.431,96.816,111.493,375.373,372.645,375.373,374.975,375.373,377.259,501.329,509.417,370.06,369.921,425.796,424.961,425.796,412.329,425.796,438.171,425.796,422.42,187.543,190.807,624.136,628.737,216.124,195.126,475.246,472.96,469.936,474.225,289.405,286.949,490.919,494.814,236.919,241.709,420.836,407.045,420.836,417.407,305.397,310.323,227.578,231.77,227.578,255.217,738.923,745.925,738.923,729.37,514.512,510.987,65.959,63.112,613.163,619.003,438.744,442.7,717.155,701.696,670.273,673.878,547.59,550.27,136.857,127.018,513.698,509.417,288.522,300.604,288.522,280.28,86.095,87.418,86.095,85.12,236.885,205.051,236.885,269.107,236.885,238.628,236.885,239.645,112.294,111.493,112.294,112.463,385.623,382.917,385.623,380.854,63.112,64.099,63.112,59.685,437.969,433.926,447.699,449.107,323.488,346.077,329.401,327.45,187.54,175.559,187.54,185.995,187.54,201.11,703.682,700.152,300.7,307.495,300.7,296.691,158.349,154.147,158.349,165.491,58.68,62.378,135.895,139.721,52.618,39.881,568.731,572.062,415.077,415.707,261.454,264.573,261.454,259.942,704.41,704.232,704.41,708.037,134.059,145.349,533.968,532.031,268.984,262.441,159.745,145.349,159.745,159.234,39.881,28.313,374.94,374.975,165.491,175.559,195.262,185.702,458.411,465.366,682.525,681.566,682.525,701.696,682.525,685.896,74.161,71.59,545.369,547.044,412.684,418.53,560.219,554.656,197.695,201.11,197.695,194.7,18.563,28.313,18.563,10.352,195.842,200.096,555.529,560.434,555.529,557.08,555.529,552.141,237.926,239.634,195.641,190.807,195.641,201.11,161.153,167.311,161.153,158.164,161.153,157.653,466.522,470.319,504.424,494.083,504.424,515.66,504.424,503.159,554.656,557.713,554.656,558.762,365.372,368.451,261.583,260.249,563.109,562.522,415.707,416.956,65.438,67.722,65.438,64.099,316.56,315.563,750.0,745.925,98.407,103.391,98.407,94.245,357.116,360.408,33.747,31.316,468.723,468.788,494.083,484.52,494.083,491.471,28.313,24.956,28.313,31.316,370.131,374.89,639.074,641.153,613.494,619.003,84.113,87.418,688.088,698.82,688.088,696.777,688.088,667.496,688.088,691.051,187.483,185.702,376.029,372.846,73.774,80.014,374.91,374.89,80.014,86.632,579.587,572.062,572.062,566.414,391.012,388.782,467.967,468.723,467.967,466.689,391.057,390.11,479.164,479.74,403.097,388.782,392.619,388.782,503.463,522.387,450.194,451.986,450.194,448.696,587.75,613.329,587.75,562.484,10.352,3.972,67.617,67.193,67.617,67.722,427.703,414.675,321.125,322.933,219.656,221.208,133.385,124.126,133.385,144.751,133.385,134.015,133.385,129.953,511.38,507.32,550.99,559.209,484.52,476.685,439.211,438.171,619.003,629.371,345.871,346.077,698.82,706.25,438.171,441.29,241.848,242.355,67.722,71.59,67.722,65.093,644.832,641.153,644.832,646.797,87.418,89.028,87.418,90.646,192.142,188.905,192.142,195.842,476.685,470.319,469.11,470.319,175.555,205.051,462.099,452.969,385.075,388.782,705.346,701.696,645.048,641.153,154.242,150.999,542.16,540.838,564.298,567.578,564.298,559.209,564.243,560.434,564.243,562.484,563.2,566.414,145.349,139.721,145.349,145.987,468.788,468.828,514.11,511.071,201.11,221.208,3.972,0.0,627.976,625.334,127.018,111.493,116.075,109.121,113.416,117.384,490.562,487.383,307.495,306.323,353.313,354.361,322.933,325.134,140.662,138.062,86.632,89.313,86.632,99.692,471.293,463.358,689.668,687.968,382.472,385.055,697.614,693.631,631.632,629.371,631.632,633.167,41.941,46.631,235.865,227.978,675.691,672.292,242.697,240.96,255.217,271.663,255.217,258.365,442.997,431.736,608.792,609.728,635.919,605.815,485.316,478.183,84.509,85.12,368.808,365.022,465.366,470.392,368.891,364.098,368.891,372.846,286.949,283.021,275.753,280.28,241.712,238.628,187.159,195.126,605.617,625.334,326.824,324.914,696.777,701.505,331.608,328.129,473.709,470.392,629.371,635.919,372.513,372.846,701.38,697.02,706.25,710.168,545.071,545.951,545.071,544.162,346.077,342.825,185.702,188.905,185.702,179.941,326.122,324.914,326.122,327.043,363.217,356.389,674.766,674.43,202.83,205.051,452.969,442.997,207.992,206.533,501.001,463.358,501.001,540.838,501.001,507.32,238.553,241.709,468.174,466.689,115.796,117.71,434.942,439.565,192.774,194.7,163.009,159.745,514.956,515.66,399.766,387.195,399.766,412.329,429.618,431.081,634.056,634.461,634.056,633.167,388.399,388.782],
y: [449.044,450.827,449.044,453.232,449.044,436.693,449.044,459.531,654.41,649.175,654.41,657.562,47.797,52.96,47.797,44.686,212.42,207.945,212.42,208.352,212.42,222.543,143.187,140.734,143.187,139.355,143.187,163.196,143.187,134.728,143.187,129.687,143.187,143.286,373.68,364.991,373.68,381.805,634.299,638.148,634.299,622.353,634.299,631.951,634.299,636.359,634.299,645.102,293.513,285.315,611.793,614.446,460.647,453.415,460.647,464.976,168.393,164.598,168.393,174.352,622.353,611.093,203.263,207.993,203.263,198.414,241.208,231.621,241.208,247.402,241.208,248.127,567.76,562.626,567.76,572.65,567.76,570.802,567.76,571.274,633.202,620.868,633.202,644.294,357.021,361.181,377.836,371.359,377.836,381.732,467.287,469.335,467.287,457.993,467.287,474.194,467.287,488.026,467.287,446.974,467.287,464.521,356.5,364.991,356.5,348.378,356.5,355.846,356.5,353.204,259.235,248.042,259.235,262.349,259.235,269.712,212.066,212.359,671.132,657.28,671.132,683.618,250.917,266.355,250.917,247.574,250.917,235.935,250.917,251.38,103.438,104.582,339.455,342.665,620.868,620.758,620.868,613.612,620.868,633.573,620.868,606.887,620.868,623.529,620.868,622.833,533.982,535.148,533.982,532.947,257.324,249.738,257.324,255.033,257.324,266.355,257.324,256.304,186.738,186.621,186.738,187.465,477.671,477.219,477.671,480.896,692.729,683.618,692.729,697.376,358.551,361.668,396.739,405.42,396.739,394.118,209.944,219.78,209.944,194.78,209.944,213.637,452.693,439.259,452.693,452.52,622.833,624.662,435.384,431.771,435.384,440.374,334.242,335.971,538.355,546.514,285.315,295.433,285.315,266.355,285.315,287.361,134.728,128.728,115.455,120.399,667.839,643.368,403.993,405.42,79.553,65.593,79.553,77.022,79.553,92.487,409.713,387.435,409.713,412.656,409.713,415.893,631.684,629.461,631.684,631.985,631.684,633.706,219.78,230.121,219.78,216.462,219.78,218.312,417.864,398.374,417.864,436.693,606.887,595.161,606.887,643.368,606.887,567.266,606.887,606.654,606.887,607.053,298.424,308.028,298.424,287.004,298.424,300.933,298.424,295.925,298.424,301.161,209.093,220.988,209.093,199.773,209.093,199.446,209.093,214.409,488.026,509.278,152.996,157.63,152.996,150.559,231.621,220.988,165.907,170.998,165.907,162.366,165.678,145.266,165.678,187.711,67.342,65.942,587.69,586.308,555.6,563.259,555.6,546.767,620.758,618.799,190.51,190.878,190.51,181.769,190.51,199.446,390.242,401.127,390.242,391.982,390.242,391.393,390.242,381.805,390.242,391.393,646.481,642.105,413.381,405.42,230.127,233.981,230.127,225.951,507.649,510.38,507.649,484.029,705.596,711.961,705.596,697.974,577.561,582.379,711.961,715.526,247.402,287.361,247.402,211.696,452.52,443.744,624.685,628.405,405.42,364.735,405.42,408.604,405.42,446.974,405.42,402.631,77.706,82.467,710.924,714.378,710.924,724.152,710.924,697.974,212.568,212.359,212.568,212.597,667.678,657.28,667.678,676.806,163.196,187.465,163.196,157.63,501.839,497.599,501.839,509.278,139.231,135.873,545.17,547.625,547.117,541.946,547.117,551.24,547.117,555.353,235.935,231.814,235.935,222.543,117.65,114.808,117.65,132.617,117.65,104.582,117.65,116.151,117.65,129.14,117.65,120.932,117.65,104.279,287.361,327.967,287.361,286.447,613.612,610.879,613.612,609.335,342.665,348.378,190.835,189.129,190.835,193.142,537.159,547.117,537.159,529.68,537.159,535.991,459.785,456.897,459.785,461.822,273.717,272.84,247.26,254.818,247.26,237.222,107.227,107.742,107.227,106.286,109.383,113.926,109.383,125.126,109.383,92.827,109.383,106.157,456.897,453.232,393.158,394.118,608.475,606.654,521.261,493.022,191.363,194.648,308.028,312.859,626.533,614.446,626.533,638.698,598.251,601.564,387.435,364.735,247.536,248.042,247.536,246.334,248.042,235.48,552.47,548.029,552.47,560.228,286.316,286.207,355.366,354.557,562.626,555.353,391.449,391.835,391.449,398.374,391.449,385.384,225.755,230.121,187.339,187.711,731.685,733.446,731.685,737.257,457.993,456.259,457.993,450.121,574.342,570.939,35.179,47.801,35.179,24.802,477.611,480.241,136.451,129.14,568.72,567.266,446.974,469.963,678.446,681.375,678.446,657.921,678.446,697.974,683.933,688.208,683.933,676.806,160.88,175.433,160.88,159.698,160.88,146.616,92.157,96.546,668.07,662.076,668.07,671.581,631.985,632.548,667.577,663.439,112.461,110.837,112.461,107.78,112.461,107.408,112.461,124.133,474.194,482.436,474.194,477.2,486.306,480.709,486.306,493.022,212.597,215.628,212.597,187.465,212.597,242.102,263.02,262.914,665.584,660.989,553.259,552.953,213.637,216.317,480.241,482.436,183.021,194.78,183.021,173.495,185.833,188.275,185.833,181.829,175.433,176.535,175.433,177.968,175.433,190.81,405.348,406.805,367.24,370.539,367.24,362.536,657.921,634.808,657.921,663.439,657.921,658.667,158.931,157.63,291.943,299.632,291.943,292.436,291.943,287.909,291.943,286.306,145.266,125.126,290.045,290.119,290.045,290.748,572.795,570.939,350.952,362.536,350.952,345.621,350.952,343.843,350.952,352.702,391.126,392.865,577.224,580.678,260.937,254.818,260.937,266.866,389.827,382.267,389.827,401.007,307.404,310.975,47.801,62.179,245.529,252.113,245.529,237.222,407.445,394.325,205.153,209.944,211.11,219.78,211.11,206.534,391.393,387.67,391.393,392.865,391.393,391.79,146.616,132.617,381.858,386.036,626.546,622.463,626.546,634.808,626.546,623.188,626.546,620.527,626.546,627.779,487.313,496.712,443.744,440.374,443.744,439.743,443.744,453.415,443.744,446.278,296.619,300.097,296.619,290.748,193.142,197.706,724.635,731.685,438.917,435.736,438.917,443.994,120.399,129.687,423.112,419.425,406.805,409.713,278.283,272.106,278.283,284.534,538.218,535.938,151.57,156.021,435.256,431.128,435.256,439.743,557.083,553.562,557.083,546.514,450.121,443.994,720.067,716.56,278.102,269.712,278.102,284.228,188.18,194.648,473.884,477.219,155.287,138.115,155.287,151.147,155.287,152.315,513.047,510.38,65.593,65.942,65.593,52.96,134.473,135.873,393.535,390.962,214.409,218.822,221.714,218.822,187.711,211.696,322.62,327.967,322.62,316.771,551.417,550.297,284.228,285.815,284.228,288.15,284.534,288.359,284.534,286.326,477.697,477.219,653.633,644.294,653.633,661.675,286.306,284.057,286.306,287.068,286.306,282.438,482.436,491.959,547.625,544.063,547.625,550.297,397.717,390.962,397.717,401.622,570.939,590.041,570.939,568.223,570.939,560.228,570.939,557.083,570.939,573.306,570.939,570.068,327.967,364.735,632.548,633.449,662.076,662.502,589.325,582.168,589.325,594.246,589.325,589.985,190.81,205.119,197.706,204.133,535.938,538.033,535.938,544.676,580.678,579.053,263.251,266.923,186.583,187.465,283.783,285.898,82.409,92.827,82.409,72.423,157.63,153.963,419.291,415.893,242.945,247.574,242.945,236.468,242.945,240.156,643.368,657.28,643.368,645.543,252.113,256.047,176.535,177.227,472.03,463.763,472.03,476.688,262.914,275.325,262.914,242.62,262.914,272.213,653.247,660.989,653.247,657.016,653.247,633.449,653.247,650.859,653.247,662.305,3.356,8.903,463.763,452.52,745.684,750.0,198.414,199.656,198.414,194.145,198.414,195.424,470.339,467.015,649.175,643.615,569.614,563.259,342.024,343.843,135.873,141.83,135.873,129.14,390.077,396.739,390.077,386.012,382.091,385.72,262.393,258.621,541.946,538.153,181.769,174.352,124.133,120.752,124.133,138.115,563.259,565.349,196.254,199.773,689.881,699.835,689.881,703.979,689.881,667.839,595.161,589.491,595.161,588.92,385.663,383.426,385.663,381.842,385.663,390.242,661.444,661.675,661.444,660.289,69.46,72.17,69.46,62.179,69.46,73.706,334.233,334.076,334.233,335.971,726.689,724.635,601.566,604.36,337.374,333.351,337.374,335.824,337.374,340.002,588.92,584.982,708.853,699.835,708.853,716.56,128.728,125.406,642.105,633.573,92.827,94.833,499.957,503.36,299.632,335.971,299.632,303.5,299.632,272.106,299.632,299.285,193.683,201.763,193.683,189.289,549.361,552.953,551.24,580.678,551.24,521.261,551.24,553.247,532.921,538.355,532.921,530.025,679.043,675.226,232.583,230.121,663.439,665.164,604.36,611.093,604.36,600.367,62.179,72.423,62.179,59.731,389.521,394.118,397.191,401.007,166.287,173.495,278.599,275.325,733.95,741.063,733.95,724.152,59.817,59.731,646.447,643.368,381.793,385.384,585.905,589.491,654.18,662.076,654.18,645.102,629.923,628.302,629.923,632.168,153.869,156.021,100.247,104.582,669.11,673.05,419.288,416.973,675.226,669.404,654.268,659.287,654.268,648.2,92.487,89.834,92.487,104.279,472.177,467.592,472.177,475.938,460.419,460.381,575.078,572.65,607.192,601.564,607.192,614.446,628.405,633.613,665.23,661.675,141.83,145.39,637.318,633.573,382.267,378.462,250.522,247.402,253.463,255.033,390.962,391.667,390.962,385.72,390.962,389.181,253.105,251.871,253.105,247.574,616.615,614.446,610.426,606.887,334.026,334.076,334.026,334.034,156.021,163.059,617.604,620.527,386.036,394.596,386.036,382.203,467.784,459.531,467.784,473.838,460.381,484.029,460.381,463.328,382.244,379.234,447.601,440.449,194.648,222.117,194.648,174.509,544.063,541.035,151.147,147.274,151.147,151.07,447.702,449.044,519.124,514.968,576.111,574.527,233.244,230.121,645.805,644.294,529.68,525.397,541.035,538.57,434.721,435.256,285.898,285.315,258.621,253.105,91.676,89.228,91.676,88.893,91.676,82.467,91.676,103.58,564.626,567.266,650.678,655.167,650.678,638.698,650.678,647.886,650.678,657.28,633.449,614.446,229.927,233.981,229.927,226.277,354.051,366.362,354.051,350.191,354.051,344.783,567.266,527.897,479.434,476.135,479.434,484.029,201.763,201.29,201.763,211.696,343.843,335.971,364.694,364.735,659.729,657.016,44.495,47.801,462.568,467.015,462.568,467.592,462.568,485.197,462.568,460.315,462.568,446.285,462.568,452.693,222.68,222.117,222.68,222.514,290.748,286.297,361.668,366.362,266.866,273.407,115.891,116.151,59.305,62.179,59.305,57.291,724.152,727.323,286.297,280.519,661.675,669.404,662.305,669.11,113.926,117.506,242.102,272.106,448.085,466.468,448.085,453.022,525.65,536.719,525.65,524.423,525.65,509.278,525.65,535.938,549.304,544.676,205.119,220.055,648.2,643.615,391.047,393.832,383.746,375.676,473.838,477.362,186.833,190.953,399.589,396.592,326.432,319.555,326.432,330.395,104.582,96.546,308.407,310.975,574.971,573.306,574.971,576.111,199.773,190.953,394.118,392.865,394.118,392.34,392.865,389.416,581.732,585.73,429.139,431.477,429.139,427.22,643.615,634.808,301.321,298.424,507.493,509.278,250.244,248.127,586.308,585.73,473.741,476.135,381.733,398.374,381.733,366.362,316.326,313.836,316.326,318.316,710.72,710.829,253.009,248.127,287.004,275.325,550.478,562.713,550.478,535.93,662.947,659.287,662.947,665.027,188.715,190.987,364.735,335.971,364.735,366.182,582.379,590.041,582.379,580.356,570.661,569.614,319.264,319.555,319.264,318.316,367.587,367.775,508.654,509.278,269.712,273.623,509.278,512.894,509.278,514.968,174.509,172.244,174.509,155.287,201.006,207.436,201.006,197.431,405.046,405.11,550.703,545.298,410.042,416.883,410.042,401.127,272.106,272.84,272.106,266.923,419.425,413.381,235.48,222.117,500.608,502.232,500.608,507.783,500.608,491.959,477.219,477.174,341.492,337.374,103.58,107.185,103.58,111.414,103.58,106.286,103.58,102.605,379.234,373.337,301.161,302.735,272.84,273.407,231.814,229.081,514.968,515.61,749.764,746.457,606.654,604.316,371.359,362.536,716.56,724.635,716.56,715.97,555.353,552.953,634.808,632.168,634.808,611.093,388.41,386.197,388.41,391.047,145.39,147.78,548.754,545.298,405.11,405.518,189.129,188.023,393.832,396.592,573.306,574.488,655.167,658.241,233.981,237.222,476.765,477.174,57.416,59.731,57.416,55.568,427.351,439.259,427.351,419.069,431.477,448.085,431.477,409.713,431.477,440.449,431.477,429.55,217.31,222.117,217.31,213.673,737.257,741.229,737.257,737.708,545.298,534.551,545.298,548.094,524.423,523.707,245.49,249.738,493.022,469.963,0.0,3.356,353.347,354.557,353.347,355.816,353.347,354.504,354.155,354.051,477.501,480.709,477.501,477.167,357.3,357.937,357.3,356.133,269.982,269.712,572.655,572.725,446.285,431.092,281.381,280.405,304.042,299.973,293.342,299.632,293.342,289.375,344.783,340.11,344.783,341.977,582.168,572.714,686.803,683.618,710.829,710.924,562.713,572.714,562.713,566.598,431.092,416.016,511.944,507.783,356.133,354.557,538.57,535.93,107.742,108.295,398.374,402.07,398.374,396.592,398.374,400.344,514.649,511.313,101.366,104.279,286.207,285.315,388.127,389.181,346.16,354.504,346.16,339.472,414.999,416.016,414.999,413.801,482.828,466.468,207.436,214.251,207.436,204.222,207.436,208.323,342.028,345.621,364.886,373.337,364.886,354.504,532.13,532.947,532.13,529.437,532.13,534.099,18.072,19.808,44.47,36.301,44.47,52.96,44.47,41.558,389.181,385.409,389.181,391.676,248.127,250.583,303.5,306.744,638.698,633.613,299.973,293.513,521.678,505.737,521.678,534.551,482.927,486.306,384.774,386.197,367.775,375.676,367.775,361.181,95.452,94.833,409.497,412.329,728.885,738.465,36.301,29.604,36.301,34.463,416.016,401.007,416.016,412.329,190.987,193.683,223.114,219.78,394.596,405.518,437.196,439.259,216.432,224.53,216.432,214.422,216.432,209.944,216.432,218.576,533.18,535.93,74.788,77.842,163.059,170.998,190.775,193.683,170.998,181.829,272.213,280.405,280.405,286.329,208.652,211.696,717.442,728.885,717.442,703.979,183.838,187.711,421.059,416.883,204.133,211.696,213.451,211.696,391.393,391.667,271.147,274.386,271.147,266.355,242.62,230.121,242.62,236.468,413.801,412.728,485.197,488.657,485.197,505.737,536.719,546.767,24.802,16.087,349.843,352.702,423.442,407.445,423.442,443.744,423.442,419.183,423.442,421.14,528.467,528.193,510.38,513.58,29.604,24.322,110.062,106.286,405.518,416.973,473.498,469.963,224.53,229.899,106.286,104.841,708.95,705.596,505.737,511.313,505.737,508.237,227.695,219.78,227.695,231.903,439.259,435.45,439.259,439.964,499.329,516.759,499.329,482.828,24.322,19.808,15.69,19.808,446.278,448.085,319.555,312.455,212.148,211.696,395.063,396.592,220.758,219.78,223.203,225.951,503.36,507.649,516.764,518.856,516.764,513.58,220.055,214.251,220.055,236.468,289.181,286.329,572.714,572.725,572.714,576.337,738.465,745.684,365.99,364.991,354.504,352.702,412.728,412.016,585.73,590.041,237.222,222.117,394.325,383.746,596.6,594.246,311.776,313.836,480.709,477.301,310.975,316.771,16.087,8.903,440.374,442.813,181.829,180.982,181.829,188.18,496.712,509.278,535.055,538.355,573.186,569.614,578.574,576.111,406.577,416.973,406.577,397.042,472.351,472.177,207.993,212.597,202.49,205.153,451.561,447.601,611.093,580.678,611.093,611.465,304.485,295.433,222.294,225.755,436.693,460.381,480.896,487.313,414.441,419.069,410.603,408.604,108.295,109.172,84.875,92.827,84.875,77.842,746.457,741.063,54.505,55.568,441.634,440.449,280.519,273.407,614.446,590.041,361.336,364.735,214.422,213.413,198.831,199.773,110.632,109.172,416.973,436.693,73.517,77.842,462.931,461.822,229.899,232.782,142.517,145.961,142.517,136.451,469.963,469.223,535.93,516.759,535.93,535.148,371.804,364.735,371.804,375.859,333.351,327.967,161.971,166.287,445.808,448.085,312.455,304.485,456.469,453.022,527.897,509.278,527.897,507.649,527.897,528.193,362.909,362.536,706.792,703.979,454.97,452.52,622.33,620.758,335.523,339.472,565.068,562.713,49.668,52.96,118.532,125.126,118.532,111.414,485.111,488.026,389.442,384.914,389.442,397.042,215.799,211.696],
z: [375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0,375.0],
},
};

    </script>
    
    <script>

      //status on whether to show or not the background canvas
      let FullMolinBkg = false;

      class Faerun {
        constructor() {
          this.body = document.getElementsByTagName('body')[0];

          this.selectedItems = [];
          this.selectedIndicators = [];
          this.selectedCurrent = [];
          this.scatterMeta = [{"categorical": [false, true, true, true, false, false, true, true, true, true, true], "fog_intensity": 0.0, "has_legend": true, "interactive": true, "is_range": [true, false, false, false, true, true, false, false, false, false, false], "label_index": [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], "legend": [[[[0.993248, 0.906157, 0.143936, 1.0], "0.015772870662460567"], [[0.974417, 0.90359, 0.130215, 1.0], "0.015772870662460567"], [[0.945636, 0.899815, 0.112838, 1.0], "0.015772870662460567"], [[0.926106, 0.89733, 0.104071, 1.0], "0.015772870662460567"], [[0.89632, 0.893616, 0.096335, 1.0], "0.04153522607781283"], [[0.866013, 0.889868, 0.095953, 1.0], "0.04153522607781283"], [[0.845561, 0.887322, 0.099702, 1.0], "0.06309148264984227"], [[0.814576, 0.883393, 0.110347, 1.0], "0.06309148264984227"], [[0.79376, 0.880678, 0.120005, 1.0], "0.08464773922187172"], [[0.762373, 0.876424, 0.137064, 1.0], "0.08464773922187172"], [[0.730889, 0.871916, 0.156029, 1.0], "0.10672975814931651"], [[0.709898, 0.868751, 0.169257, 1.0], "0.10672975814931651"], [[0.678489, 0.863742, 0.189503, 1.0], "0.129863301787592"], [[0.657642, 0.860219, 0.203082, 1.0], "0.129863301787592"], [[0.626579, 0.854645, 0.223353, 1.0], "0.129863301787592"], [[0.595839, 0.848717, 0.243329, 1.0], "0.15562565720294427"], [[0.575563, 0.844566, 0.256415, 1.0], "0.15562565720294427"], [[0.545524, 0.838039, 0.275626, 1.0], "0.18349106203995794"], [[0.515992, 0.831158, 0.294279, 1.0], "0.18349106203995794"], [[0.496615, 0.826376, 0.306377, 1.0], "0.18349106203995794"], [[0.468053, 0.818921, 0.323998, 1.0], "0.2092534174553102"], [[0.449368, 0.813768, 0.335384, 1.0], "0.2092534174553102"], [[0.421908, 0.805774, 0.35191, 1.0], "0.2092534174553102"], [[0.395174, 0.797475, 0.367757, 1.0], "0.231335436382755"], [[0.377779, 0.791781, 0.377939, 1.0], "0.231335436382755"], [[0.35236, 0.783011, 0.392636, 1.0], "0.2565720294426919"], [[0.335885, 0.777018, 0.402049, 1.0], "0.2565720294426919"], [[0.311925, 0.767822, 0.415586, 1.0], "0.2565720294426919"], [[0.288921, 0.758394, 0.428426, 1.0], "0.29547844374342797"], [[0.274149, 0.751988, 0.436601, 1.0], "0.29547844374342797"], [[0.252899, 0.742211, 0.448284, 1.0], "0.29547844374342797"], [[0.239374, 0.735588, 0.455688, 1.0], "0.29547844374342797"], [[0.220124, 0.725509, 0.466226, 1.0], "0.33753943217665616"], [[0.202219, 0.715272, 0.476084, 1.0], "0.33753943217665616"], [[0.19109, 0.708366, 0.482284, 1.0], "0.33753943217665616"], [[0.175707, 0.6979, 0.491033, 1.0], "0.33753943217665616"], [[0.162016, 0.687316, 0.499129, 1.0], "0.37066246056782337"], [[0.153894, 0.680203, 0.504172, 1.0], "0.37066246056782337"], [[0.143303, 0.669459, 0.511215, 1.0], "0.37066246056782337"], [[0.137339, 0.662252, 0.515571, 1.0], "0.4027339642481598"], [[0.130067, 0.651384, 0.521608, 1.0], "0.4027339642481598"], [[0.12478, 0.640461, 0.527068, 1.0], "0.4027339642481598"], [[0.122312, 0.633153, 0.530398, 1.0], "0.43112513144058884"], [[0.120081, 0.622161, 0.534946, 1.0], "0.43112513144058884"], [[0.119483, 0.614817, 0.537692, 1.0], "0.43112513144058884"], [[0.119738, 0.603785, 0.5414, 1.0], "0.4547844374342797"], [[0.121148, 0.592739, 0.544641, 1.0], "0.4547844374342797"], [[0.122606, 0.585371, 0.546557, 1.0], "0.4758149316508938"], [[0.125394, 0.574318, 0.549086, 1.0], "0.4758149316508938"], [[0.127568, 0.566949, 0.550556, 1.0], "0.4942166140904311"], [[0.131172, 0.555899, 0.552459, 1.0], "0.4942166140904311"], [[0.135066, 0.544853, 0.554029, 1.0], "0.5189274447949527"], [[0.13777, 0.537492, 0.554906, 1.0], "0.5189274447949527"], [[0.141935, 0.526453, 0.555991, 1.0], "0.5189274447949527"], [[0.14618, 0.515413, 0.556823, 1.0], "0.5404837013669821"], [[0.149039, 0.508051, 0.55725, 1.0], "0.5557308096740273"], [[0.153364, 0.497, 0.557724, 1.0], "0.5557308096740273"], [[0.15627, 0.489624, 0.557936, 1.0], "0.5720294426919033"], [[0.160665, 0.47854, 0.558115, 1.0], "0.5914826498422713"], [[0.165117, 0.467423, 0.558141, 1.0], "0.5914826498422713"], [[0.168126, 0.459988, 0.558082, 1.0], "0.5914826498422713"], [[0.172719, 0.448791, 0.557885, 1.0], "0.613564668769716"], [[0.175841, 0.44129, 0.557685, 1.0], "0.613564668769716"], [[0.180629, 0.429975, 0.557282, 1.0], "0.6309148264984227"], [[0.185556, 0.41857, 0.556753, 1.0], "0.6503680336487907"], [[0.188923, 0.41091, 0.556326, 1.0], "0.6503680336487907"], [[0.1941, 0.399323, 0.555565, 1.0], "0.6503680336487907"], [[0.19943, 0.387607, 0.554642, 1.0], "0.6787592008412198"], [[0.203063, 0.379716, 0.553925, 1.0], "0.6787592008412198"], [[0.208623, 0.367752, 0.552675, 1.0], "0.6787592008412198"], [[0.212395, 0.359683, 0.55171, 1.0], "0.7066246056782335"], [[0.21813, 0.347432, 0.550038, 1.0], "0.7066246056782335"], [[0.223925, 0.334994, 0.548053, 1.0], "0.7339642481598317"], [[0.227802, 0.326594, 0.546532, 1.0], "0.7339642481598317"], [[0.233603, 0.313828, 0.543914, 1.0], "0.7339642481598317"], [[0.237441, 0.305202, 0.541921, 1.0], "0.7660357518401683"], [[0.243113, 0.292092, 0.538516, 1.0], "0.7660357518401683"], [[0.248629, 0.278775, 0.534556, 1.0], "0.7660357518401683"], [[0.252194, 0.269783, 0.531579, 1.0], "0.7660357518401683"], [[0.257322, 0.25613, 0.526563, 1.0], "0.7886435331230284"], [[0.260571, 0.246922, 0.522828, 1.0], "0.8123028391167192"], [[0.265145, 0.232956, 0.516599, 1.0], "0.8123028391167192"], [[0.269308, 0.218818, 0.509577, 1.0], "0.8123028391167192"], [[0.271828, 0.209303, 0.504434, 1.0], "0.8512092534174553"], [[0.275191, 0.194905, 0.496005, 1.0], "0.8512092534174553"], [[0.278012, 0.180367, 0.486697, 1.0], "0.8512092534174553"], [[0.279574, 0.170599, 0.479997, 1.0], "0.8512092534174553"], [[0.281412, 0.155834, 0.469201, 1.0], "0.8512092534174553"], [[0.28229, 0.145912, 0.46151, 1.0], "0.8906414300736067"], [[0.283072, 0.130895, 0.449241, 1.0], "0.8906414300736067"], [[0.283197, 0.11568, 0.436115, 1.0], "0.8906414300736067"], [[0.28291, 0.105393, 0.426902, 1.0], "0.9290220820189274"], [[0.281924, 0.089666, 0.412415, 1.0], "0.9290220820189274"], [[0.280894, 0.078907, 0.402329, 1.0], "0.9290220820189274"], [[0.278791, 0.062145, 0.386592, 1.0], "0.9290220820189274"], [[0.276022, 0.044167, 0.370164, 1.0], "0.9663512092534174"], [[0.273809, 0.031497, 0.358853, 1.0], "0.9663512092534174"], [[0.269944, 0.014625, 0.341379, 1.0], "0.9663512092534174"], [[0.267004, 0.004874, 0.329415, 1.0], "0.9663512092534174"]], [[[0.7019607843137254, 0.0, 0.0, 1.0], "1980-1990"], [[0.48627450980392156, 0.06666666666666667, 0.34509803921568627, 1.0], "1990-1995"], [[0.26666666666666666, 0.12941176470588237, 0.6862745098039216, 1.0], "1995-2000"], [[0.10196078431372549, 0.3254901960784314, 1.0, 1.0], "2000-2005"], [[0.050980392156862744, 0.5333333333333333, 0.9019607843137255, 1.0], "2005-2010"], [[0.0, 0.7176470588235294, 0.7803921568627451, 1.0], "2010-2015"], [[0.35294117647058826, 0.8313725490196079, 0.35294117647058826, 1.0], "2015-2020"], [[0.9215686274509803, 0.8627450980392157, 0.47058823529411764, 1.0], "2020-2022"]], [[[0.6980392156862745, 0.13333333333333333, 0.13333333333333333, 1.0], "No"], [[0.13333333333333333, 0.5450980392156862, 0.13333333333333333, 1.0], "Yes"]], [[[0.6980392156862745, 0.13333333333333333, 0.13333333333333333, 1.0], "Other"], [[0.13333333333333333, 0.5450980392156862, 0.13333333333333333, 1.0], "Oral"]], [[[0.993248, 0.906157, 0.143936, 1.0], "0.11934805467928496"], [[0.974417, 0.90359, 0.130215, 1.0], "0.5983175604626709"], [[0.945636, 0.899815, 0.112838, 1.0], "0.9279705573080967"], [[0.926106, 0.89733, 0.104071, 1.0], "0.12723449001051526"], [[0.89632, 0.893616, 0.096335, 1.0], "0.2823343848580442"], [[0.866013, 0.889868, 0.095953, 1.0], "0.14195583596214512"], [[0.845561, 0.887322, 0.099702, 1.0], "0.2823343848580442"], [[0.814576, 0.883393, 0.110347, 1.0], "0.26130389064143006"], [[0.79376, 0.880678, 0.120005, 1.0], "0.13512092534174552"], [[0.762373, 0.876424, 0.137064, 1.0], "0.34437434279705575"], [[0.730889, 0.871916, 0.156029, 1.0], "0.3785488958990536"], [[0.709898, 0.868751, 0.169257, 1.0], "0.08832807570977919"], [[0.678489, 0.863742, 0.189503, 1.0], "0.056782334384858045"], [[0.657642, 0.860219, 0.203082, 1.0], "0.7518401682439537"], [[0.626579, 0.854645, 0.223353, 1.0], "0.3922187171398528"], [[0.595839, 0.848717, 0.243329, 1.0], "0.6876971608832808"], [[0.575563, 0.844566, 0.256415, 1.0], "0.32965299684542587"], [[0.545524, 0.838039, 0.275626, 1.0], "0.9784437434279706"], [[0.515992, 0.831158, 0.294279, 1.0], "0.631440588853838"], [[0.496615, 0.826376, 0.306377, 1.0], "0.7791798107255521"], [[0.468053, 0.818921, 0.323998, 1.0], "0.8207150368033649"], [[0.449368, 0.813768, 0.335384, 1.0], "0.07045215562565721"], [[0.421908, 0.805774, 0.35191, 1.0], "0.5778128286014721"], [[0.395174, 0.797475, 0.367757, 1.0], "0.21871713985278654"], [[0.377779, 0.791781, 0.377939, 1.0], "0.7655099894847529"], [[0.35236, 0.783011, 0.392636, 1.0], "0.15562565720294427"], [[0.335885, 0.777018, 0.402049, 1.0], "0.14195583596214512"], [[0.311925, 0.767822, 0.415586, 1.0], "0.5120925341745531"], [[0.288921, 0.758394, 0.428426, 1.0], "0.11514195583596215"], [[0.274149, 0.751988, 0.436601, 1.0], "0.10199789695057834"], [[0.252899, 0.742211, 0.448284, 1.0], "0.8911671924290221"], [[0.239374, 0.735588, 0.455688, 1.0], "0.4773922187171398"], [[0.220124, 0.725509, 0.466226, 1.0], "0.4978969505783386"], [[0.202219, 0.715272, 0.476084, 1.0], "0.8590956887486856"], [[0.19109, 0.708366, 0.482284, 1.0], "0.8333333333333334"], [[0.175707, 0.6979, 0.491033, 1.0], "0.916403785488959"], [[0.162016, 0.687316, 0.499129, 1.0], "0.674553101997897"], [[0.153894, 0.680203, 0.504172, 1.0], "0.9279705573080967"], [[0.143303, 0.669459, 0.511215, 1.0], "0.24132492113564669"], [[0.137339, 0.662252, 0.515571, 1.0], "0.9532071503680336"], [[0.130067, 0.651384, 0.521608, 1.0], "0.45320715036803366"], [[0.12478, 0.640461, 0.527068, 1.0], "0.6876971608832808"], [[0.122312, 0.633153, 0.530398, 1.0], "0.30914826498422715"], [[0.120081, 0.622161, 0.534946, 1.0], "0.4978969505783386"], [[0.119483, 0.614817, 0.537692, 1.0], "0.03207150368033649"], [[0.119738, 0.603785, 0.5414, 1.0], "0.7791798107255521"], [[0.121148, 0.592739, 0.544641, 1.0], "0.9400630914826499"], [[0.122606, 0.585371, 0.546557, 1.0], "0.7166140904311251"], [[0.125394, 0.574318, 0.549086, 1.0], "0.8207150368033649"], [[0.127568, 0.566949, 0.550556, 1.0], "0.1829652996845426"], [[0.131172, 0.555899, 0.552459, 1.0], "0.4773922187171398"], [[0.135066, 0.544853, 0.554029, 1.0], "0.21871713985278654"], [[0.13777, 0.537492, 0.554906, 1.0], "0.04153522607781283"], [[0.141935, 0.526453, 0.555991, 1.0], "0.16246056782334384"], [[0.14618, 0.515413, 0.556823, 1.0], "0.45320715036803366"], [[0.149039, 0.508051, 0.55725, 1.0], "0.13144058885383805"], [[0.153364, 0.497, 0.557724, 1.0], "0.35646687697160884"], [[0.15627, 0.489624, 0.557936, 1.0], "0.6161934805467929"], [[0.160665, 0.47854, 0.558115, 1.0], "0.7949526813880127"], [[0.165117, 0.467423, 0.558141, 1.0], "0.5578338590956887"], [[0.168126, 0.459988, 0.558082, 1.0], "0.21293375394321767"], [[0.172719, 0.448791, 0.557885, 1.0], "0.5394321766561514"], [[0.175841, 0.44129, 0.557685, 1.0], "0.25236593059936907"], [[0.180629, 0.429975, 0.557282, 1.0], "0.4978969505783386"], [[0.185556, 0.41857, 0.556753, 1.0], "0.6876971608832808"], [[0.188923, 0.41091, 0.556326, 1.0], "0.4127234490010515"], [[0.1941, 0.399323, 0.555565, 1.0], "0.21293375394321767"], [[0.19943, 0.387607, 0.554642, 1.0], "0.34437434279705575"], [[0.203063, 0.379716, 0.553925, 1.0], "0.8538380651945321"], [[0.208623, 0.367752, 0.552675, 1.0], "0.9705573080967402"], [[0.212395, 0.359683, 0.55171, 1.0], "0.1829652996845426"], [[0.21813, 0.347432, 0.550038, 1.0], "0.631440588853838"], [[0.223925, 0.334994, 0.548053, 1.0], "0.3922187171398528"], [[0.227802, 0.326594, 0.546532, 1.0], "0.35646687697160884"], [[0.233603, 0.313828, 0.543914, 1.0], "0.9484752891692955"], [[0.237441, 0.305202, 0.541921, 1.0], "0.5241850683491062"], [[0.243113, 0.292092, 0.538516, 1.0], "0.5120925341745531"], [[0.248629, 0.278775, 0.534556, 1.0], "0.14773922187171398"], [[0.252194, 0.269783, 0.531579, 1.0], "0.03785488958990536"], [[0.257322, 0.25613, 0.526563, 1.0], "0.9810725552050473"], [[0.260571, 0.246922, 0.522828, 1.0], "0.4127234490010515"], [[0.265145, 0.232956, 0.516599, 1.0], "0.7003154574132492"], [[0.269308, 0.218818, 0.509577, 1.0], "0.8207150368033649"], [[0.271828, 0.209303, 0.504434, 1.0], "0.03943217665615142"], [[0.275191, 0.194905, 0.496005, 1.0], "0.8911671924290221"], [[0.278012, 0.180367, 0.486697, 1.0], "0.9716088328075709"], [[0.279574, 0.170599, 0.479997, 1.0], "0.2823343848580442"], [[0.281412, 0.155834, 0.469201, 1.0], "0.4773922187171398"], [[0.28229, 0.145912, 0.46151, 1.0], "0.15562565720294427"], [[0.283072, 0.130895, 0.449241, 1.0], "0.5120925341745531"], [[0.283197, 0.11568, 0.436115, 1.0], "0.9915878023133544"], [[0.28291, 0.105393, 0.426902, 1.0], "0.7949526813880127"], [[0.281924, 0.089666, 0.412415, 1.0], "0.8459516298633017"], [[0.280894, 0.078907, 0.402329, 1.0], "0.7166140904311251"], [[0.278791, 0.062145, 0.386592, 1.0], "0.04942166140904311"], [[0.276022, 0.044167, 0.370164, 1.0], "0.25236593059936907"], [[0.273809, 0.031497, 0.358853, 1.0], "0.7360672975814931"], [[0.269944, 0.014625, 0.341379, 1.0], "0.45320715036803366"], [[0.267004, 0.004874, 0.329415, 1.0], "0.6161934805467929"]], [[[0.987053, 0.991438, 0.749504, 1.0], "0.9274447949526814"], [[0.987691, 0.977154, 0.734536, 1.0], "0.48370136698212407"], [[0.988717, 0.955742, 0.712242, 1.0], "0.3732912723449001"], [[0.989434, 0.94147, 0.697519, 1.0], "0.8675078864353313"], [[0.99057, 0.920049, 0.675675, 1.0], "0.27024185068349105"], [[0.991688, 0.898627, 0.654202, 1.0], "0.7949526813880127"], [[0.99244, 0.88433, 0.640099, 1.0], "0.013669821240799159"], [[0.993545, 0.862859, 0.619299, 1.0], "0.21345951629863302"], [[0.994222, 0.84854, 0.605696, 1.0], "0.9043112513144059"], [[0.995131, 0.827052, 0.585701, 1.0], "0.13354363827549948"], [[0.995932, 0.805527, 0.566202, 1.0], "0.048370136698212406"], [[0.996369, 0.791167, 0.553499, 1.0], "0.6225026288117771"], [[0.996898, 0.769591, 0.534892, 1.0], "0.334384858044164"], [[0.997138, 0.75519, 0.522806, 1.0], "0.6782334384858044"], [[0.997341, 0.733545, 0.505167, 1.0], "0.2833859095688749"], [[0.997325, 0.711848, 0.488154, 1.0], "0.4058885383806519"], [[0.997186, 0.697349, 0.477182, 1.0], "0.2192429022082019"], [[0.996775, 0.675541, 0.461314, 1.0], "0.907465825446898"], [[0.996096, 0.653659, 0.446213, 1.0], "0.2171398527865405"], [[0.99548, 0.639027, 0.436607, 1.0], "0.8885383806519453"], [[0.994309, 0.616999, 0.42295, 1.0], "0.39957939011566773"], [[0.993326, 0.602275, 0.41439, 1.0], "0.8801261829652997"], [[0.991558, 0.580107, 0.402441, 1.0], "0.4726603575184017"], [[0.989363, 0.557873, 0.391671, 1.0], "0.2733964248159832"], [[0.987646, 0.543015, 0.38521, 1.0], "0.3696109358569926"], [[0.984622, 0.520713, 0.376698, 1.0], "0.8722397476340694"], [[0.982279, 0.505851, 0.371874, 1.0], "0.07991587802313355"], [[0.97821, 0.483612, 0.366025, 1.0], "0.19190325972660358"], [[0.973381, 0.46152, 0.361965, 1.0], "0.13564668769716087"], [[0.96968, 0.446936, 0.360311, 1.0], "0.16929547844374343"], [[0.96331, 0.42539, 0.359469, 1.0], "0.7749737118822292"], [[0.958464, 0.411324, 0.360014, 1.0], "0.20399579390115669"], [[0.95021, 0.39082, 0.362468, 1.0], "0.09200841219768664"], [[0.940687, 0.371224, 0.366762, 1.0], "0.6624605678233438"], [[0.933606, 0.358764, 0.370541, 1.0], "0.37960042060988436"], [[0.921884, 0.341098, 0.377376, 1.0], "0.629863301787592"], [[0.908884, 0.324755, 0.385308, 1.0], "0.6167192429022083"], [[0.899552, 0.314616, 0.391037, 1.0], "0.807570977917981"], [[0.884651, 0.30053, 0.400047, 1.0], "0.022082018927444796"], [[0.874176, 0.291859, 0.406205, 1.0], "0.6635120925341745"], [[0.857763, 0.279857, 0.415496, 1.0], "0.2234490010515247"], [[0.840636, 0.268953, 0.424666, 1.0], "0.20031545741324921"], [[0.828886, 0.262229, 0.430644, 1.0], "0.05783385909568875"], [[0.810855, 0.252861, 0.439305, 1.0], "0.11093585699263933"], [[0.798608, 0.24704, 0.444848, 1.0], "0.9758149316508938"], [[0.779968, 0.238851, 0.452765, 1.0], "0.6603575184016824"], [[0.761077, 0.231214, 0.460162, 1.0], "0.7097791798107256"], [[0.748378, 0.226377, 0.464794, 1.0], "0.7523659305993691"], [[0.729216, 0.219437, 0.471279, 1.0], "0.5793901156677181"], [[0.716387, 0.214982, 0.47529, 1.0], "0.26603575184016826"], [[0.697098, 0.208501, 0.480835, 1.0], "0.03995793901156677"], [[0.677786, 0.202203, 0.485819, 1.0], "0.10672975814931651"], [[0.664915, 0.198075, 0.488836, 1.0], "0.6025236593059937"], [[0.645633, 0.191952, 0.49291, 1.0], "0.22082018927444794"], [[0.626401, 0.185867, 0.496456, 1.0], "0.1288117770767613"], [[0.613617, 0.181811, 0.498536, 1.0], "0.9221871713985279"], [[0.594508, 0.175701, 0.501241, 1.0], "0.4637223974763407"], [[0.581819, 0.171596, 0.502777, 1.0], "0.38853838065194535"], [[0.562866, 0.165368, 0.504692, 1.0], "0.5457413249211357"], [[0.544015, 0.159033, 0.506159, 1.0], "0.2628811777076761"], [[0.531507, 0.154739, 0.506895, 1.0], "0.6834910620399579"], [[0.512831, 0.148179, 0.507648, 1.0], "0.4437434279705573"], [[0.500438, 0.143719, 0.50792, 1.0], "0.6361724500525763"], [[0.481929, 0.136891, 0.507989, 1.0], "0.2334384858044164"], [[0.463508, 0.129893, 0.507652, 1.0], "0.5630914826498423"], [[0.451271, 0.125132, 0.507198, 1.0], "0.8354363827549948"], [[0.432967, 0.117855, 0.50616, 1.0], "0.014721345951629864"], [[0.414709, 0.110431, 0.504662, 1.0], "0.6456361724500526"], [[0.402548, 0.10542, 0.503386, 1.0], "0.7150368033648791"], [[0.384299, 0.097855, 0.501002, 1.0], "0.843322818086225"], [[0.372116, 0.092816, 0.499053, 1.0], "0.017875920084121977"], [[0.353773, 0.085373, 0.495501, 1.0], "0.7917981072555205"], [[0.335308, 0.078236, 0.491024, 1.0], "0.10147213459516298"], [[0.322899, 0.073782, 0.487408, 1.0], "0.26813880126182965"], [[0.304081, 0.067835, 0.480812, 1.0], "0.7765509989484752"], [[0.291366, 0.064553, 0.475462, 1.0], "0.5772870662460567"], [[0.271994, 0.060994, 0.46566, 1.0], "0.8654048370136698"], [[0.25222, 0.059415, 0.453248, 1.0], "0.7234490010515248"], [[0.238826, 0.059517, 0.443256, 1.0], "0.9737118822292324"], [[0.218512, 0.061158, 0.425392, 1.0], "0.9369085173501577"], [[0.204935, 0.062907, 0.411514, 1.0], "0.21556256572029442"], [[0.184801, 0.065732, 0.387973, 1.0], "0.5909568874868559"], [[0.165308, 0.067911, 0.361816, 1.0], "0.68664563617245"], [[0.152839, 0.068637, 0.343404, 1.0], "0.9579390115667719"], [[0.135053, 0.068391, 0.315, 1.0], "0.8201892744479495"], [[0.118405, 0.066479, 0.286321, 1.0], "0.7928496319663512"], [[0.107899, 0.064335, 0.267289, 1.0], "0.7444794952681388"], [[0.092949, 0.059904, 0.239164, 1.0], "0.7413249211356467"], [[0.083446, 0.056225, 0.220755, 1.0], "0.9064143007360673"], [[0.069764, 0.049726, 0.193735, 1.0], "0.39274447949526814"], [[0.056615, 0.04216, 0.167446, 1.0], "0.9411146161934806"], [[0.048062, 0.036607, 0.150327, 1.0], "0.7707676130389064"], [[0.03552, 0.028397, 0.125209, 1.0], "0.6398527865404837"], [[0.028123, 0.023201, 0.108787, 1.0], "0.555205047318612"], [[0.018815, 0.016026, 0.084584, 1.0], "0.9505783385909569"], [[0.011465, 0.009828, 0.06075, 1.0], "0.4589905362776025"], [[0.007588, 0.006356, 0.044973, 1.0], "0.6088328075709779"], [[0.003279, 0.002305, 0.023708, 1.0], "0.17034700315457413"], [[0.001462, 0.000466, 0.013866, 1.0], "0.5814931650893796"]], [[[0.6980392156862745, 0.13333333333333333, 0.13333333333333333, 1.0], "No"], [[0.13333333333333333, 0.5450980392156862, 0.13333333333333333, 1.0], "Yes"]], [[[0.6980392156862745, 0.13333333333333333, 0.13333333333333333, 1.0], "No"], [[0.13333333333333333, 0.5450980392156862, 0.13333333333333333, 1.0], "Yes"]], [[[0.6980392156862745, 0.13333333333333333, 0.13333333333333333, 1.0], "No"], [[0.13333333333333333, 0.5450980392156862, 0.13333333333333333, 1.0], "Yes"]], [[[0.6980392156862745, 0.13333333333333333, 0.13333333333333333, 1.0], "No"], [[0.13333333333333333, 0.5450980392156862, 0.13333333333333333, 1.0], "Yes"]], [[[0.6980392156862745, 0.13333333333333333, 0.13333333333333333, 1.0], "No"], [[0.13333333333333333, 0.5450980392156862, 0.13333333333333333, 1.0], "Yes"]]], "legend_title": ["", "Approved", "Approved", "Approved", "Approved", "Approved", "Approved", "Approved", "Approved", "Approved", "Approved"], "mapping": {"c": "c", "cs": "cs", "knn": "knn", "labels": "labels", "s": "s", "x": "x", "y": "y", "z": "z"}, "max_c": [0.9921135646687698, 7.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0], "max_legend_label": ["2022", "7.00", "1.00", "1.00", "21", "7183", "1.00", "1.00", "1.00", "1.00", "1.00"], "max_point_size": 100.0, "min_c": [0.015772870662460567, 0.0, 0.0, 0.0, 0.0010515247108307045, 0.0010515247108307045, 0.0, 0.0, 0.0, 0.0, 0.0], "min_legend_label": ["1985", "0.00", "0.00", "0.00", "-42", "77", "0.00", "0.00", "0.00", "0.00", "0.00"], "name": "Approved", "ondblclick": [null, null, null, null, null, null, null, null, null, null, null], "point_scale": 8, "selected_labels": [null, null, null, null, null, null, null, null, null, null, null], "series_title": ["Approval Year", "Approval Period", "Approved in 2022", "Route of administration", "logP", "MW", "Benzene and substituted derivatives", "Carboxylic acids and derivatives", "Steroids and steroid derivatives", "Organooxygen compounds", "Quinolines and derivatives "], "shader": "sphere", "title_index": [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1]}];
          this.treeMeta = [{"color": "#666666", "fog_intensity": 0.0, "mapping": {"c": "c", "from": "from", "to": "to", "x": "x", "y": "y", "z": "z"}, "name": "Drugs_tree", "point_helper": "Approved"}];
          this.seriesState = {};
          this.el = {};

          this.currentPoint = null;

          this.lore = null;
          this.clearColorHex = '#111111';
          this.clearColor = null;
          this.view = 'front';
          this.antiAliasing = true;
          this.alphaBlending = false;
          this.thumbnailWidth = 250;
          this.thumbnailFixed = false;

          this.treeHelpers = [];
          this.pointHelpers = [];
          this.octreeHelpers = [];
          this.coordinatesHelper = null;

          this.ohIndexToPhName = [];
          this.ohIndexToPhIndex = [];
          this.phIndexMap = {};
          this.ohIndexMap = {};

          this.min = [Number.MAX_VALUE, Number.MAX_VALUE, Number.MAX_VALUE];
          this.max = [-Number.MAX_VALUE, -Number.MAX_VALUE, -Number.MAX_VALUE];
          this.maxRadius = -Number.MAX_VALUE;

          this.coords = {
            show: false,
            grid: false,
            ticks: true,
            tickCount: 10,
            tickLength: 2.0,
            color: '#888888',
            box: false,
            offset: 5.0
          };

          this.legend = {
            show: true,
            title: 'Legend'
          };

          
          this.sdMolOpts = {
            width: this.thumbnailWidth / window.devicePixelRatio,
            height: this.thumbnailWidth / window.devicePixelRatio,
            experimental: true
          }

          this.sdSelected = new SmiDrawer(this.sdMolOpts);

          if (this.thumbnailFixed) {
            this.sdMolOpts = {
              scale: 0.75,
              experimental: true
            }
          }

          this.sd = new SmiDrawer(this.sdMolOpts);

          this.el = Faerun.bindElements();

          this.scatterMeta.forEach(s => {
            this.seriesState[s.name] = 0;
          });

          this.clearColor = Lore.Core.Color.fromHex(this.clearColorHex);
          this.alphaBlending = (this.view === 'free' ? false : true) || this.alphaBlending;

          this.initLore();
          this.initTreeHelpers();
          this.initPointHelpers();
          this.initCoords();
          this.initAxes();
          this.initView();
          this.initEvents();
          this.renderLegend();
        }

        initLore() {
          this.lore = Lore.init('lore', {
            antialiasing: this.antiAliasing,
            clearColor: this.clearColorHex,
            alphaBlending: this.alphaBlending,
            preserveDrawingBuffer: true
          });
        }

        initTreeHelpers() {
          this.treeMeta.forEach(t => {
            let th = new Lore.Helpers.TreeHelper(this.lore, t.name, 'tree');
            th.setXYZHexS(data[t.name].x, data[t.name].y, data[t.name].z, t.color);
            th.setFog([this.clearColor.components[0], this.clearColor.components[1], 
                       this.clearColor.components[2], this.clearColor.components[3]],
                      t.fog_intensity);
            this.treeHelpers.push(th);
          });
        }

        initPointHelpers() {
          this.scatterMeta.forEach(s => {           
            let ph = new Lore.Helpers.PointHelper(
              this.lore, s.name, s.shader, { maxPointSize: s.max_point_size }
            );

            ph.setXYZRGBS(data[s.name].x, data[s.name].y, data[s.name].z, 
                          data[s.name]['colors'][0].r, data[s.name]['colors'][0].g, 
                          data[s.name]['colors'][0].b, data[s.name]['s'] ? data[s.name]['s'][0] : 1.0);

            ph.setPointScale(s.point_scale);
            ph.setFog([this.clearColor.components[0], this.clearColor.components[1],
                       this.clearColor.components[2], this.clearColor.components[3]],
                      s.fog_intensity)

            this.phIndexMap[s.name] = this.pointHelpers.length;
            this.pointHelpers.push(ph);

            this.min[0] = Faerun.getMin(data[s.name].x, this.min[0]);
            this.min[1] = Faerun.getMin(data[s.name].y, this.min[1]);
            this.min[2] = Faerun.getMin(data[s.name].z, this.min[2]);
            this.max[0] = Faerun.getMax(data[s.name].x, this.max[0]);
            this.max[1] = Faerun.getMax(data[s.name].y, this.max[1]);
            this.max[2] = Faerun.getMax(data[s.name].z, this.max[2]);
            this.maxRadius = ph.getMaxRadius();
    
            if (s.interactive && data[s.name].labels) {
              this.octreeHelpers.push(
                new Lore.Helpers.OctreeHelper(this.lore, 'Octree_' + s.name, 'tree', ph)
              );

              this.ohIndexMap[s.name] = this.octreeHelpers.length - 1;
              this.ohIndexToPhName.push(s.name);
              this.ohIndexToPhIndex.push(this.phIndexMap[s.name]);
            }
          });
        }

        initCoords() {
          if (!this.coords.show) return;

          let min = [0, 0, 0];
          let max = [0, 0, 0];

          for (var i = 0; i < 3; i++) {
            min[i] = this.min[i] - this.coords.offset;
            max[i] = this.max[i] + this.coords.offset;
          }

          this.coordinatesHelper = new Lore.Helpers.CoordinatesHelper(this.lore, 'Coordinates', 'coordinates', {
            position: new Lore.Math.Vector3f(min[0], min[1], min[2]),
            axis: {
              x: {
                length: max[0] - min[0],
                color: Lore.Core.Color.fromHex(this.coords.color)
              },
              y: {
                length: max[1] - min[1],
                color: Lore.Core.Color.fromHex(this.coords.color)
              },
              z: {
                length: max[2] - min[2],
                color: Lore.Core.Color.fromHex(this.coords.color)
              }
            },
            ticks: {
              enabled: this.coords.ticks,
              x: {
                length: this.coords.tickLength,
                color: Lore.Core.Color.fromHex(this.coords.color),
                count: this.coords.tickCount
              },
              y: {
                length: this.coords.tickLength,
                color: Lore.Core.Color.fromHex(this.coords.color),
                count: this.coords.tickCount
              },
              z: {
                length: this.coords.tickLength,
                color: Lore.Core.Color.fromHex(this.coords.color),
                count: this.coords.tickCount
              }
            },
            box: {
              enabled: this.coords.box,
              x: {
                color: Lore.Core.Color.fromHex(this.coords.color)
              },
              y: {
                color: Lore.Core.Color.fromHex(this.coords.color)
              },
              z: {
                color: Lore.Core.Color.fromHex(this.coords.color)
              }
            }
          });
        }

        initAxes() {
          // Wait for DOM to get ready
          setTimeout(() => {
            this.updateTitle(true);
            this.updateXAxis(true);
            this.updateYAxis(true);
          }, 500);
        }

        initView() {
          let center = new Lore.Math.Vector3f(
              (this.max[0] + this.min[0]) / 2.0, 
              (this.max[1] + this.min[1]) / 2.0, 
              (this.max[2] + this.min[2]) / 2.0
            );
          this.lore.controls.setLookAt(center);
          this.lore.controls.setRadius(this.maxRadius + 100);
          this.lore.controls.setView(0.9, -0.5)
          this.lore.controls.setViewByName(this.view);
        }

        initEvents() {
          this.lore.controls.addEventListener('updated', () => {
            // Update the position / content of the annotations every time
            // the view changes
            this.updateTitle();
            this.updateYAxis();
            this.updateXAxis();
            this.updateSelectedIndicators();
          });

          Lore.Helpers.OctreeHelper.joinHoveredChanged(this.octreeHelpers, e => {
            let phName = this.ohIndexToPhName[e.source];
            if (e.e && data[phName].labels) {
              let fullLabel = data[phName].labels[e.e.index];
              let labelIndex = this.scatterMeta[this.ohIndexToPhIndex[e.source]]
                                  .label_index[this.seriesState[phName]];
              let titleIndex = this.scatterMeta[this.ohIndexToPhIndex[e.source]]
                                  .title_index[this.seriesState[phName]];

              let rgbColor = this.pointHelpers[e.source].getColor(e.e.index);
              let hexColor = Lore.Core.Color.rgbToHex(rgbColor[0], rgbColor[1], rgbColor[2]);

              this.currentPoint = {
                index: e.e.index,
                fullLabel: fullLabel.split('__'),
                source: phName,
                label: fullLabel.split('__')[labelIndex],
                color: hexColor,
                labelIndex: labelIndex,
                titleIndex: titleIndex
              }
              
              if (FullMolinBkg == true) {

                document.getElementById("overlay-structure-container").style.visibility = "visible";

                var overlayStruc_Width = document.getElementById("overlay-structure-container").offsetWidth
                var overlayStruc_Height = document.getElementById("overlay-structure-container").offsetHeight

                if (overlayStruc_Width > overlayStruc_Height) {overlayStruc_Width = overlayStruc_Height}

                this.sd = new SmiDrawer({
                  width: overlayStruc_Width / window.devicePixelRatio,
                  height: overlayStruc_Width / window.devicePixelRatio,
                  bondThickness: 1.4,
                  experimental: true
                });

                this.setTipContent();
                this.sd = new SmiDrawer(this.sdMolOpts);
              } else {

                document.getElementById("overlay-structure-container").style.visibility = "hidden";
                this.setTipContent__();

                this.el.tip.classList.add('show');

                let pointSize = this.pointHelpers[e.source].getPointSize() / window.devicePixelRatio;
                let x = e.e.screenPosition[0];
                let y = e.e.screenPosition[1];

                this.el.hoverIndicator.style.width = pointSize + 'px';
                this.el.hoverIndicator.style.height = pointSize + 'px';
                this.el.hoverIndicator.style.left = (x - pointSize / 2.0 - 1) + 'px';
                this.el.hoverIndicator.style.top = (y - pointSize / 2.0 - 1) + 'px';

                this.el.hoverIndicator.classList.add('show');
                }

            } else {
              this.currentPoint = null;
              this.el.tip.classList.remove('show');
              this.el.hoverIndicator.classList.remove('show');
            }
          });

          Lore.Helpers.OctreeHelper.joinSelectedChanged(this.octreeHelpers, items => {
            this.selectedItems = items;
            this.updateSelected();
          });

          Lore.Helpers.OctreeHelper.joinReselected(this.octreeHelpers, item => {
            this.updateSelected(
              this.getSelectedIndex(item[0].source, item[0].item.e.index)
            );
          });

          // Event listeners
          this.el.selectedPrev.addEventListener('click', e => {
            e.preventDefault();
            this.updateSelected(this.selectedCurrent - 1);
            return false;
          });

          this.el.selectedNext.addEventListener('click', e => {
            e.preventDefault();
            this.updateSelected(this.selectedCurrent + 1);
            return false;
          });

          this.el.selectedRemove.addEventListener('click', e => {
            e.preventDefault();
            let item = this.selectedItems[this.selectedCurrent]
            this.octreeHelpers[item.source].removeSelected(item.index);
            return false;
          });

          document.addEventListener('dblclick', e => {
            if (this.currentPoint) {
              var index = this.currentPoint.index;
              var labels = this.currentPoint.label.split('__');
              var source = this.currentPoint.source;
              eval(this.scatterMeta[this.phIndexMap[source]].ondblclick[this.seriesState[source]]);
            }
          });

          document.addEventListener('mousemove', e => {
            if (FullMolinBkg == false) {
              document.getElementById("tip").style.visibility = "visible";

              if (!this.thumbnailFixed) {
                let x = e.clientX;
                let y = e.clientY;

                if (x > window.innerWidth - this.el.tip.offsetWidth - 20) {
                  x -= this.el.tip.offsetWidth;
                } else {
                  x += 10;
                }

                if (y > window.innerHeight - this.el.tip.offsetHeight - 20) {
                  y -= this.el.tip.offsetHeight;
                } else {
                  y += 10;
                }

                if (this.el.tip) {
                  this.el.tip.style.top = y + 'px';
                  this.el.tip.style.left = x + 'px';
                }
              }
            } else {
              document.getElementById("tip").style.visibility = "hidden";
            }
          });

          this.el.selectedToggle.addEventListener('click', e => {
            this.el.selectedContainer.classList.toggle('hide');
            if (this.el.selectedContainer.classList.contains('hide'))
              this.el.selectedToggle.innerHTML = '<i class="fas fa-toggle-off"></i>';
            else
              this.el.selectedToggle.innerHTML = '<i class="fas fa-toggle-on"></i>';
            
            e.preventDefault();
            return false;
          });

          this.el.showControls.addEventListener('click', e => {
            this.el.moreControls.classList.toggle('hide');
            e.preventDefault();
            return false;
          });

          this.el.search.addEventListener('click', e => {
            let searchTerm = prompt('Please enter a search term:', '');
            const results = this.search(searchTerm);

            for (const [name, indices] of Object.entries(results)) {
              if (!name in this.ohIndexMap) return;
              indices.forEach(index => {
                this.octreeHelpers[this.ohIndexMap[name]].addSelected(index);
              });
            }
            
            e.preventDefault();
            return false;
          });

          window.addEventListener('keydown', e => {
            if ((e.keyCode == 114) || (e.ctrlKey && e.keyCode == 70)) {
              this.search();
              e.preventDefault();
              return false;
            }
          });

          this.el.export.addEventListener('click', e => {
            e.preventDefault();

            let canvas = document.getElementById('lore');
            let zoom = this.lore.controls.getZoom();

            canvas.style.width = (canvas.width * 2) + 'px';
            canvas.style.height = (canvas.height * 2) + 'px';
            this.lore.controls.setZoom(zoom * 2);

            setTimeout(() => {
              let blob = this.lore.canvas.toBlob(blob => {
                let a = document.createElement('a');
                a.href = URL.createObjectURL(blob);
                a.setAttribute('download', 'export.png');
                a.click();
                
                setTimeout(() => {
                  canvas.style.width = '100%';
                  canvas.style.height = '100%';
                  lore.controls.setZoom(zoom);
                }, 2000);
              });
            }, 2000);
          });

          this.el.download.addEventListener('click', e => {
            e.preventDefault();

            let text = ''
            this.selectedItems.forEach(item => {
              let phIndex = this.ohIndexToPhIndex[item.source];
              let meta = this.scatterMeta[phIndex];
              let phName = this.ohIndexToPhName[item.source];
              let seriesState = this.seriesState[phName];

              let fullLabel = data[phName].labels[item.item.index].split('__');

              let labelIndex = meta.label_index[seriesState];
              let titleIndex = meta.title_index[seriesState];
              let selectedLabels = meta.selected_labels[seriesState];

              fullLabel.forEach((l, i) => {
                text += l + ';'
              });
              text = text.slice(0, -1); 
              text += '\n';
            });

            var a = document.createElement('a');
            a.setAttribute('href', 'data:text/plain;charset=utf-8,' + encodeURIComponent(text));
            a.setAttribute('download', 'faerun_list.csv');

            a.style.display = 'none';
            document.body.appendChild(a);

            a.click();

            document.body.removeChild(a);

            return false;
          });

          this.el.largepreview.addEventListener('click', e => {
            
            //Switch display mode:
            if (FullMolinBkg == false) {
              FullMolinBkg = true;
            } else {
              FullMolinBkg = false;
              //HIDE BIG CANVAS IN BACKGROUND:
              document.getElementById("overlay-structure-container").style.visibility = "hidden";
            }
          });
        }

        setTipContent__() {
          this.sd.draw(this.currentPoint.label, this.thumbnailFixed ? 'svg' : 'img', "light", element => {
            this.el.tipText.innerHTML = '';
            if (this.currentPoint.titleIndex !== this.currentPoint.labelIndex)
              this.el.tipText.innerHTML = `${this.currentPoint.fullLabel[this.currentPoint.titleIndex]}<br />`;
            this.el.tipText.appendChild(element);
            this.el.tip.style.borderColor = this.currentPoint.color;
            document.getElementById("tip").style.visibility = "visible";
          });
        }

        setTipContent() {
          this.sd.draw(this.currentPoint.label, "#overlay-structure", "dark");
          document.getElementById("tip").style.visibility = "hidden";
        }

        setSelectedContent(fullLabel, labelIndex, selectedLabels, img) {
          this.el.selectedContainer.innerHTML = '';
          if (img)
            this.el.selectedContainer.appendChild(img);

          fullLabel.forEach((l, i) => {
            if (i === labelIndex) return;
            if (selectedLabels && selectedLabels[i]) {
              this.el.selectedContainer.appendChild(
                Faerun.createElement('div', { classes: 'label', content: selectedLabels[i] })
              );
            }
            this.el.selectedContainer.appendChild(
              Faerun.createElement('div', { classes: 'content', content: l })
            );
          });

          // Update the indicator
          this.updateSelectedIndicators();
        }

        renderLegend() {
          if (!this.legend.show) return;

          
          let legend = document.getElementById('legend');
          
          if (legend) this.body.removeChild(legend);

          legend = Faerun.createElement('div', { id: 'legend' });
          this.body.appendChild(legend)
          
          if (this.legend.title && this.legend.title !== '')
            legend.appendChild(Faerun.createElement('h2', { content: 'Legend' }));
          
          let container = Faerun.createElement('div', { classes: 'container' });
          legend.appendChild(container);

          this.scatterMeta.forEach(s => {
            let index = this.seriesState[s.name];
            if (s.has_legend) {
              let legendSection = []
              if (!s.is_range[index]) {
                s.legend[index].forEach(v => {
                  legendSection.push(Faerun.createElement('div', { classes: 'legend-element' }, [
                    Faerun.createColorBox(v[0]),
                    Faerun.createElement('div', { classes: 'legend-label', content: v[1] }),
                  ]))
                })
              } else {
                legendSection.push(Faerun.createElement('div', { classes: 'legend-element-range' }, [
                  ...Faerun.createColorScale(s.legend[index]),
                  Faerun.createElement('div', { 
                    classes: 'legend-label max', 
                    content: s.max_legend_label[index] 
                  }),
                  Faerun.createElement('div', {
                    classes: 'legend-label min',
                    content: s.min_legend_label[index] 
                  })
                ]))
              }

              let series = [];
              for (var i = 0; i < s.series_title.length; i++) {
                series.push(
                  Faerun.createElement('option', { 
                    value: i, 
                    content: s.series_title[i], 
                    selected: i === index
                  })
                );
              }


              let sectionHeader = Faerun.createElement(
                'h3', { content: s.legend_title[index] }
              );
              sectionHeader.addEventListener('click', e => {
                this.toggleLegendSection(s.name);
              });

              let seriesSelector = Faerun.createElement(
                'select', 
                { 
                  id: `select-${s.name}`, 
                  classes: 'series-selector',
                  'data-name': s.name,
                  hidden: s.series_title.length < 2,
                }, 
                [ ...series ]
              );
              seriesSelector.addEventListener('change', e => {
                let value = document.getElementById(`select-${s.name}`).value;
                this.changeSeries(value, s.name);
              });


              container.appendChild(
                Faerun.createElement(
                  'div', { id: `legend-${s.name}`, 
                  classes: 'legend-section', 
                  'data-name': `${s.name}` },
                  [ sectionHeader, seriesSelector, ...legendSection ]
                )
              );
            }
          });
        }

        toggleLegendSection(name) {
          let section = document.getElementById('legend-' + name);
          let geometry = this.pointHelpers[this.phIndexMap[name]].geometry;
          let isVisible = geometry.isVisible;

          if (isVisible) {
            geometry.hide();
            section.style.opacity = 0.5;
          } else {
            geometry.show();
            section.style.opacity = 1.0;
          }
        }

        getSelectedIndex(source, index) {
          let selectedIndex = null;
          this.selectedItems.forEach((item, i) => {
            if (item.source == source && item.item.index == index) {
              selectedIndex = i;
              return;
            }
          });
          return selectedIndex;
        }

        updateSelected(current = -1) {
          let n = this.selectedItems.length
          // Hide the container if no items are selected
          if (n === 0) {
            this.el.selected.style.display = 'none';
            return;
          } else {
            this.el.selected.style.display = 'block';
          }

          if (current < 0) current = n - 1;
          if (current >= n) current = 0;
          this.selectedCurrent = current;

          let item = this.selectedItems[current];

          let phIndex = this.ohIndexToPhIndex[item.source];
          let meta = this.scatterMeta[phIndex];
          let phName = this.ohIndexToPhName[item.source];
          let seriesState = this.seriesState[phName];

          let fullLabel = data[phName].labels[item.item.index].split('__');

          let labelIndex = meta.label_index[seriesState];
          let titleIndex = meta.title_index[seriesState];
          let selectedLabels = meta.selected_labels[seriesState];

          this.sdSelected.draw(fullLabel[labelIndex], 'img', 'dark', img => {
            this.el.selectedCurrent.innerHTML = current + 1;
            this.el.selectedTotal.innerHTML = n;
            this.el.selectedTitle.innerHTML = fullLabel[titleIndex];

            this.setSelectedContent(fullLabel, labelIndex, selectedLabels, img);
          });

          // Remove all indicators
          this.selectedIndicators.forEach(indicator => {
            indicator.element.parentElement.removeChild(indicator.element);
          });
          this.selectedIndicators.length = 0;

          // Add the indicator for this object
          let indicatorElement = Faerun.createElement(
            'div', 
            { classes: 'selected-indicator' },
            [
              Faerun.createElement('div', { classes: 'crosshair-x' }),
              Faerun.createElement('div', { classes: 'crosshair-y' })
            ]
          );

          this.body.appendChild(indicatorElement);
          this.selectedIndicators.push({
            element: indicatorElement,
            index: item.item.index,
            ohIndex: item.source,
            phIndex: phIndex
          });
          this.updateSelectedIndicators();
        }

        updateSelectedIndicators() {
          this.selectedIndicators.forEach(indicator => {
            let pointSize = this.pointHelpers[indicator.phIndex].getPointSize();
            let screenPosition = this.octreeHelpers[indicator.ohIndex]
                                     .getScreenPosition(indicator.index);
            
            // Make the crosshairs larger than the point
            pointSize = Faerun.getMax([pointSize / window.devicePixelRatio, 10 / window.devicePixelRatio]);
            pointSize *= 1.25;
            let halfPointSize = pointSize / 2.0;
            indicator.element.style.left = (screenPosition[0] - halfPointSize) + 'px';
            indicator.element.style.top = (screenPosition[1] - halfPointSize) + 'px';
            indicator.element.style.width = pointSize + 'px';
            indicator.element.style.height = pointSize + 'px';
          });
        }

        updateTitle(first = false) {
          if (this.el.title === undefined) return;

          let bb = this.el.title.getBoundingClientRect();
          let scenePosition = new Lore.Math.Vector3f(
            (this.min[0] + this.min[0]) / 2.0, this.min[1], 
            (this.min[2] + this.min[2]) / 2.0
          );

          let screenPosition = this.lore.controls.camera.sceneToScreen(scenePosition, this.lore);
          
          this.el.title.style.left = (screenPosition[0] - (bb.width / 2.0)) + 'px';
          this.el.title.style.top = (screenPosition[1] - bb.height) + 'px';

          if (first) this.el.title.classList.add('show');
        }

        updateXAxis(first = false) {
          if (this.el.xAxis === undefined) return;
          
          let bb = this.el.xAxis.getBoundingClientRect();
          let scenePosition = new Lore.Math.Vector3f(
            (this.min[0] + this.min[0]) / 2.0, this.min[1], 
            (this.min[2] + this.min[2]) / 2.0
          );

          let screenPosition = this.lore.controls.camera.sceneToScreen(scenePosition, this.lore);
          
          this.el.xAxis.style.left = (screenPosition[0] - (bb.width / 2.0)) + 'px';
          this.el.xAxis.style.top = (screenPosition[1]) + 'px';

          if (first) this.el.xAxis.classList.add('show');
        }

        updateYAxis(first = false) {
          if (this.el.yAxis === undefined) return;
            
          let bb = this.el.yAxis.getBoundingClientRect();
          let scenePosition = new Lore.Math.Vector3f(
            this.min[0], (this.min[1] + this.min[1]) / 2.0, 
            (this.min[2] + this.min[2]) / 2.0
          );
          
          let screenPosition = this.lore.controls.camera.sceneToScreen(scenePosition, this.lore);
          
          this.el.yAxis.style.left = (screenPosition[0] - bb.height) + 'px';
          this.el.yAxis.style.top = (screenPosition[1] - bb.width / 2.0) + 'px';

          if (first) this.el.yAxis.classList.add('show');
        }

        changeSeries(value, name) {
          value = parseInt(value);
          this.seriesState[name] = value;
          this.renderLegend();

          this.pointHelpers[this.phIndexMap[name]].setRGBFromArrays(
            data[name]['colors'][value].r, 
            data[name]['colors'][value].g, 
            data[name]['colors'][value].b
          );

          if (data[name]['s']) {
            if (data[name]['s'][value]) {
              this.pointHelpers[this.phIndexMap[name]].setSize(
                data[name]['s'][value]
              );
            } else {
              this.pointHelpers[this.phIndexMap[name]].setSize(1.0);
            }
          }
        }

        search(term) {
          let results = {}
          let re = new RegExp(term, 'i');

          Object.keys(data).forEach(name => {
            if (!('labels' in data[name])) return;
            results[name] = []
            data[name]['labels'].forEach((label, i) => {
              if (re.test(label))
                results[name].push(i)
            });
          });

          return results;
        }

        static createColorBox(value) {
          return Faerun.createElement(
            'div', 
            { 
              classes: 'color-box', 
              style: `background-color: rgba(${value[0] * 255}, ${value[1] * 255 }, ${value[2] * 255 }, ${value[3] });
                      border-color: rgba(${value[0] * 255 }, ${value[1] * 255 }, ${value[2] * 255 }, ${value[3] })`
            }
          );
        }

        static createColorScale(values) {
          let scale = [];

          values.forEach(value => {
            scale.push(
              Faerun.createElement(
                'div', 
                { 
                  classes: 'color-stripe', 
                  style: `background-color: rgba(${value[0][0] * 255}, ${value[0][1] * 255}, ${value[0][2] * 255}, ${value[0][3]});
                          border-color: rgba(${value[0][0] * 255}, ${value[0][1] * 255}, ${value[0][2] * 255}, ${value[0][3]})`,
                  alt: value[1]
                }
              ),
            )
          });

          return scale;
        }
        
        static createElement(tag, values = {}, children = []) {
          let element = document.createElement(tag);

          for (const key of Object.keys(values)) {
            if (key === 'classes')
              element.classList.add(...values[key].split(' '));
            else if (key === 'content')
              element.innerHTML = values[key];
            else if (key === 'hidden') {
              if (values[key])
                element.setAttribute('hidden', true);
            }
            else if (key === 'selected') {
              if (values[key])
                element.setAttribute('selected', true);
            }
            else
              element.setAttribute(key, values[key]);
          }

          if (children) {
            if (Array.isArray(children)) {
              children.forEach(child => {
                element.appendChild(child);
              })
            } else {
              element.appendChild(children);
            }
          }

          return element;
        }

        static bindElements() {
          let result = {};
          document.querySelectorAll('[data-bind]').forEach(e => {
            result[e.getAttribute('data-bind')] = e;
          });
          return result;
        }

        static getMin(arr, other = Number.MAX_VALUE) {
          let m = Number.MAX_VALUE;
          for (var i = 0; i < arr.length; i++)
              if (arr[i] < m) m = arr[i];
          
          if (m < other) return m;
          return other;
        }

        static getMax(arr, other = -Number.MAX_VALUE) {
          let m = -Number.MAX_VALUE;
          for (var i = 0; i < arr.length; i++)
              if (arr[i] > m) m = arr[i];
          
          if (m > other) return m;
          return other;
        }
      }

      let f = new Faerun();
    </script>
  </body>
</html>